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ABSTRACT
Neoplastic transformation by the FBR fos oncogene is associated with aspects of the 
transformed phenotype such as morphological alterations, anchorage-independent growth and 
metastasis. The products of the FBR and FBJ fos oncogenes are members of the transcription 
factor AP-1, which operates downstream of the growth factor - ras - MAP Kinase pathway in 
mammalian cells. The constituents of this pathway, such as the protein kinases Raf-1 and MEK- 
1 are necessary for normal and oncogenic cell growth.
By contrast to other oncogene transformed fibroblasts, cell transformed by the FBR fos 
display a reduced intensity of MAPK signalling. This suggested to us that /bs-induced 
transformation might be independent of upstream signalling elements.
To investigate the role of MAP Kinase signalling and its requirement during /bs-induced 
transformation dominant negative mutations that previously have been reported to interfere with 
transformation by other oncogenes were employed. A transfection approach was used to 
introduce TAM-67, a dominant negative deletion mutant of the c-jun protooncogene, and kinase 
inactive mutants of Raf-1 and MEK-1. The cell lines isolated as stable clones after transfection 
had the properties of the revertant, but nevertheless all contained the FBR v-/bs oncogene.
This investigation suggested that although the MAP Kinase pathway might not be 
efficiently activated in v-/bs transformed fibroblasts, it is required for some aspects of the 
transformed phenotype. This finding extends previous observations that growth factor - ras 
signalling is important for oncogenesis by various oncogenes and that feedback mechanisms 
are of biological relevance in transformation by nuclear oncogenes.
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CHAPTER 1 INTRODUCTION
1
CHAPTER 1. 
INTRODUCTION
1.1 The FBJ and FBR RNA-containing Murine Sarcoma Viruses
1.1.1. The role and origin of retroviral oncogenes
The early observations of Rous, Gross and Harvey implicated a transmissible agent as the 
cause of murine and avian neoplasms (Rous, 1911; Gross, 1951; Harvey, 1964). These agents 
were identified as RNA tumour viruses containing cellular-derived oncogenes using molecular 
hybridisation and mutants of the transforming genes (Martin, 1972; Scolnick et a/., 1973; Stehelin 
ef a/., 1976).
Diverse types of viruses can induce a neoplastic phenotype including the large and 
small DNA viruses, such as adenoviruses and papovaviruses respectively, and the retroviruses 
which are RNA-containing viruses. The retroviruses are formed after the capture of cellular 
genes involved in cell proliferation and acquire oncogenic properties through interaction with the 
host genome (Bishop, 1983).
The oncogene carrying retroviruses elicit a specific series of events that lead to 
tumourigenicity and to the transformed phenotype in vitro. The induction of malignancy follows a 
pattern of high selectivity for certain tissues with remarkable specificity. Bishop (1982) 
suggested that retroviral oncogenes are considered to be evolutionary luxuries of the 
retroviruses, since they are not required for the viral cycle of infection and they play no role in 
replication of the retrovirus. The role oncogene products, the oncoproteins are usually present in 
high levels and that seems to be necessary for the induction and maintenance of the 
transformed phenotype in vitro and in vivo (Collett et al., 1978b). When the levels of retroviral 
oncogenes decrease cells revert to a normal phenotype (MacPherson, 1965; Deng et al., 1974; 
Deng et a/., 1977). The proteins encoded by retroviral oncogenes are components of mitogenic 
signalling (Bishop, 1985, 1991; Cantley et al., 1991; Hatakeyama et al., 1994) with diverse 
functions such as : Protein kinases (Collett and Erikson, 1978a; Levinson et al., 1978), Guanine 
nucleotide binding proteins (Scolnick et al., 1979), Growth factors (Doolittle et al., 1983; 
Waterfield et al., 1983), Growth factor Receptors (Downward et al., 1984; Ullrich et al., 1984) and 
Transcriptional activators (Weinberger etal., 1985; Sap etal., 1986; Bohmann etal., 1987).
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The identification of the fos oncogene of the Finkel-Biskis-Jinkins (FBJ) and Finkel- 
Biskis-Reilly (FBR) Murine Sarcoma Viruses (Finkel et al., 1966; Finkel et al., 1975) and the 
establishment of its relationship to the transcription factor AP-1, opened a new area in the 
molecular biology of experimental cancer. The v-fos oncogene exists in two different forms: as a 
truncated transforming oncogene and as a gag-fos oncogene with multiple alterations (van 
Beveren etal., 1983; van Beveren etal., 1984). The fos oncogenes are involved in the generation 
of murine osteosarcoma-like tumours and transform cells of mesenchymatic origin in vitro 
(Jenuwein et al., 1985).
1.1.2. Isolation of the FBJ and FBR Murine Sarcoma Viruses
The FBJ-MuSV was isolated from a radiation-induced spontaneous mouse osteosacroma in a 
CF1 mouse (Finkel et al., 1966). Extracts derived from such tumours subsequently showed 
tumourigenic activity in vivo. Subcutaneous injection of tumours extracts into newborn mice 
resulted in the production of tumours with a short incubation time (Finkel etal., 1966).
This virus showed specificity towards bone tissue with no other tumours reported to 
occur at other sites. Electron microscopy showed viral particles similar to those of Moloney (Mo- 
MuLV), Rauscher (Ra-MuLV) and Friend Murine Leukemia viruses, demonstrating evolutionary 
relationships among different types of retroviruses, prior to the molecular cloning of the FBJ 
virus specific oncogene (Van Beveren etal., 1983).
A second osteosarcoma-inducing virus was also isolated from a 90Sr-induced 
osteosarcoma in a X/Gf mouse, termed FBR-Murine Sarcoma Virus (Finkel et al., 1975). The 
FBR-MuSV Virus is an acute oncogenic, type-C replication-defective retrovirus, with high 
competence single-hit transformation kinetics. The FBR-MuSV induces morphological 
transformation of all rodent fibroblastic-like cells of mesodermal origin. In tissue culture assays 
FBR-MuSV caused complete transformation of cells in a rapid manner which was enhanced by 
the presence of corticosteroids (Lee et al., 1979).
The FBJ-MuSV and FBR-MuSV are according to Finkel some of the ubiquitous naturally 
occurring Murine Sarcoma Viruses (Lee et al., 1979). This is due to the fact that they comprise 
natural viral isolates and not viral strains that have been recovered by other means, such as the 
injection of Murine Leukemia Viruses in recipient animals (Scolnick etal., 1973).
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1.1.3. Histological Characteristics of the FBJ-induced neoplasms
Early studies showed that specificity towards bone tissue was prevalent among different strains 
of mice after infection with the FBJ-MuSV. Locally invasive tumours attached to bone tissue 
were common in the infected mice. All the locally dividing and invasive cells were of mesoderm 
origin suggesting that a cell of fibroblastic origin is the target of the FBJ Virus. Electron 
microscopy studies suggested that a variety of cell types was present (Yumoto et a/., 1970). The 
more malignant populations of these cells show differences in the amount of organelles, a 
phenomenon that is observed also in tissue culture cells infected with the FBJ-MuSV. Collagen 
fibres were also observed between cell layers in the tumours. These tumours displayed 
chondrogenic and fibrosarcomatic characteristics with undifferentiated cell types and shared 
homology, but not identity with human osteosarcomas, where cellular pleiomorphism is 
restricted.
Further investigation in CBA mice showed that a statistically significant number of mice 
infected with the FBJ virus developed bone tumours in a short incubation time (Price et 
al., 1972). According to microscopic examination, a variety of cell types was present with a low 
proliferative mitotic index, low invasiveness, minimal vascularisation, presence of collagen fibres 
and rich in alkaline phosphatase staining.
Another study with the FBJ-MuSV showed (Ward and Young, 1976) that bone and 
muscle tumours were formed after a relatively long incubation period in Swiss NIH mice. Small 
neoplastic foci with periosteal cells of spindle shape with a rounded morphology appeared 
attached to bone tissue. Neoplastic regions were covered by stroma and extracellular 
components. Locally invasive regions were identified and no metastases were detected 
consistent with the previous study. The tumours that are formed by the FBJ-MuSV are mainly 
localised in the periosteum, in contrast to the human osteosarcomas that arise in the deep bone 
cortex.
The histological variation, the low degree of metastasis and the cellular pleiomorphism 
found in the tumours derived from infection with the FBJ-MuSV suggested that no real 
osteosarcoma is observed after injection with the virus, but that the tumours formed are of a 
parosteal type of bone tumour as suggested by Verma (Verma and Graham, 1987).
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1.1.4. FBJ and FBR Murine Sarcoma Viruses can induce focus formation
Studies with cultured cells showed that the FBJ-MuSV was a replication defective retrovirus, that 
was present in the infectious extracts as a mix of a transforming virus and a non-pathogenic, 
helper Leukaemia Virus (Levy et a i, 1973). In tissue culture assays the FBJ-MuSV induced the 
formation of discrete foci of rat and mouse cells in tissue culture, whereas the FBJ-MuLV did 
not. These foci contained a large number of flat elongated Non-Producer (NP) cells that were 
different from those infected by Mo-MuSV and Ha-MuSV. The non-producer cells are cells that 
retain their oncogenic potential without releasing viral particles, and they were proven to be a 
valuable tool in the isolation of the v-fos gene encoded by FBJ MuSV.
The transformation kinetics reported by this group had a single-hit profile for the FBJ- 
MuSV. However another group later showed that the FBJ-MuSV is not so potent in terms of its 
transforming ability, and serial passaging of the cell lines was required to achieve morphological 
transformation, and to produce tumours upon injection into new-born mice (Rhim e ta i, 1979).
More recent studies suggest a different role for the two viruses: FBJ-MuSV causes 
transformation but not immortalisation of cells in tissue culture whereas FBR-MuSV is a potent 
inducer of both functions (Jenuwein et ai., 1985). The induction of immortalisation and 
transformation of tissue culture cells as a property of the FBR-MuSV is unique among retroviral 
oncogenes.
The v-fos oncogene can transform other cell types such as those of epithelial origin and 
lymphocytes (Lee et a/., 1993; Valge-Archer et al., 1990). These findings raise new questions in 
the role of v-fos issues in cellular transformation, since the identified targets for v-fos are cells of 
mesenchymal origin, a rather restricted cell type. The v-abl oncogene also has been shown to 
be able to induce transformation of diverse cell types, such as lymphoid cells and fibroblasts in 
vitro (Prywes et al., 1983).
1.1.5. Identification and cloning of Viral and Cellular fos genes
Curran and Teich (1982a) first reported the isolation of the FBJ MuSV. The establishment of a 
non-producer cell (NP) line was a prerequisite to isolate and to study the FBJ viral complex. 
From transformed foci and colonies in soft agar, colonies enriched in transformed cells were
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obtained, using the 208F cell line, a thioguanine-resistant derivative of Rat-1 cells (Quade, 
1979).
Injection of syngeneic mice with NP cells gave rise to tumours. Tumour Bearing Rat 
Sera (TBRS) derived from these mice was tested for precipitation of material from f 5S] labelled 
FBJ-MuSV NP cells. This anti-sera precipitated a 39 Kd protein of cellular origin. This protein 
seemed to be specific for the FBJ-MuSV NP cells since it was not precipitated from 208F 
uninfected and cells transformed by Kirsten-MuSV (Ki-MuSV), Moloney-MuSV (Mo-MuSV), 
Abelson-MuLV (A-MuLV) or Rausher-MuLV (Ra-MuLV), and also not by sera that recognise 
structural proteins of the virus. In vivo labelling and tryptic peptide studies showed that this 
protein was structurally unrelated to envelope proteins of the FBJ-MuSV.
Further investigation identified the transforming component of the FBJ-MuSV as a 
protein of 55 Kd (Curran and Teich, 1982b). In these experiments TBRS precipitated two 
different proteins: one of 39 Kd and a novel protein of 55 Kd. The 55 Kd protein is specific for 
the FBJ Virus Non Producer cells and is not detected in cells transformed by Ki-MuSV, Ab-MuLV 
and Mo-MuSV. Two dimensional separation of [^S] labelled fingerprints from cell extracts 
showed that these two proteins are different and distinct from those of gag and env encoded 
products (Curran and Teich, 1982b). Studies with in vitro translated viral RNA in a reticulocyte 
lysate and subsequent peptide mapping and immunoprecipitation showed that only the 55 Kd 
protein was specific for the FBJ complex. Phosphoamino acid analysis showed that this protein 
is phosphorylated on Serine residues, but not Tyrosine residues and that it does not possess 
protein kinase activity.
Molecular cloning of a restriction fragment that contained the FBJ-MuSV proviral DNA 
established the relationship between the fos viral genes to those of human and rodent origin 
(Curran etai., 1983). Sequence analysis showed that the FBJ v-fos oncogene is derived from the 
mouse homologue with a major substitution at the 3’ end. The fourth exon, which is the last of 
the mouse c-fos protooncogene, is deleted during the biogenesis of the FBJ-MuSV (Van 
Beveren etai., 1983). The product of the FBJ-MuSV is a 381 amino acid protein while the normal 
c-Fos protein is composed of 380 amino acids with a molecular weight of 55 kD. The two 
proteins are identical in the first 332 amino acids with the exception of 5 amino acid 
substitutions. The C-terminus of the FBJ-MuSV-encoded Fos protein however is different 
compared to the p55c Fos, due to a alternative reading frame.
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The mouse c-fos protooncogene, an intron containing gene, is highly conserved 
between humans and mice (Van Straaten et al., 1983). This high evolutionary conservation 
suggests an important role for the c-fos gene in normal cellular physiology. The human and 
mouse fos genes are 70% homologous at the nucleotide level with higher conservation at the 3’ 
Untranslated Region (UTR) (Van Straaten etai., 1983).
The FBR v-fos oncogene encodes the p75v Fos , a gag-Fos fusion protein (Curran and 
Verma, 1984). This protein has a significant number of alterations. It is fused to gag viral 
sequences at the N-terminus and has a significant substitution of eight amino acids at the C- 
terminus, which are derived from cellular genomic sequences termed fox. FBR p75vFos also 
lacks also the first 24 and the last 98 amino acids of the mouse c-Fos protein and has three in­
frame deletions: one in the N-terminus and two in the main fos region (Van Beveren etai., 1984) 
[Fig. 1a and b].
7
Mouse c-fos
FBJ-MuSV 175
 1—
FBR-MuSVt t -*"------------  ■ -  H ----------------------------------------------
138
Figure 1a. Structure of cellular and Viral fos genes (Vingron et al., 1988).
In the mouse c-fos gene the red regions represent conserved regions through evolution. The 
red domain in the middle represents the basic-zipper region (bZip), that is required for 
transformation and transactivation.
In the FBJ-MuSV DNA, amino acid 175 represents a single amino acid change that acts to 
suppress transformation. The magenta bar in the FBJ C-terminus represents the region that is 
deleted during the biogenesis of the FBJ-MuSV.
In the FBR-MuSV DNA the green N-terminal fragment represents the gag region of the gene. 
Amino acid 138 is a point mutation that activates the immortalising potential of the FBR 
oncogene. The two red C-terminal deletions in the FBR DNA present in the c-fos gene have a 
negative role in transformation and the blue line represents the cellular fox sequences.
Gag 310 aa fos 236 aa fox 8 aa
P75 FBR v-Fos
p55 c-Fos 24 13 9 98
380 aa-------------------------------------------------------------P ® -------------------------------H -----H -F
p55 FBJ v-Fos
332 aa  H
Figure. 1b. Structure of the mouse Fos protein and of the products of the FBR and FBJ 
oncogenes (Muller, 1986) [See 1.1.5. and 1.3.5]. In the FBR v-Fos protein the white region 
represents the gag moiety, and the red bar in the C-terminus the cellular fox sequences. In the 
c-Fos protein the three blue bars represent deletions that occur in these particular regions in 
the sequence of the FBR v-Fos and the black bar in the C-terminus represents the in frame 
deletion that occurs in the FBJ v-Fos. The same alteration is presented in the FBJ v-Fos 
protein by a black bar in the C-terminus of the protein.
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1.1.6 Genes with similarities with fos: fra-1 and fosB
Genes with homology to c-fos have been identified and molecularly cloned. These genes have 
not been identified as retroviral oncogenes but instead their isolation was performed by antibody 
screening of phage libraries or by using oligonucleotide probes with homology to c-fos. The 
genes that show homology to fos are the fos-Related Antigen-1: fra-1 (Cohen and Curran,
1988), fosB (Zerial et al., 1989) and the fos-Related Antigen-2: fra-2 (Matsui etai., 1990). Figure 
2 shows the homologies of the two more extensively studied proteins FosB and Fra-1.
139 193 332 380
Fos
142 227 237 338
FosB
93 179 275
Fra-1
Basic region r ”"l Leucine Zipper
Figure 1.2. Structure of the Fos and Fos-related proteins.
The light grey boxes represent the basic region, the dark grey boxes represent the 
Leucine zipper domain. The black box in Fos represents the region that is missing from 
the C-terminus of the FBJ v-Fos protein. The black box in FosB protein represents the 
region that is missing from the FosB/short form which is an alternatively spliced form of 
the fosB gene resulting in a protein truncated at the C-terminus
The proteins were firstly identified in experiments using two-dimensional high resolution 
gel electrophoresis and immunoprecipitation with Fos-specific antibodies from [^ -lab e lled  
extracts (Franza et al., 1987 , 1988; Rauscher et al., 1988b). Screening of a cDNA library with 
antibodies to a conserved region of Fos lead to the isolation of a fos-related antigen named fra-1 
(Cohen and Curran, 1988). This gene showed similarity to Fos at the amino acid level, but not at 
the nucleotide acid sequences. The Fra-1 protein is induced by serum and its kinetics are 
delayed compared to the kinetics of the induced p55c Fos which is very rapid. A functional region 
mostly conserved between fra-1 and c-fos was shown previously to correspond to a functional
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domain of the GCN4 yeast trans-activator and to sequences of the Jun protein (Vogt et al., 1987; 
Bohmann etai., 1987) that are required for DNA-binding.
Bergers et al. (1995) have shown that the fra-1 gene is up-regulated in fibroblasts 
transfected with viral or conditional mutants of the c-fos, fosB, fra-1 and c-jun genes. Their study 
shows that the fra-1 gene is under positive control by the transcription factor AP-1 in fibroblasts 
transfected with a Fos-ER fusion protein, and that upon estrogen induction there is a dramatic 
up-regulation of the fra-1 mRNA compared to other AP-1 family members such as fra-2, c-jun, 
junB, and junD. fra-1 mRNA is also induced at high levels after ectopic expression of the FBJ v- 
fos and fosB transforming genes in rat-1 fibroblasts. In soft agar assays the fra-1 gene induces 
colony formation to a level similar to that induced by c-fos, and the fra-1 clones showed 
tumourigenic potential when injected into nude mice (Bergers etai. 1995).
In ras transformed fibroblasts fra-1 is over-expressed and the Fra-1 protein is modified 
by a post-translational mechanism, most probably by phosphorylation, as shown by its retarded 
mobility after SDS-polyacrylamide electrophoresis (Mechta et al., 1997). In FBR v-fos 
transformed fibroblasts the fra-1 gene and Fra-1 protein are also up-regulated. Results from this 
laboratory show that Fra-1 protein levels are higher in the FBR v-fos transformed fibroblasts 
compared to the normal 208F cells (Dr. K. Hawker, L. McGarry and B.W. Ozanne, unpublished 
observations).
The fosB gene was originally identified by screening of a mouse cDNA library using a 
fos-specific probe. This gene displayed considerable homology to fos, and the fosB mRNA 
displayed similar kinetics to c-fos mRNA. After stimulation of fibroblasts with serum and purified 
growth factors the fosB gene is rapidly induced similar to other immediate early genes (Zerial et 
al., 1989). The product of fosB, the FosB protein can form in vitro dimers with products of the jun 
family genes such as Jun and JunB, in the presence or in the absence of an oligonucleotide 
containing an AP-1 site. fosB can transform rodent fibroblasts in vitro and it encodes a protein 
with the properties of a transactivator (Schuermann et al., 1991).
The cloning of a short form of the fosB, (Nakabeppu and Nathans, 1991; Mumberg et 
al., 1991; Yen et al., 1991; Dobrzanski et al., 1991) was reported which is a natural occurring form 
of fosB resulting from alternative mRNA splicing. The resulting protein lacks the C-terminus of 
FosB, and is shorter by 100 amino acids in comparison to the parental FosB protein. This
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feature is not novel for an oncogene, since a similar transcription event has been described for 
the c-abl protooncogene (Ben-Neriah etai., 1986; Bernards etai., 1988). The truncated version of 
fosB is a negative regulator of cellular transformation and suppresses /bs-induced 
transformation (Mumberg etai., 1991).
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2. Structure of c-Fos and v-Fos Proteins
2.1. Structure of Fos proteins
2.1.1. Functional Domains in the Fos protein
The p55 c-Fos protein is composed of distinct domains which are responsible in functions 
including transactivation, dimerization with Jun family members and DNA-binding, and also 
cellular transformation. A representation of these domains is presented in Figure 1.3.
N-TA bZip HOB 1 HOB2 C-TM TBD
Figure 1.3. Structure of the p55c Fos protein
The p55c Fos protein contains a N-terminal transactivation domain (N-TA: dark grey box) 
and the Leucine zipper/basic region (light grey box).Towards the C-terminus is found the 
recently identified C-Terminal domain (C-TM) and the TATA-binding domain (TBD).
The Fos protein contains an N-Terminal Activation domain (NT-A) which is an independent 
domain involved in transactivation and transformation (Jooss et al., 1994). Adjacent to the N-TA 
domain is the basic/zipper region (BZip region) which is involved in DNA-binding and 
dimerisation with Jun family of proteins. The BZip domain includes the basic region which 
contacts DNA and the Leucine repeat which forms a characteristic helical structure that 
stabilises protein dimers.
In the C-terminus the HOB domains are involved in transactivation and are conserved 
between different AP-1 family members. The HOB 1 motif is absent from the FBR p75vFos 
protein (Sutherland et al., 1992). At the C-terminus of the Fos protein is found a TATA-binding 
motif which is absent from the FBJ and FBR v-Fos proteins (Metz et al., 1994a; 1994b). The C- 
TM domain is present in the c-Fos protein and in the FBJ p55vFos, but deleted from the FBR 
p7 5 v F°s |n case pgp p7 5 v Fos( jts transforming potential is rescued by the presence of 
the cellular fox sequences, that partially substitute the C-terminus of the wild type Fos protein 
(Funk etai., 1997). In the following sections we give describe in detail the function and the role of 
these regions in transformation by Fos proteins.
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2.1.2. The N-termini of Fos proteins have a role in transformation
Wisdom and Verma (1993a) demonstrated that the region between amino acids 41 and 73 in 
the N-terminus of FosB and FosB/sf is highly conserved between all Fos family members. 
Deletion of these amino acids results in a compromised transforming ability of FosB. These 
studies suggested that in addition to the Leucine zipper/basic an intact region N-terminus of Fos 
is required for transformation.
Similar findings exist for the c-Jun oncoprotein. Angel et al. (1989) identified different 
regions in the c-Jun protein that could affect the transcriptional activity of the protein in a 
sequence-specific manner. Region II that spans amino acids 68 to 81 in the c-Jun protein is 
essential for transcriptional activation by Jun in an Jun-independent and Fos-dependent 
transcriptional activation assays. This region, is homologous to the N-terminal transactivation 
domain (N-TA): a Fos-specific domain that was identified in deletion analysis of Fos proteins 
(Jooss etai., 1994). The NT-A domain, located between amino acids 72 to 84 was found to have 
an important role in transformation, and is highly conserved throughout all Fos cellular and viral 
proteins and also in Fra proteins. N-TA contains Proline and Glutamine residues that usually are 
present in transactivation domains :
c -Jun human ASPELER LIIQ
Fos / 66-79 SPDLQW LVQP
c-Fos human TSPDLQWLVQP
Fos B human TSQDLQWLVQP
Fra-1 rat TSQELQWMVQP
Fra-2 human TSQDLQWMVQP
FBJ-MuSV TSPDLQWLVQP
FBR-MuSV TSPDLQWLVQP
Fig. 1.4. The N-termini of Fos and Jun proteins contain Serine residues that could be 
phosphorylated by MAP Kinases. The underlined protein sequences represent 
conserved motifs found in the various Fos proteins (Jooss etai., 1994).
This region of Fos shares homology with the N-terminal domain of the c-Jun oncoprotein, in a 
region that has been found to be regulated by Serine phosphorylation. The Serine 70 in Fos 
proteins corresponds to the Serine 73 in the c-Jun protein which is phosphorylated by Stress 
Activated Protein Kinases (SAPK/JNK) and is required for transactivation and transformation 
(Alani et al., 1991; Binetruy et al., 1991; Smeal et al., 1991; Pulverer et al., 1991). This suggests
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that the transactivation potential of Jun and Fos proteins can be regulated by phosphorylation in 
vivo, affecting also the transformation potential of various Fos and Jun members.
2.1.3. The Leucine zipper is required for dimerisation and DNA-binding
Fos and Jun oncoproteins act in a co-operative fashion both in trans-activation and 
DNA-binding to an AP-1 specific binding site termed TRE (TPA-Resposive Element) (Angel et 
al., 1988; Chiu et al., 1988; Sassone-Corsi et al., 1988b). This demonstrated the existence of a 
physical interaction between the products of the fos and jun protooncogenes. Studies with in 
vitro translation products were employed in order to identify the DNA-binding potential of the Fos 
and Jun proteins, as well as the nature of the dimers that were formed during in vitro translation. 
Jun was found to bind to the TRE forming dimers with itself and with other jun family members 
such as JunB and JunD, and as heterodimers with fos family members (Kouzarides and Ziff, 
1988; Halazonetis et ai., 1988; Nakabeppu et al., 1988; Rauscher et al., 1988c). The Fos-Jun 
heterodimers display an increased binding affinity for the TRE compared to Jun homodimers, 
due possibly to a reduced stability of the Jun-Jun homodimer. In this case the stability of the 
heterodimer might be important its capability to transform primary cells (Schutte et al., 1989b).
The interaction between all the members of fos and jun protooncogenes is mediated 
by the Leucine zipper, a helical structure first identified in the liver CCAAT Enhancer binding 
Protein by Steven McKnight and his colleagues (Landschulz et al., 1988). The Leucine zipper 
forms a coiled coil in which the Leucine residues are located in a canonical structure spaced 
every seven amino acids along the polypeptide chain.
Jun ESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQL 
Fos SPEEEEKRRIRRERNKHAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKL 
Basic Motif Leucine Repeat
Figure 1.5 . The structure of the Bzip domain in Fos and Jun proteins
A, Alanine; C, Cysteine; D, Aspartic Acid; E, Glutamic Acid; F, Phenylalanine; G, Glycine; H, 
Histidine; I, IsoLeucine; K, Lysine; L,Leucine; M, Methionine; N, Asparagine; P, Proline; Q, 
Glutamine; R, Arginine; S, Serine; T, Threonine; V, Valine; W, Tryptophane; Y, Tyrosine
This canonical structure favours interactions between two Leucine repeats from two 
different polypeptides and allows them to dimerize. In all the Jun and Fos family members and
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other transactivators such as GCN4, CREB and C/EBP these Leucine residues are found in the 
same conserved positions, supporting the importance of these residues through the evolution of 
DNA-binding domains. Additionally site-directed mutagenesis of the Leucine zipper has shown 
that this region is also important for DNA-binding (Kouzarides and Ziff, 1988; Turner and Tjian, 
1989; Gentz et al., 1989; Neuberg et al., 1989a).
Fos proteins can bind to a TRE when the Fos Leucine zipper is replaced by the Jun 
Leucine zipper (Neuberg et al., 1989b). These results show that the Leucine zipper somehow 
affects the DNA-binding activity of individual Fos and Jun proteins (Neuberg et al., 1989b) and 
that is highly specific in terms of the recognition of another Leucine zipper, for instance the 
Leucine zipper of Fos does not interact with other Leucine zippers (Kouzarides and Ziff, 1988;
1989).
2.1.4. The Leucine zipper is required for transformation
Characterisation of the regions of the FBR v-fos oncogene has shown that the region between 
amino acids 111 to 220 is crucial for the induction of transformation. This region contains an 
acidic domain, the basic domain that contacts DNA, and the Leucine zipper (Jenuwein and 
Muller, 1987). Sequences important for transformation by the FBJ v-fos were also determined by 
deletion analysis and span amino acids 111 to 206, in a domain which is homologous to the 
FBR v-fos region mentioned above (Yoshidaetai., 1989).
Analysis of the function of Fos proteins in terms of their interaction with the Jun proteins 
showed that most of the Leucine residues contribute to the formation of an intact, functional 
zipper. In the case of a single Leucine mutant residue (Leu-179) in the highly transforming v-Fos 
protein E300, showed the least important functional effect, whereas mutation of the Leu-165 
completely abolishes binding to c-Jun and represses the transforming properties of the protein. 
From this analyses it is apparent that an intact Leucine zipper is necessary for the induction of 
transformation in vitro (Schuermann etai., 1989).
Using Fos proteins with various mutations domains, including the Leucine zipper it was 
shown that the several Leucine zipper mutants had the ability of inhibiting transformation by FBR 
v-fos to a significant level (Wick et al., 1992). It should be noted that although the transforming 
properties of the v-Fos protein were partially suppressed, the proliferative properties of the cell 
lines expressing the dominant negative mutants were not altered. These Leucine Zipper/Basic
15
region mutant Fos proteins were found to inhibit transformation by other oncogenes, such as the 
EJ Ha-ras oncogene by 50%. These results suggest that the retroviral oncogene v-fos is a part 
of the ras signal transduction pathway and correlates with microinjection experiments, were 
injection of ras proteins could induce c-fos expression in cultured cells (Stacey etai., 1987).
2.1.5. An altered C-terminus determines the transforming potential of FBJ v-Fos
The c-fos gene is undetected in quiescent cells and is induced to high levels after the addition of 
growth factors or serum; its levels decline soon after mitogenic stimulation (Greenberg and Ziff, 
1984; Kruijer et al., 1984; Muller et al., 1984). The FBJ v-fos escapes from this tight regulation 
and has alterations in its coding domain that account for its increased transforming potential. 
The FBJ v-Fos has a different C-terminus as a result of an out of frame deletion during the 
generation of the transforming FBJ v-fos sequences (Van Beveren et al., 1983; Van Stratten et 
al., 1983). This different carboxyl terminus is absent in the product of the mouse and human c- 
fos gene.
Using plasmids encoding c-fos genes with altered C-termini and under strong 
transcription signals, Miller et al (1984) and Meijlink e ta i (1985) demonstrated that the altered 3’ 
sequences from the coding region of the v-fos gene are sufficient for the induction of 
transformation. This shows that a nuclear protooncogene can possess oncogenic potential after 
structural modifications. Additional evidence showed that sequences at the 3’ end of the c-fos 
gene destabilise the message (Lee et al., 1988 ; Wilson and Treisman, 1988). Replacement of 
the c-fos terminal sequences with those of the FBJ v-fos stabilise the hybrid c-fosN-fos mRNA.
2.1.6. Point mutation and structural alterations determine the transforming potential of FBR v- 
Fos
Along with its transforming potential, FBR v-fos has an immortalisation function, essential during 
the passage of rodent cultures towards a neoplastic stage. The product of the FBJ v-fos gene 
transforms early passage cells, but it is unable to immortalise them (Jenuwein et al., 1985). 
Extensive detailed analysis of the FBJ-FBR-c-fos chimeras showed that two different alterations 
determine the transforming potential of the FBR v-Fos protein (Jenuwein and Muller, 1987). The 
first mutation that is involved in the induction of immortalisation is an amino acid change from a
16
polar Glutamine to Valine at position 138. When this mutation is introduced into the FBJ v-Fos 
protein activates its immortalising potential. This point mutation suggests that in the FBR v-Fos 
protein this single exchange is sufficient for the induction of immortalisation. Replacement of this 
mutation in the c-Fos protein results in an increased transactivation potential (Lucibello et 
al., 1991). The presence of another point mutation, a Glutamine 175 to Lysine in the FBJ v-Fos 
protein, when introduced to the FBR v-Fos, results in a decrease in the transforming potential of 
the protein approximately 80%.
It should be noted that under strong transcriptional signals oncogenes such as mutated 
human Ha -ras, v-myc and v-src they can induce transformation and immortalisation of primary 
fibroblast cultures in vitro without the assistance of other co-operating oncogenes (Spandidos 
and Wilkie, 1984; Vennstrom ef a/., 1984; Helle etai., 1988).
A second alteration that contributes to the transforming potential of FBR v-Fos is the 
presence of two internal deletions which exist in the C-terminus. If these deletions are replaced 
by the equivalent c-fos sequences in the FBR v-Fos, the resulting v-Fos chimeric protein has a 
reduced transforming potential (Jenuwein and Muller, 1987). Analysis using a 5X TRE construct, 
which allows monitoring of the transcriptional activity of Fos proteins, showed that there is a co­
operation phenomenon between the FBR-specific point mutations and the two C-terminal 
deletions. Replacement of the deletions does not affect the transactivation potential but 
dramatically suppresses transformation (Lucibello et a/., 1991). This observation is important, 
since the transactivation domain of Fos is located at the C-terminus of the protein (Lucibello et 
al., 1988; Sassone-Corsi et al., 1988c) and an expression plasmid encoding a C-terminally 
truncated FBR v-Fos protein inhibited transactivation of a TRE-containing construct (Lucibello et 
al., 1988).
Domains which play a positive regulatory role in transcriptional activation by Fos such as 
the HOB1 and the TATA-Binding Domain (TBD) are deleted in the FBR v-Fos (Sutherland et 
al., 1992; Metz et al., 1994). The contribution to the transforming potential is rescued by two 
alternative domains: the N-Terminal Transactivating domain, N-TA and C-TM (Jooss etai., 1994; 
Funk et al., 1997) and by replacement of the C-terminus by cellular /bx-sequences (Jenuwein 
and Muller, 1987). Detailed analysis of the C-terminus identified the novel C-TM domain in c- 
Fos, FosB and FBJ v-Fos proteins which shows close similarity with the transcriptional activation 
domain of the viral transactivator VP16 at conserved hydrophobic amino acid residues (Funk et
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al., 1997). The C-TM module can activate transcription in a co-operative fashion with the N-TA 
module.
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2.2. FOS Proteins and the Transcription Factor c-Jun/AP-1
“There are likely to be epigenetic 
influences in tumourigenesis, as well, 
but we know little of these
Bishop (1991)”
2.2.1. Fos is related to Transcription Factor AP-1
Early experiments demonstrated that Fos is a protein which had DNA-binding properties 
under certain conditions suggesting a putative role of cellular and viral Fos proteins in the 
regulation of transcription. In transfection assays FBJ and FBR encoded v-fos oncogenes were 
found to induce transcriptional activation(Sambucetti and Curran 1986; Renz et al., 1987). They 
were shown to induce the a , (III) Collagen promoter and the Rous Sarcoma Virus Long Terminal 
Repeat, but not the SV40 or p-actin promoter regions (Setoyama etai., 1986).
Direct evidence that Fos is a member of a nuclear factor which activates transcription 
came from studies on a gene implicated in adipocyte differentiation termed aP-2, which encodes 
for a lipid-binding protein. A 7-base pair DNA sequence in the promoter region of the aP-2 gene 
termed Fat Specific Element: FSE, was found to be a binding site for Fos. These experiments 
demonstrated a correlation with specific binding of factors in this element that was abolished by 
Fos-specific antibodies in gel retardation assays, and by immunoprecipitation of covalently- 
linked proteins to the FSE (Distel et al., 1987; Rauscher et al., 1988a).
The FSE shows homology to a c/'s-acting element that was identified in promoter 
regions of diverse genes and is involved in the transcriptional response by TPA, a tumour 
promoter phorbol ester. This element was found to be required for the basal and induced 
transcriptional activity of the promoter region of human Metallothionein Ilex (hMTIIa) and human 
collagenase (Karin etai., 1984; Angel etai., 1987).
This c/'s-acting element, termed TRE for TPA-Responsive Element was identified in the 
promoter regions of various genes such as: hMTIIa (Karin et al., 1984), human Collagenase 
(Angel et al., 1987), IL-2 (Fujita et al., 1986) and Viral Enhancers as : SV40 (Imbra and Karin 
1987), and Polyoma Virus enhancer (Wasylyk et al., 1987). In 1987 the laboratories of Robert
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Tjian and Michael Karin isolated a TPA-inducible factor, which showed sequence specific DNA- 
binding to TRE found in the promoter region of hMtlla and Human Collagenase, as 
demonstrated by footprinting assays. This sequence specific transactivator was termed Activator 
Protein-1: AP-1 (Lee et al., 1987a; Angel et al., 1987).
2.2.2 The v-jun oncogene is an activator of transcription
The transcription factor AP-1 shares a common DNA-binding sequence with the transcriptional 
activator GCN4, which is required for amino acid biosynthesis in yeast (Struhl, 1987). A 
database computer search showed sequence homology between GCN4 and a retroviral 
oncogene, v-jun (Maki et al., 1987; Vogt et al., 1987).The v-jun oncogene was isolated and 
cloned by Peter Vogt and its colleagues from a retrovirus that caused fibrosarcomas in chickens 
(Cavallieri et al., 1985). A combination of experimental approaches showed the relationship 
between Jun and Fos oncoproteins to the transcription factor AP-1.
2.2.3. Identification of the c-jun protooncogene
Studies using high resolution two-dimensional gel electrophoresis showed that Fos proteins and 
Fos-related antigens (FRA’s) were complexed with a basic 39-kDa protein (Franza et al., 1987). 
This cellular protein was first identified by Curran and co-workers (Curran and Teich, 1982a; 
Curran et al., 1985). The identification of Fos-associated p39 as the product of c-jun 
protooncogene contributed significantly to our understanding of the molecular mechanisms that 
are involved in transcriptional regulation by AP-1(Bohmann et al., 1987; Rauscher et al., 1988b; 
Angel et al., 1988b; Sassone-Corsi et al., 1988b).
The cellular homologue of v-jun, c-jun was identified using an oligonucleotide derived 
from the coding sequence of v-jun oncogene to screen a genomic DNA library (Bohmann et 
al., 1987). The isolated c-jun cDNA was inserted into a bacterial expression vector in order to 
express the protein in bacterial lysates. After purification of the c-Jun fusion protein expressed in 
bacteria it was shown that this protein could bind the same SV40 enhancer elements with the 
specificity of AP-1 demonstrating that c-jun had essentially the properties of AP-1.
Using similar screening procedures Karin and co-workers cloned the c-jun 
protoncogene from a human fibroblast cDNA library (Angel et al., 1988b). By DNA-transfection
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experiments It was also shown that the v-jun protooncogene acts as a.sequence specific 
transactivator in F9 cells, which contain very low levels of endogenous AP-1 activity.
Curran and co-workers using an elegant biochemical approach, in DNA-affinity 
precipitation assays followed by high-resolution two-dimensional electrophoresis showed that 
Fos proteins and Fos-related antigens share a common binding site with AP-1 in the promoters 
of cellular and viral genes (Franza etai., 1988). This was followed by electrophoretic mobility shift 
analysis and photoaffinity cross-linking and showed that the FSE could bind efficiently Fos 
proteins (Rauscher et al., 1988a) and that /bs-associated protein p39 is directly related to c-jun 
protooncogene (Rauscher et al., 1988b).
p-39/Jun was subsequently identified as an AP-1-associated protein in 
immunoprecipitation experiments using Fos-specific and Jun-specific antibodies (Sassone-Corsi 
et al. 1988b). Using immunoprecipitated material from [^SJ-labelled cells, it was shown that 
Jun/AP-1 and p39 share identical two dimensional tryptic maps and that in an electrophoretic 
mobility shift assay gel purified p39 bound a TRE.
These findings were the first demonstration that fos and jun oncogenes form the AP-1 
complex and, as a result of this association could activate transcription in vitro and in vivo. This 
illustrates the necessity of transactivation or deregulation of transcription during oncogenic 
transformation. It also suggests that this interaction is a co-operative event between the actions 
of the fos and jun protooncogenes.
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3. Regulation of AP-1 activity
3.A. Transcriptional regulation of the AP-1 components
3.A.1. Transcriptional regulation of the c-fos protooncogene
If serum is withdrawn from tissue culture cells then a decrease in various metabolic processes 
takes place. This metabolic response includes events which are important for cell proliferation 
and growth, such as RNA and protein synthesis. This suggests that serum contains a 
component which is required for cell proliferation and growth. When serum is added to 
quiescent cultures, a rapid increase in total RNA synthesis takes place (Todaro etai., 1966). This 
type of stimulation is a very rapid event, with RNA synthesis ensuing within minutes, whereas 
protein synthesis and DNA synthesis occurs much later. These researchers first suggested that 
these events might be due to the presence of a macromolecular substance in the serum, a 
serum growth factor.
A number of cellular genes are acutely transcribed after the addition of purified growth 
factors to serum-deprived fibroblasts. These sequences were identified as Immediate Early 
response elements of gene transcription in vitro, comparable with the products of the Early 
genes of DNA tumour viruses (Cochran etai., 1983; Linzer and Nathans, 1983; Zullo et al., 1985; 
Lau and Nathans, 1985, 1987). Among the sequences that can be induced after growth factor 
stimulation are those of c-myc and c-fos protooncogenes, c-myc is induced by PDGF and 
lymphocyte mitogens in blood cells (Kelly et al., 1983) and the c-fos protooncogene is induced 
rapidly within minutes after the addition of PDGF or EGF to the quiescent cultures of NIH 3T3 
mouse fibroblasts (Greenberg and Ziff, 1984; Kruijer et al., 1984; Muller et al., 1984). The 
induction of c-fos is followed by the rapid synthesis of the 55kD c-Fos protein. In a attempt to 
understand the regulation of the c-fos expression site-directed mutagenesis of the 5 ’ regulatory 
region of c-fos identified a minimal region that was responsive to growth stimulation (Treisman, 
1985). This sequence, the Serum Response Element (SRE), contains a 56 base pair region that 
responds to a variety of extracellular stimuli. Most of this sequence is highly homologous with 
sequences in the human c-fos promoter. A factor that binds to this region was identified in 
electrophoretic mobility shift analysis experiments (Treisman, 1986). DNAase I protection 
studies showed that the region of factor binding is a region of dyad symmetry (DSE) which is
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the shorter sequence within the SRE that is required for induction. The DNA-binding protein that 
binds to this region was identified and cloned. This protein is called Serum Response Factor 
(SRF) and it is bound to the SRE in the absence of growth factor stimulation (Norman et 
al., 1988). The formation of a complex over the SRE seems to require another protein factor 
termed Ternary Complex Factor, TCF (Shaw et al., 1989). The c-fos SRE contains an Ets 
binding site that does not bind directly TCF, but only in the presence of the additional contacts 
with SRE-bound SRF (Treisman etai., 1992).
3.A.2. The ras Pathway
c-fos expression in mammalian cells and AP-1 activity is regulated by a signal transduction 
pathway that involves the small GTP-binding protein p21ras and kinases acting downstream of 
p21ras (Karin, 1995). The protein kinase Raf-1 is a direct target of the ras protooncogene 
(Leevers et al., 1994), and activated Raf-1 regulates the c-fos promoter in a signal-dependent 
manner (Jamal and Jiff, 1990). p21ras -induced activation of Raf-1 results in the phosphorylation 
of MEK-1 a MAP Kinase Kinase. MEK-1 is a dual specificity kinase and has the ability to 
phosphorylate Mitogen Activated Protein Kinases (MAP Kinases) on Tyrosine and Threonine 
residues. MAP Kinases were originally identified as insulin regulated kinases that were activated 
by phosphorylation on Tyrosine and Threonine residues (Ray and Sturgill, 1987). MAP Kinases 
have a variety of substrates, including nuclear transactivators. After mitogenic stumulation MAP 
Kinases translocate to the nucleus (Chen et al., 1992) where they phosphorylate transcriptional 
activators such as Elk-1. Elk-1 is a protein that belongs to the group of Ternary Complex Factors 
(TCF) which forms a complex with SRF (Hipskind etai., 1991). Phosphorylation of Elk-1 by MAP 
Kinases leads to the activation of its transcriptional properties (Gille et al., 1992; Hill et al., 1993; 
Marais et al., 1993; Janknecht et al., 1993).
In the next part of the introduction the role of phosphorylation in the post-translational 
modification of AP-1 activity is presented in more detail. The regulation of viral Fos and cellular 
Jun, Fos, and Fra-1 proteins by phosphorylation with a focus into the modulation of their 
transforming potential is discussed.
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Figure 1.6. ras dependent regulation of AP-1 activity (Karin , 1995).
Phosphorylation of TCF/Elk-1 by MAP kinases (ERK) in the fos promoter stimulates its 
transcriptional activity, regulating fos induction. JNK mediated phosphorylattiom of c-Jun 
regulates jun promoter and c-jun induction.
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3.B. Postranslational modification of the AP-1 components
Initially, there was a concern that cooperation 
might be due to one of the oncogene products 
in a co-operating pair acting to stabilise or 
increase the expression of the other oncogene 
product, but where it has been examined this 
trivial explanation has been ruled out
-Hunter (1991)”
3.B.1. The Ha-ras oncogene potentiates the transcriptional activity of c-Jun by phosphorylation 
Several lines of evidence are highly suggestive of phosphorylation as an important factor in 
modulating the regulation and function of the c-Jun oncoprotein. In co-transfection experiments 
it was found that c-Ha-ras modulated c-fos (Schontal et al., 1988) and c-jun (Binetruy et al., 1991; 
Smeal etai., 1991) expression and transcriptional activation function.
Transactivation by c-jun was enhanced 2 to 3-fold by co-transfection with the activated 
Ieu61 Ha -ras oncogene. This effect was independent of Fos, since a mutant Jun protein that is 
unable to heterodimerise with Fos was still transcriptionally active (Smeal etai., 1989). The c-Ha- 
ras induces phosphorylation of c-Jun oncoprotein as shown by immunoprecipitation analysis of 
f 2P] labelled cells and the incorporation of p2P] into c-Jun protein. The amino acids that are 
modified are located at the c-Jun N-terminus as demonstrated by tryptic phosphopeptide 
analysis (Boyle etai., 1991). These N-terminal residues are required for transcriptional activation 
since a Jun protein lacking these sites can not be activated by Ha-ras (Binetruy etai., 1991).
Substitution of these phosphorylatable residues by Alanine resulted in the absence of 
the peptides in the two dimensional peptide maps, showing that these residues are subject to 
ras dependent phosphorylation. These mutants were ineffective in transcriptional activation 
assays and in focus forming assays, suggesting an important biological role of the 
phosphorylation of Serines 63 and 72 in transformation by the c-jun oncogene.
3.B.2. Identification of the Protein Kinases that phosphorylate c-Jun oncoprotein
c-Jun oncoprotein is a substrate for MAP Kinases in vitro, on residues which correlate with in
vivo identified sites (Alvarez et al., 1991; Pulverer et al., 1991). The sites identified by these two
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groups are not identical: Alvarez et al. (1991) have identified Serine 243 in the C-terminus and 
Pulverer et al. (1991) have identified Serines 63 and 73. These phosphorylation sites stimulate 
the transcriptional activation properties of c-Jun, thus they have a positive role in AP-1-mediated 
trans-activation.
Pulverer eta i (1991) obtained convincing evidence regarding the identity and the in vivo 
role of the kinase that phosphorylates c-Jun. Using a combination of approaches such as 
peptide mapping, site-directed mutagenesis and synthetic peptides, it was shown that Serines 
62 and 73 are the critical residues targeted by a protein kinase that is activated by phorbol 
esters. As shown by chromatographic methods this enzyme has a molecular weight similar to 
other MAP Kinases of approximately 40kD. In 1993 the laboratory of Michael Karin identified a 
kinase, belonging to the MAP Kinase family, that binds and potentiates the c-Jun N-terminal 
activation domain (Hibi etai., 1993). These kinases phosphorylate Serine or Threonine residues 
immediately preceding a Proline residue and so are often referred to as Pro line-directed 
kinases; they are themselves activated by dual phosphorylation at Threonine and Tyrosine 
residues(Payne etai., 1991). However this enzyme has different activators since it was shown to 
be effectively activated by UV irradiation rather than by growth factors and serum as the typical 
MAP Kinases. Molecular cloning identified that this enzyme is related to the ERK1/ERK2 MAP 
family Kinases and is termed Jun-N terminal Kinase (JNK), since it is highly specific for the Jun 
N-terminus (Derijard et al., 1994). This protein kinase is identical to a protein kinase that is 
activated by stress and protein synthesis inhibitors (Kyriakis and Avruch, 1990; Kyriakis et 
al., 1991; Kyriakis et al., 1994).
c-Jun can also be negatively regulated by phosphorylation. Casein Kinase II and a MAP 
Kinase negatively regulate DNA-binding to a TRE in vitro. Serine and Threonine residues 
located at the C-terminus are involved in this type of regulation in vivo (Lin et al., 1992; Chou et 
al., 1992).
3.B.3. Phosphorylation of the FBJ v-Fos oncoprotein
Barber and Verma (1987) studied the phosphorylation of c-Fos and p55v Fos from cells labelled 
with |®5S] and f 2P] and have found that the c-Fos protein is extensively modified in serum 
stimulated fibroblasts compared to p55vFos. This was confirmed by incubating 
immunoprecipitated proteins from labelled lysates with alkaline phosphatase and comparing the
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mobilities of Fos proteins after SDS-polyacrylamide gel electrophoresis. Tryptic phosphopeptide 
analysis also showed that the c-Fos protein contains unique Serine residues, which are 
phosphorylated after stimulation of cultured cells.
A hybrid Fos protein that contained the main amino terminus of p55v Fos and the carboxy 
terminus from the c-Fos protein had the same electrophoretic mobility and similar 
phosphopeptide map with wild type c-Fos protein. These results argue that the c-Fos protein is 
regulated by phosphorylation of the C-terminus. The c-Fos protein can also be phosphorylated in 
vitro by various protein kinases such as p34cdc2, PKA and PKC at regions that are required in 
vivo for transcriptional activation (Abate etai., 1991).
Studies with mutated proteins in the C-termini have shown that a C-terminus site of the 
c-Fos protein encompasses a PKA consensus phosphorylation site containing a Serine residue 
(Tratner et al., 1992). Mutation of this phosphorylation site to Alanine reduces the in vitro 
phosphorylation content of c-Fos and decreases its transforming potential in transfection 
assays. These data suggested that phosphorylation of the c-Fos protein contributes positively to 
its transforming potential.
3.B.4. Phosphorylation of the c-Fos protein interferes with transactivation 
Sequence homology analysis showed that there is a similarity between the N-terminus of c-Jun 
and the C-terminus of c-Fos. These homology regions in c-Fos contain conserved amino acid
modules termed HOB1 and HOB2 (Sutherland et al., 1992). The HOB1 motif contains a
Threonine residue, the equivalent of Serine 73 of c-Jun oncoprotein that is involved in 
transcriptional activation (Sutherland etai., 1992). These motifs show independent transcriptional 
activation as well as co-operational modularity, and the HOB1 motif co-operates with the C- 
terminus of c-Fos protein to activate heterologous promoters.
Fos HOB 1 226 G L P E A T I P E S E  236
Jun HOB 1 67 G L L K L A  S P E L E 77
Figure 1.7. HOB modules in the Fos protein contain a motif which is a target site for 
MAP Kinase. The underlined residues in the HOB motifs represent amino acids 
phosphorylated by MAP Kinases.
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The c-Fos HOB1 motif can also be activated in a ras-dependent manner. Threonine 232 
in the HOB1 module can be phosphorylated by ERK2 in vitro. Replacement in this motif by a 
PKA-responsive phosphorylation site activates the transcriptional properties of the protein by 
PKA phosphorylation (Bannister et al., 1994). Similar results were found for the the c-Jun 
oncoprotein in vitro and in vivo (Smeal etai., 1994).
Deng and Karin (1994) have demonstrated that Threonine 232 in the c-Fos HOB1 motif 
is a target for a kinase other than ERK2, in contrast to the study of Bannister et al (1994). 
Experiments with GST-fusion proteins and in situ kinase assays identified an 88 Kd kinase 
activity in A431 epidermoid carcinoma cells that is distinct from MAPK or SAPK/JNK family 
kinases. The identity of this protein kinase remains to be established (Deng and Karin, 1994).
3.B.5. Regulation of the transforming potential of Fos protein by phosphorylation 
The C-terminus of the FosB protein is required for transformation (Wisdom and Verma, 1993b). 
This C-terminal function is localised at a region that is required for transactivation by c-Fos and 
FosB proteins and not by the fos-related antigens Fra-1 and Fra-2. GAL4 fusion proteins with 
the respective C-termini from different Fos proteins show transcriptional activation only in the 
case of c-Fos and FosB proteins but not for the fos-related antigens. Generation of various 
chimeric Fos proteins with C-termini from FosB show transactivation of AP-1 regulated 
transcription and transformation in a FosB dependent-manner (Wisdom and Verma, 1993b).
The FosB C-terminus contains two regions required for transactivation :a region 
between amino acids 256-275 and a Proline rich region between amino acids 265-275 (Wisdom 
etai., 1992). The latter domain contains a cluster of Serines some of may represent target sites 
for MAP Kinases. Mutational analysis of individual Serines in this region showed that there was 
not a stringent requirement for phosphorylation by MAP Kinases but if more than one of these 
Serine residues are converted to Alanine then the transactivation potential and the transforming 
ability is dramatically reduced. This shows that multiple sites possibly are regulated by 
phosphorylation in vivo resulting in the modulation of the transactivation potential of FosB protein 
(Skinner et a/., 1997). Indirect evidence such as stimulation with diverse agonists that stimulate 
MAP Kinases and JNK/SAPK family kinases suggests that the kinase that phosphorylates FosB 
protein might be distinct from ERK family or JNK/SAPK family of kinases (Skinner et al., 1997).
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Work from another group was more conclusive regarding transcriptional activation of c- 
Fos by phosphorylation. The c-Fos C-terminus is absent from the transforming FBJ v-Fos 
oncoprotein, however the region studied by this group is conserved in Fos proteins and Fos- 
Related Antigens (Chen et al., 1996).
c-Fos AH RKGSSSN EPSSDSLSSPTLLAL
FosB GA QRTSGS EQPSDPLNSPSLLAL
Fra-1 AH RKSSSS SG DPSSDPLGSPTLLAL
Fra-2 AH RRSSSSG DQSSDSLNSPTLLAL
Ser 362 Ser 374
Figure 1.8. The C-termini of Fos proteins contain consensus sites for phosphorylation by 
ribosomal S6 kinase, p90RSK and MAP Kinase. Serine 362 is a Target site for p90RSK 
and Serine 374 for MAP Kinase.
Analysis of Fos proteins lacking N- and C-termini showed that two distinct kinases could 
phosphorylate c-Fos proteins in its C-terminus (Chen et al., 1993). In vitro kinase reactions with 
purified S6 Kinase and MAP Kinase, together with tryptic phosphopeptide analysis showed that 
Serine 362 was a site for ribosomal S6 kinase, p90RSK and Serine 374 a site for MAP Kinase. 
Mutation of these Serine residues to Aspartic acid resulted in Fos proteins with increased 
transforming potential (Chen etai., 1996) possibly due to increased stability of the modified c-Fos 
protein. This demonstrates that regulation of Fos protein by phosphorylation could contribute 
significantly to the induction of the transformed phenotype in vitro.
3.B.6 Regulation of Fos-Related Antigens by phosphorylation
Immunoprecipitation with antibodies against Fos from serum stimulated fibroblasts labelled with 
f 5S] identifies protein species of 35, 38 and 45 kD (Franza et al., 1987). These proteins belong 
to the family of Fos-Related Antigens. A 38kD band could be specifically immunoprecipitated 
with Fra-1 specific antiserum was also identified by two dimensional high-resolution gel 
electrophoresis in samples from denatured and non-denatured cell lysates (Franza etai., 1987).
During pulse-chase experiments, various protein species appeared to migrate between 
35-40 kD, suggesting that differentially modified forms the Fra-1 proteins exist in vivo (Cohen et 
al., 1989). [^P] labelling showed a dramatic increase in the incorporation of phosphate into the
29
Fra-1 polypeptides. All these findings suggest that phosphorylation accounts for the post- 
translational modifications of Fra proteins in vivo (Cohen etai., 1989).
Experiments with [^S] and [^P] labelling and subsequent immunoprecipitation, and with 
in vitro synthesised proteins demonstrated that Fra-1 and Fra-2 proteins were post-translationaly 
modified by serum in stimulated Swiss 3T3 cells (Gruda et al., 1994). This effect could be 
reversed by treatment with a phosphatase in vitro. In vivo labelling with ^ P ] showed that a large 
amount of phosphate was incorporated into these proteins after serum induction and resulted in 
higher migrating forms in SDS-Polyacrylamide gels suggesting phosphorylation by a MAP 
Kinase. Different kinases were found to stimulate the incorporation of f 2P] into Fra-1 and Fra-2, 
but the higher phosphorylated forms appeared only after incubation with purified MAP Kinase 
and phosphorylation was associated with increased DNA-binding activity of Fra polypeptides in 
vitro. These data argue for a role for MAP Kinase in the post-translational modifications and the 
increased in vitro DNA-binding activity of Fra-1 and Fra-2 proteins
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1.4. Biological models of fos in the development of neoplasms
1.4.1. fos genes as regulators of cellular growth
1.4.1.1. Inhibition of cellular proliferation by antisense fos-RNA
Experiments with rodent fibroblasts argue for a role for fos genes in regulating proliferation and 
cell cycle progression. Holt et al (1986) showed that an expression vector containing antisense 
c-fos sequences under the control of an inducible promoter inhibited proliferation of Swiss 3T3 
cells in vitro. This demonstration was supported further by experiments that showed that the 
same antisense-fos vectors inhibit the re-entry of quiescent fibroblastic cells into the cell cycle 
(Nishikura and Murray, 1987). Other groups have shown that the expression of fos in an anti­
sense orientation, in sis (Mercola et a/., 1988) and ras transformed cell lines (Ledwith et a/., 1990) 
could reduce their proliferative potential and induce reversion of morphological transformation.
1.4.1.2. Inhibition of cellular proliferation by microinjection of Fos-specific antibodies 
Microinjection of antibodies that recognised a conserved region of Fos proteins were found to 
inhibit DNA synthesis in quiescent cells stimulated with serum to re-enter the cell cycle, and also 
in asynchronously growing cells (Riabowol etai., 1988).
Detailed studies with a variety of different antibodies suggested that the regulation of cell 
cycle progression by Fos and Jun proteins might be of a more complex nature (Kovary and 
Bravo, 1991a; 1991b). These experiments demonstrated the requirement for Jun proteins in cell 
cycle progression of Swiss 3T3 cells in tissue culture. JunB is the predominant Jun protein in 
Swiss 3T3 cells. Its induction by serum is not attenuated and it is more stable compared to Fos 
proteins (Kovary and Bravo, 1991a). Antibodies against Fos, Fra-1 and FosB proteins were less 
effective in inhibiting DNA synthesis following serum stimulation, but if all the Fos-specific 
antibodies were combined then an additive effect was observed suggesting that individual Fos 
proteins have a redundant role in cell cycle progression. However it should be noted that these 
studies do not explain the role of junB in cell cycle progression thoroughly since junB is a 
negative regulator of c-jun and of AP-1 transcriptional activation (Chiu et al., 1989; Schutte et 
al., 1989b).
31
The Fos-related antigens Fra-1 and Fra-2 are not detected during quiescence but they 
appear to be persistent in cycling and serum-stimulated Swiss 3T3 fibroblasts, and remained at 
high levels after serum-stimulation (Kovary and Bravo, 1992). Immunoprecipitation analysis 
showed that after serum induction c-Jun is complexed with Fra-1 and JunB with Fra-2 proteins
(Kovary and Bravo, 1992) and that these association are stable suggesting a co-operative effect
in the action of Fos and Jun family members in vivo.
1.4.1.3. Cell growth studies with cells that lack c-fos or c-jun
The use of vectors that disrupted the genomic integrity of fos and jun loci made it possible to 
generate embryonic stem (ES) cells that lack one of the members of the AP-1 factor such as c- 
fos (Field et al., 1992; Brusselbach ef al., 1995) and c-jun (Hilberg and Wagner, 1992). These 
knockout ceils are tools in defining the role of AP-1 in cell cycle and cell proliferation.
The proliferative potential of ES fos -/- cells remained unaltered in comparison with wild 
type cells, both in terms of the saturation densities and doubling times. Serum induction of 
quiescent fos -/- cultures showed that they retained the same proliferative potential as the 
parental wild type fos +/+ cells (Field et al., 1992). Also the ES fos -/- cells retained the potential 
to differentiate in vitro in a spontaneous manner as do the wild type ES cells under the same 
culture conditions.
The study of Brusselbach etai. (1995) showed that proliferation and serum re-entry into 
the cell cycle was very similar between fos +/+ and fos -I- ES cells and fibroblastic-like cells. 
Analysis of proliferation using growth curves showed that there was no difference between fos 
+/+ and fos -/- fibroblasts. FACS analysis of these cell lines showed that cell cycle progression 
and re-entry was not impaired in the two different cell lines. Other important parameters for AP-1 
activation such as DNA-binding to the TRE, and TRE-dependent trans-activation in transfection 
assays showed that there was no major difference in between fos-/- and wild type cells.
Hilberg and Wagner (1992) generated ES cells that lacked both alleles of the c-jun 
protooncogene. These cells had similar proliferative potential to wild type ES cells and their 
morphology and differentiation ability remained the same. In terms of the AP-1 gene expression 
of the jun, junB and c-fos genes after serum stimulation, these were largely unaffected, except 
the c-jun message which was reduced by 2 to 5-fold. The c-jun -I- ES cells also induce tumours 
poorly upon injection into syngeneic mice, compared to the wild type ES cells that form tumours
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efficiently. This evidence suggested that the c-jun gene is necessary at some stage of 
tumourigenesis by ES cells after injection into recipient animals but not for cell proliferation.
All this evidence converge upon the idea that the main AP-1 components, c-fos and c- 
jun, are not necessary for cell proliferation in vitro. This is in contrast with the previously 
published evidence that suggests that cell proliferation is indeed affected when the expression 
(Holt et al., 1986) or the function of fos and jun is impaired in vitro (Riabowol et al., 1988; Kovary 
and Bravo, 1991a, 1991b).
The evidence from the targeted disruption of fos and jun genes in vivo gave a more 
direct role for these genes in development and differentiation, and suggested that they are 
essential for mouse development. Targeted disruption of c-jun in vivo causes embryonic lethality 
(Johnson et al., 1993) and the absence of fos is associated with bone defects (Wang et al., 1992; 
Johnson etai., 1992).
1.4.2. In vivo models of fos and the development of oncogenesis
1.4.2.1. Studies with fos transgenic mice
The generation of transgenic mice carrying c-fos genes (Ruther et al., 1987) under a 
regulatable metallothionein promoter (MT) (Ruther et al., 1985) showed that high levels of fos 
could be induced in different cellular backgrounds. These mice surprisingly did not develop any 
neoplasms in their bones. The targeted expression of a c-fos transgene in mice under a H2-Kb 
MHC promoter impaired the function of the immune system but again no lymphoid or thymic 
neoplasms appeared (Ruther efa/.,1988).
Wang et al. (1991) used ES cells transfected with a MT c-fos transgene to generate 
chimeric animals. High expression was maintained during development and these mice 
developed chondrogenic sarcomas irrespective of the degree of the chimerism. An important 
observation was the specificity of the tumour formation, since the MT fos transgene was 
expressed in other tissues apart from bone, but these tissues did not develop tumours. These 
results contrast with findings of the same group (Ruther et al., 1989), since they showed the 
main target cell is the osteogenic progenitor cells and not chondroblasts. However in the study 
of Wang etai. (1991) the fos genes were expressed ectopically early in development. This might 
reflect the potency of fos in regulating a different progenitor cell that leads to chondroblastic
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tumours. These studies show that when a fos gene is expressed in early development it can 
transform specific cell types which apparently appear to be distinct from the usual targets of the 
v-fos oncogene.
When c-fos is expressed under the control of an MHC H-2K13 promoter with a 3’ FBJ- 
MuSV LTR, then osteosarcomas could be induced with a short latency (Grigoriadis etai., 1993). 
These tumours grew rapidly into large masses in all bones with evidence of osteoblastic activity. 
The main cell types present in these tumours are osteoblasts and chondrocytes that stain rich 
for alkaline phosphatase. These neoplasms showed a large degree of neovascularisation and 
are highly invasive with an increased mitotic index. Cell lines established from these tumours 
exhibited transformed fibroblastic morphology and displayed the characteristics of osteoblastic 
gene expression. The same transgene was employed with the fosB or c-jun genes but in this 
case no osteosarcomas were formed (Grigoriadis et al., 1993). This however is in contrast to 
previous evidence that argue for a transforming role for the fosB gene when expressed under 
the transcriptional signals of the FBR-MuSV LTR (Schuermann etai., 1991).
1.4.2.2 Oncogene co-operation models in studies with fos oncogenes
The mouse epidermis has been used successfully to model the role of oncogenes in neoplastic 
development (Balmain et al., 1984; Quintanilla et al., 1986; Brown et al., 1986). Greenhalgh and 
Yuspa (1988) suggested that there is a role for the fos oncogene in the generation of epidermal 
tumours. Introduction of the v-fos oncogene into papilloma cell lines expressing an activated Ha­
ras oncogene made them tumourigenic when injected into nude mice. Similarly papilloma cell 
lines expressing E1A or myc oncogenes did not form tumours, specifying the role of v-fos in the 
generation of these epidermoid malignancies. These investigators postulated that tumours could 
have formed through a co-operation event, between c-Ha-ras and a nuclear oncogene with the 
properties of a transcriptional activator, such a the v-fos oncogene. Later they reported that this 
co-operation was actual when they found that injected keratinocytes infected with v-ras and v-fos 
MuSV’s into nude mice induced the formation of squamous cell carcinomas (Greenhalgh et 
al., 1990).
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Taken together, these studies suggested a role for the fos oncogenes and AP-1 family 
members in experimental models of oncogenesis and a role for ras and fos oncogenes in this in 
vivo model of oncogene co-operation.
1.4.2.3. In vivo models with fos and Jun knockout m ice: implications for malignancy 
Disruption of c-fos in mice by homologous recombination (Johnson et al., 1992; Wang et 
al., 1992) resulted in mice which showed retarded growth and a low survival rate (Johnson et 
al., 1992). Additionally disruption of the fos gene resulted in abnormalities in the formation of 
bone, reduction of the proliferating cartilaginous tissues and hypertrophy of the chondrocytes 
(Wang et al., 1992). An important feature of the mice was the impaired function of the 
haemopoetic cells as demonstrated by FACS analysis.
Cells from fos -/- mice were used as a tool to investigate the role of the AP-1 family 
members in tumourigenesis. In vitro experiments with 3T3-like cells from fos -I- mice (Hu et 
al., 1994) showed that the growth rates of these cell lines are not substantially different from 
parental fos +/+ cells, arguing for a redundant role of AP-1 components in cellular proliferation 
in contrast to previously published observations (Holt et al., 1986; Nishikura and Murray, 1987; 
Riabowol et al., 1988). In fos -I- cells the expression of AP-1 members, such as fra-1 and fra-2 
as well as jun family members showed variations after induction by growth factors and phorbol 
esters. The levels of the AP-1 binding activity did not show variations between the fos +/+ and 
the fos-/- cells indicating that fos has a questionable role to the in vitro AP-1 binding activity to 
the TRE. Gene expression studies showed that stromelysin, a tumour matrix degrading 
metalloprotease (Matrisian et al., 1986; Kerr et al., 1988), was absent and induced to very low 
levels by phorbol ester. Transformation studies with fos -I- cells showed that there was no 
significant difference in the focus formation induced by oncogenes upstream of AP-1 such as v- 
raf, v-src and v-ras, compared to the wild type fos +/+ cells. In fact in all cases there was a 
reduction in focus formation.
It was also suggested that the c-fos gene is an essential factor in the development of 
epidermal neoplasia, as shown in the chemically-treated mouse epidermis (Saez etai., 1995). In 
these studies, fos -I- mice were treated with phorbol esters which resulted in the formation of 
epidermal tumours. The c-fos -I- cells from these mice when transfected with a virus carrying a
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ras oncogene and grafted into the skin of recipient animals, did not lead to tumour formation. 
This suggested that the fos null mutation impairs the initiating signals from the viral ras 
oncogene and that c-fos is required for tumourigenicity in vivo and that AP-1 lies downstream of 
the ras oncogene in this signalling pathway.
1.4.2.4. Co-operation models from the cells of jun knockout mice
Evidence obtained with cells from c-jun -/- mice (Johnson et al., 1993; Johnson et al., 1996) 
demonstrate that there is an important role for c-jun protooncogene in pathways downstream of 
ras protooncogene, c-jun -I- embryonic fibroblasts are unable to grow in the presence of growth 
factors, suggesting a blockage of the growth factor -ras pathway, due to lack of the c-jun 
protooncogene (Johnson et al., 1993). Johnson et al. (1996) introduced a SV40 T Antigen to 
restore the proliferation capacity of the jun -/- cells. The c-jun -/- cells are unable to grow in soft 
agar even after the transfection of a c-jun gene or after transfection of a retrovirus carrying a ras 
oncogene. Introduction of both ras and jun oncogenes restored the ability of the cells to grow in 
soft agar and to form tumours in mice (Johnson etai., 1996).
The introduction of a ras gene with junB of junD suprisingly led to the formation of 
tumours but in the case of the junD no colony formation in soft agar appeared. This suggests 
that the absence of the c-jun protooncogene can be rescued by other jun-family members in 
tumourigenicity assays.
Taken in consideration that previously junB and junD are considered to be negative 
regulators of transformation and AP-1 activity (Chiu et al., 1989; Schutte et al., 1989b; Pfarr et 
al., 1994) these results are of a conflicting nature and the reason for the oncogenic ability of junB 
and junD remains to be explained.
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Aims of this Thesis
There is evidence that the c-jun protooncogene is required for oncogenesis in vivo and 
morphological transformation in vitro. Therefore the trans-dominant deletion mutant of c-jun 
protooncogene TAM-67 was tested in its ability to inhibit AP-1 activity and subsequently v-fos 
transformation. While Interested in the effect of TAM-67 in fos-induced transformation we 
decided to extent our investigation by studying elements of upstream signal transduction 
pathways, and their requirement in morphological transformation.
It is established that components of the ras pathway such as Raf-1 (Kolch et a l, 1991; 
Bruder et al., 1992) and MEK-1 (Pages et al., 1993; Cowley et al., 1994) are involved in a 
signalling pathway leading to AP-1 activation. To dissect the role of the constituents of the ras 
pathway in FBR v-/bs-induced transformation dominant negative mutants have been transfected 
into FBR cells. The effect of the Raf-1 and MEK-1 dominant negative mutants in transformation 
and anchorage independence is discussed.
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CHAPTER 2. MATERIALS
2.1 Plasmids
pSV2neo provided by Dr. Liz Black, Beatson Institute
pCMV-TAM-67 (Brown et al., 1993) provided by Dr. M.J. Birrer, NIH, USA
pBABE puro (Cowley et al.,1994) provided by Prof. C.J. Marshall, Institute for Cancer
Research, London
pBABE puro MEK-1 (Cowley et al.,1994) provided by Prof. C.J. Marshall, ICR, London 
pBABE puro MEK-1 A221 (Cowley et al.,1994) provided by Prof. C.J. Marshall, ICR, 
London
pEXV NA Raf-1 (Schaap et al., 1993) provided by Prof. C.J. Marshall, ICR, London
2.2. Cell Culture Materials
2.2.1. Cell Culture Plasticware
Source: FALCON, Becton Dickinson Labware, Piymouth, Devon, England.
10 mm cell culture dishes 
30mm cell culture dishes 
24 well plates 
12 well plates 
6 well plates
Source: Nunc, Rocksilde, Denmark 
Nunc cryotubes
2.2.2. Cell Culture Solutions
Source: Fisher Scientific UK, Ltd, Loughborough, Leicestershire, UK 
Dimethyl Sulfoxide
40
Source : GIBCO Europe, Life Technologies Ltd, Paisley, Scotland. 
Geneticin, G418, dessicate 
Gentamycin 10 mg/ml, solution 
L-Glutamine 200mM, solution 
MEM Non-essential amino acids 100X, solution 
Sodium Pyruvate 100mM, Solution 
Trypsin 2,5%, Solution
Source: Oxoid Ltd., Basingstoke, England 
PBS Tablets
Source : SIGMA Co Ltd., Poole, Dorset, England.
10X DMEM, solution 
10X F-10 Ham’s, Solution 
Penicillin, dessicate 
Pyromycin, dessicate 
Streptomycin, dessicate
Source: TCS Biologicals
Foetal Calf Serum
Source: Fluka Chemie, Buchs, CH-9470 
Methylcellulose 64630, dessicate
2.3. Antibodies
2.3.1. Primary Antibodies
Mouse anti-ERK1, Transduction Laboratories, KY, USA.
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Mouse anti-ERK2 (WB 1 : 5000), Transduction Laboratories, KY, USA.
Mouse anti-FAK (WB 1 : 5000), Transduction Laboratories, KY, USA.
Rabbit anti-Fra-1 (WB - 1 : 250), Santa Cruz Biotechnology, CA, USA.
Rabbit anti-Fos [K-25] (WB - 1 : 400), Santa Cruz Biotechnology, CA, USA.
Rabbit anti-c-Jun (WB 1:400), Oncogene Science, UK.
Goat anti-gag MuLV (WB 1 : 1000), Dr Alan Rein, NCI Facility, Frederick, MD, USA. 
Rabbit anti-MAPK [Activated form] (WB 1 : 10000), Promega Corp., Wisconsin, USA. 
Rabbit anti-MEK-1 (WB 1:500), Santa Cruz Biotechnology, CA, USA 
Rabbit anti-MEK-1 [Activated form] (WB 1: 500), New England BioLabs, USA.
Mouse anti-phosphotyrosine [PY-20] (IF 1:100), Affiniti Labs, UK.
Mouse anti-Raf-1 (WB 1: 2000), Affiniti Labs, UK.
[Key : WB : Western Immunoblotting IF : Immunofluorescence]
2.3.2. Secondary Antibodies
Donkey Anti-Rabbit HRP-linked Whole IgG, Amersham, Bucks, England.
Sheep Anti-Mouse HRP-linked F(ab) fragment, Amersham, Bucks., England.
Goat Anti-Mouse FITC-linked, F0257, Sigma, Poole, Dorset, England.
2.4. Chemicals
2.4.1. Isotopes
Source: Amersham International PLC, Amersham, Buckinghamshire, England.
Redivue [y-32P] ATP 3000 Ci/mmol
2.4.2. Chemicals for Molecular Biology
Source: Boehringer Manheim UK Ltd., Lewes, East Sussex, England 
HEPES, dessicate 
Cesium Chloride, dessicate 
DOTAP Transfection Reagent, solution
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Source: Sigma Co Ltd., Poole, Dorset, England.
Ethidium Bromide, solution 10 mg/ml
Source: GIBCO Europe, Life Technologies Ltd, Paisley, Scotland. 
Tris hydroxymethylaminomethane [TRIS], dessicate
2.4.3 General Chemicals
Source: FISCHER Scientific Equipment LtD, Loughborough, England 
EDTA, dessicate 
EGTA, dessicate 
Glucose, dessicate 
Glycine, dessicate 
Hydrochloric Acid 11M, solution 
Paraformaldehyde, dessicate 
Potassium Chloride, dessicate 
Potassium Hydroxide, dessicate 
Sodium Dodecyl Sulfate, desiccate 
Sodium Chloride, dessicate 
Sodium Hydroxide, dessicate
2.4.4. Detergents
Source: Sigma Co Ltd., Poole, Dorset, England 
Nonidet NP-40, solution 
Triton X-100, solution 
Tween-20, solution 
Sodium Deoxycholate, dessicate
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2.4.5. Enzyme Inhibitors
Source: Sigma Co Ltd., Poole, Dorset, England 
Aprotinin, solution 
Benzamidine, dessicate 
Leupeptin, dessicate
Phenyl-Methyl-Sylfonyl-Fluoride (PMSF), dessicate 
Sodium Fluoride, dessicate 
Sodium Pyrophosphate, dessicate 
Sodium Orthovanadate, dessicate
Source: Calbiochem, San Diego, CA, USA
PD 98059, MEK-1-specific inhibitor (dissolved in DMSO)
Source: Dr. David Heimbrook, Merck Co., West Point, PA, USA
L-779 450 Raf-1 kinase-specific inhibitor (dissolved in PBS)
2.4.6. Electrophoresis Reagents
Source:Severn Biotech Ltd., Kidderminster, Worcestershire, England 
30% acrylamide/ 0.8% bisacrylamide solution 
40% acrylamide /1 ,5%  bisacrylamide solution
Source: BDH Ltd, Poole, Dorset, England 
Acrylamide ; ElectranR , dessicate 
bis-Acrylamide; ElectranR, dessicate
Source: Sigma Co. Ltd, Poole, Dorset, England 
TEMED, solution
44
2.4.7. Reagents for Protein determination
Source: Sigma Chemical Ltd. Co, Poole, Dorset, England 
Bichinoninic Acid, solution 
Bovine Serum Albumin, dessicate 
Copper (++), solution
2.5. Membranes, Paper and X-Ray Film
Source: Sigma Chemical Ltd. Co, Poole, Dorset, England 
Paper for pH determination ( pH 1-7, specific)
Source: Whatman International Ltd., Maidenstone,Kent, UK. 
3MM, Chromatography paper
Source: Sartorius, Gmbh, Gottingen, Germany 
Dialysis Tubes
Source: Millipore, UK Ltd, Watford, Hertfordshire, UK
Immobilon-P, Polyvinyl-Difluoride (PVDF) Membrane
Source: Eastman Kodak Co., Rochester, N.Y., USA 
X-Ray Film (XAR-5)
Source: Fuji Photo Co, Ltd., Japan.
X-Ray Film (RX)
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2.6. Molecular Biologicals
2.6.1 Media and Plasticware
Source: Difco Laboratories, Detroit, Michigan 
Agar, Microbiological Grade
Source: GIBCO Europe, Life Technologies Ltd., Paisley, Scotland.
Agarose, dessicate
Agarose, Low Melting Point, dessicate
Source: Boehringer Manheim UK Ltd., Lewes, East Sussex, England.
Ampicillin
Source: Bibby Sterilin Ltd., Stone, Staffs., England.
Bacteriological Dishes
2.6.2 Molecular Weight Markers
Source: Life Tehnologies, Ltd., Paisley, Scotland
Bacteriophage I (Hind III Digested), solution (for DNA agarose gel 
electrophoresis)
Bacteriophage <E>x 174 (Hind III Digested, solution (for DNA agarose gel 
electrophoresis)
Source: Amersham International PLC, Buckinghamshire, UK
Prestained Rainbow MW Markers, RPN 756, solution (for SDS polyacrylamide 
electrophoresis)
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Source: BIO-RAD Labs, CA, USA
Molecular Weight Markers, High Range, solution (for SDS polyacrylamide 
electrophoresis)
2.6.3 Enzymes
Source: GIBCO, Europe, Life Tech., Ltd., Paisley, Scotland 
Restriction Endonucleases and buffers
Source: NBL Northumbria Biochemicals
T4 Polynucleotide Kinase -T4 Kinase and 10X reaction Buffer 
Alkaline Phosphatase - Alkaline Phosphatase and 10X reaction Buffer
2.7. Solvents and Dyes
Source: Fischer Scientific UK Ltd, Loughborough, Leicestershire, UK 
Chloroform 
Butanol 
Formaldehyde 
Isopropanol
Source: J. Burrough (FAD) Ltd., Witham, Essex, England.
Ethanol
Source: Fischer Scientific UK Ltd, Loughborough, Leicestershire, UK 
Giemsa Stain, solution
Source: Sigma Chemical Ltd. Co, Poole, Dorset, England 
Bromophenol Blue, dessicate 
Xylene Cyanol, dessicate
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Source: Sigma Chemical Ltd.Co, Poole, Dorset, England 
TRITC-Phalloidin
2.8. Kits
Source: Amersham International PLC, Amersham, Buckinghamshire, England 
Enhanced Chemiluminescence Reagent, solution
2.9. Growth Factors
Growth factors were provided by Dr. A. Malliri, Dr. Pierre Schembri-Wismayer, Jim O’Prey, and 
Dr. Val Brunton [Beatson Institute], di-butiryl cAMP. EGF, IGF-I, LPA, PDGF-BB, Insulin were 
dissolved in PBS. TPA in DMSO. Their commercial origin is described below : 
di-butiryl cAMP, from Sigma Chemical Ltd.Co, Poole, Dorset, England 
EGF from R&D Systems, Abingdon, OXON, UK 
IGF-I from R&D Systems, Abingdon, OXON, UK 
Insulin from Sigma Chemical Ltd.Co, Poole, Dorset, England 
LPA from Sigma Chemical Ltd.Co, Poole, Dorset, England 
PDGF-BB from Sigma Chemical Ltd.Co, Poole, Dorset, England 
TPA from Sigma Chemical Ltd.Co, Poole, Dorset, England
48
CHAPTER 3 METHODS
49
CHAPTER 3. METHODS
3.1. Cell culture
3.1.1. Cell lines
208F is a thioguanine derivative of Rat-1 cells (Quade, 1979). FBR cells are 208F cells 
transformed with the FBR v-fos oncogene under the control of the MuLV LTR.
3.1.2. Cell maintenance and storage
All cell lines were grown in DMEM supplemented with 10% FCS (500ml dd H20, 50 ml DMEM, 5 
ml NaPuryvate 100mM, 25 ml Sodium Bicarbonate, 5 ml 200mM Glutamine, 2.5 ml Gentamycin 
10mg/ml). Cell lines were trypsinized in 1 ml of PE/trypsin and resuspended in DMEM with 10% 
FCS and divided to analogous number of dishes cells. Cell lines were kept in liquid Nitrogen for 
long term storage. For such a purpose cell lines were washed once with PBS and 1 ml of 
PE/trypsin solution was added to the plate. After trypsinization cells were centrifuged for 5 
minutes at 1,000 g at room temperature, the tryspin-containing medium was aspirated and 1 ml 
freezing solution (90% FCS, 10 % DMSO) was added, mixed and the aliquot placed to a 2ml 
Nunc tube and put to - 70 °C. After 2-4 days the aliquots were placed in liquid nitrogen barrels. 
To recover cells from nitrogen, the nunc vials were thawed in 37 °C and resuspended in DMEM 
supplemented with 10% FCS, centrifuged for 5 minutes at 1,000 g at room temperature and the 
DMSO-containing media were aspirated. Immediately after this step the cells were resuspended 
in DMEM supplemented with 10% FCS and plated to 10 cm dishes.
3.1.2. Growth in semi-solid medium
Methylcellulose was used to prepare semi-solid medium. Initially 3g of methyllcellulose were 
mixed with 200 ml H20. The solution was autoclaved and after sterilisation it was left to cool in 
room temperature and then stirred for 24 hours at 4 °C with the use of a mangetic stirrer. After 
methylcellulose was thoroughly mixed it was supplemented with the following:
22 ml 10X F10 Ham’s Medium
4ml MEM minimal essential amino acids
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4ml 0.1 M NaPyruvate 
5ml Na Bicarbonate 
20ml FCS
5 ml 200mM Glutamine
For each experiment aliquots of 2x104 cells were mixed with 10-14 ml of semi-solid 
medium and plated into duplicate or triplicate 10cm bacteriological grade dishes (Bibby, Sterilin). 
Fresh medium was added every 4 days. Cells were allowed to grow and colonies were counted 
after 3-4 weeks.
3.1.4. Immunofluorescence of actin stress fibres
Immunofluorescence was performed according to Nobes et al. (1994). 2x104 cells were seeded 
on 16mm coverslips in 12-well plates for 48 hours. After the cells formed monolayers they were 
deprived from serum as following: the wells were washed three times with PBS and medium 
was changed to DMEM supplemented with 0.1 % FCS. The cultures were remained quiescent 
for a period of 7 days. After 7 days the cells were treated with agonists as long as required and 
fixation was performed by adding 3% Paraformaldehyde pH 7.0 for 20 minutes at 37 °C. After 
this step the coverslips were washed once with PBS, permabilisation buffer (PBS, 0.01% Triton 
X-100) was added for 5 minutes at room temperature. This step was repeated once and then 
samples were incubated with PBS containing Rhodamine-labelled Phalloidin for 45 minutes in 
an orbital shaker at room temperature covered with foil. After staining was completed the wells 
were washed three times in PBS over 5 minutes at room temperature and mounted in glass 
slides with Vectashield reagent (Vector Labs, Burlingame, CA, USA), sealed with nail polish and 
processed for fluorescence microscopy.
3.1.5. Immunofluorescence of Focal Adhesion Components
Cells were processed for fixing as in (3.1.4.)and after permabilisation was completed they were 
incubated with a mouse anti-phosphotyrosine antibody (PY-20) in a dilution 1:100 in blocking 
solution (1%FCS, PBS) for 18 hours at 4 °C. After the addition of the primary antibody the wells 
were washed three times with PBS over 5 minutes and incubated with an anti-mouse FITC- 
conjugated antibody in a dilution 1:100 in blocking solution (1%FCS, PBS) for 45 minutes at 
room temperature covered with parafilm. After this stage the samples were washed three times
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with PBS over 5 minutes and the coverslips were transferred to glass slides, mounted with 
Vectashield Reagent, sealed with nail polish, and processed for immunofluorescence.
3.1.5. Preparation of conditioned media
Cells were passaged in DMEM supplemented with 10% FCS and grown into subconfluence. 
Then the growth medium was removed and the plates were washed 3 times with PBS. The 
medium was changed to serum-free DMEM and the dishes were incubated in a tissue culture 
incubator at 37 °C for 48 hours. After this 48 hours the medium was harvested, filtered with a 2.5 
micron filter and used for replacing the medium of serum-deprived cultures of FBR and 208f 
cells.
3.2.Recombinant DNA Techniques
3.2.1 Transformation of competent E. Coli
Competent E.coli (DH5a E.Coli, Gibco, Life Tech., Paisley, Sco.) thawed on ice, and 50 jxl 
aliquots were transferred to chilled polypropylene 5 ml Falcon tubes. Approximately 50 ng of 
plasmid DNA was added to the bacteria and the mix incubated on ice for 25 minutes. Then the 
cells heat-shocked for 45 seconds at 42 °C and immediately transferred to ice for 2 minutes. 
After this step 900 \i\ SOC medium (2% Bacto-tryptone, 0.5% bacto-yeast extract, 20 mM 
Glucose, 10 mM NaCI, 10 mM MgCI) was added and the beacterial solution was incubated for 1 
hour in an orbital shaker at 37°C. After completion of this step 50 jxl of bacterial solution was 
plated to bacteriological grade dishes (Bibby Sterilin) containing 1.5% Agar and the appropriate 
selection antibiotic. The plates were incubated in an inverted position for 18 hours at 37°C. 
Colonies were picked from the plates using an inoculating loop and transferred to 20 ml 
Universal tubes (Bibby Sterilin) containing L-Broth. The cultures were incubated overnight at 
37°C in a orbital shaking incubator for preparation of bacterial samples for small and large scale 
analysis of DNA.
3.2.2 Small scale plasmid DNA preparation
1ml of bacterial culture was pelleted in a eppendorf microfuge at 12000 g for 5 minutes at 4°C. 
The supernatant was discarded and the pellet was resuspended in 200 fxl of 2 mg/ml lysozyme
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in Solution I (50mM Glucose, 25 mM Tris pH 8.0, 10 mM EDTA pH 8.0). The mix was vortexed 
briefly and placed for 5 minutes at room temperature. Then 400 fxl Solution II (0.2 M NaOH, 1% 
SDS) was added to the tubes and the tubes were placed on ice. Then 300pJ 3M NaAc pH 4.8 
was added, the precipitate was vortexed immediately and the tubes were incubated for 10 
minutes on ice. After this step tubes were centrifuged in a microfuge at 12000 g for 5 minutes at 
4°C. 800 ml of the supernatant was transferred to a new eppendorf tube and mixed with 480 p,l 
of isopropanol and the tubes were placed in for 1 hour-70°C to facilitate the precipitation of 
plasmid DNA. After this step tubes were centrifuged in a microfuge at 12000 g for 20 minutes at 
4°C. The supernatant was discarded and the pellet was washed with 1 ml of 70 % v/v ethanol, 
the supernatant was discarded and the pellet was lyophilised for 20 minutes under vacuum. The 
DNA plasmid pellet was resuspended in 1X TE buffer pH 8.0 and stored at 4°C.
3.2.3. Large scale plasmid DNA preparation
Large flasks with 500 ml of L-Broth were inoculated with 0.5 ml from cultures of bacterial stocks 
and incubated for 18 hours in an orbital shaker, at 37°C. Cultures were divided into three 
Beckman 500ml bottles and centrifuged at 5000 g for 5 minutes at 4°C in a Beckman J2-21 
centrifuge. The supernatant was discarded and the pellet was resuspended in 20 ml of cold 
Solution I (50mM Glucose, 25 mM Tris pH 8.0, 10 mM EDTA pH 8.0). The bottles were placed 
on ice 2 ml of lysozyme (10mg/ml lysozyme in 10 mM Tris pH 8.0) was added, 80 ml of Solution 
II (0.2 M NaOH, 1% SDS) were added to the samples and the lysate was mixed by inversion 
carefully and incubated at room temperature for 10 minutes. After this step 30 ml of cold 
Solution III (60ml 5M Potassium Acetate, 11ml Glacial Acetic acid, 28 ml H20  28ml) was added 
and the lysate was mixed vigorously, the samples were incubated on ice for 10 minutes and 
centrifuged at 5000 g for 15 minutes at 4°C in a Beckman J2-21 centrifuge . The supernatant 
was filtered through gauge, 0.6 vol. of isopropanol was added to the filtered solution, the solution 
was mixed well and left for 10 minutes at room temperature. Then the solution was centrifuged 
at 5000 g for 15 minutes in a Beckman J2-21 centrifuge. After centrifugation was completed the 
supernatant was removed very carefully and the pellet was washed with 70 % Ethanol (v/v) 
twice. The pellet containing the plasmid DNA of interest was dried at the 37°C in a roller bottle 
tissue culture incubation cabinet.
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3.2.4 Purification of plasmid DNA with CsCI ultracentrifugation
The dried pellet from the large scale of plasmid DNA preparation was resuspended in 12 ml of 
1X TE Buffer pH 8.0. and 12.9 g CsCI was added to the pellet. 0.8 ml of 10mg/ml EtBr stock 
solution were added for every 10 ml of DNA solution. Optical density was adjusted to 1.39 with a 
densitometer, samples were aliquoted to polycarbonate Beckman tubes and centrifuged in a 
Beckman TL-100 ultracentrifuge in a TLA 100.3 rotor at 300000 g for 20 hours at 20°C. The 
following day plasmid DNA was aspirated from the Beckman tubes under UV light using a 18 1/2 
gauge needle. EtBr present in the plasmid solution was extracted 3 times with CsCI-saturated 
isopropanol. The DNA in solution was dialysed against against 700-800 ml of 1X TE Buffer pH
7.4 for 18 hours at 4°C, with 3 or 4 changes of the buffer, using a dialysis bag (Sartorius Gmbh, 
Gottingen, Germany). After dialysis completed DNA solution volume was measured and 
precipitated with 10% 3M NaAc pH 4.8 and 2.5 volumes of 100% ethanol. The mix was 
centrifuged at 7000 g for 10 minutes at room temperature in a Beckman J2-21 centrifuge using. 
The supernatant was discarded and the plasmid DNA was washed twice with 70 % (v/v) 
Ethanol. Plasmid DNA was dried under vacuum for 10-20 minutes and resuspended in 50-100 l^ 
of TE Buffer pH 8.0.
3.2.5 Restriction analysis of plasmid DNA
To identify the size of plasmid DNA after small and large scale preparations, restriction digests 
analysis was carried out. Digests of the plasmid DNA was performed as following: 250 ng - 500 
ng of DNA was incubated with 10 Units of a restriction endonulease in a final volume sufficient to 
dilute the enzyme volume ten times, at 37° C for 1 hour. Digestion products were separated in a 
0.8 % agarose gel for 1-2 hours at 80 volts. Fragments were visualised using a UV 
transilluminator.
3.2.6. Plasmid-DNA Transfections
Transfections were performed using the DOTAP lipofection protocol [Boehringer Manheim] with 
minor modifications.
Cell were plated 48 hours before transfection at 10 cm dishes. To prepare the 
transfection solution two 2ml nunc tubes containing the following were used:
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1) 200jxl of HEPES buffer solution and 50 nJ of DOTAP solution and
2) 250 [xl of HEPES buffer solution and 5-10 plasmid DNA.
Both solutions were mixed and the mix was incubated for 10 min at room temperature. The 
transfection mix was added directly to the culture dishes. After 24 hours the cells were divided to 
four 10 cm dishes and incubated another 24 hours at 37 °C. Then media aspirated and replaced 
with fresh DMEM supplemented with 10 % FCS plus the selection antibiotic.
After approximately 3-4 weeks of selection with G418 colonies appeared and cell clones 
were collected from the 10 cm dishes with sterile steel cylinders. To isolate colonies the dishes 
were washed carefully once with PBS, steel cylinders were attached to sterile vacuum grease, 
placed on the colonies, trypsin was added (50-80 nl) and the dishes were incubated for 15 min 
at 37°C. Clones were isolated by pipetting the trypsin solution and plated at 24 well plates with 
DMEM supplemented 10% FCS plus the selection antibiotic. Clone growth were monitored daily 
and when a sufficient number of viable cells was present the cells were trypsinized and 
transferred to a 6 well plate. The individual cell clones were expanded and freezed in Liquid 
Nitrogen.
3.3. Biochemical Methods
3.3.1 Preparation of lysates from tissue culture cells
The protocol was provided by Dr. Liz Black (Beatson Institute for Cancer Research). Following 
appropriate culture conditions cell monolayers were washed twice with ice-cold PBS and 80-100 
[xl of lysis buffer (20 mM Hepes, 5mM EDTA, 10mM EGTA, 5 mM NaF, 1 mM DTT, 0.4 M KCL, 
0.4% Triton-X100, 10% Glycerol, 5 jxg/ml leupeptin, 1mM PMSF, 1mM Sodium Orthovanadate, 
10mM |3-Glycerophosphate, 1mM Benzamidine, 5 ^g/ml Aprotinin) was added immediately to 
the monolayer. Cells were scraped with disposable cell scraper (Costar), the lysate was loaded 
to an eppendorf tube, samples were incubated on ice for 20-30 minutes and cleared by 
centrifugation at 12000 g in an eppendorf microfuge for 20 min at 4°C. The supernatant which 
contains the detergent-soluble fraction which was measured with the Bichinoninic Acid method. 
If the samples were not used immediately they were frozen in a dry ice/ethanol bath and lysates 
were stored in -70°C until use.
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3.3.2. Determination of protein concetrations
Protein concentrations were determined using the Bichinoninic Acid method as following: an 10 
\i\ aliquot of protein soluble fraction prepared as in 3.3.1. was mixed with 200pil of bichinoninic 
solution (50 vol bichinoninic acid/1 vol 4% CuS04) in 96 well tissue culture plates and incubated 
for 45 minutes at 37°C in a tissue culture incubator. Absorbance was measured at 590 nm 
wavelength in a Dynatech MR.7000 Spectrophotometer. The standard curve consists of 6 BSA 
standards (80, 100, 400, 800, 1000, 2000 fig/ml BSA/H20  solutions).
3.3.3. Dephosphorylation of proteins in cell lysates using Alkaline Phosphatase
Protein concentration in cell lysates was determined and 50-100 fig of cell lysate was incubated 
with 20 U Alkaline Phosphatase and 10X dephosphorylation buffer for 2 hours at 37°C 
(Lallemand et al., 1997). The reaction was stopped with the addition of 2X SDS sample buffer 
(62.5 mM Tris pH 6.8, 2% SDS, 10% Glycerol, 0.1% Bromophenol blue, 4% p-Mercaptoethanol) 
the samples were boiled for 5 minutes at 100°C and loaded onto a 10% SDS-Polyacrylamide 
gel.
3.3.4. SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)
For SDS-polyacrylamide gel electrophoresis an ATTO assembly apparatus and 2mm-thick glass 
plates were used. For 1 such SDS-PAGE gel of 2mm thickness the following solutions were 
used:
10% SDS-PAGE Resolving Gel 
30% Acrylamide/ 0.8% Bisacrylamide 
4X RGB (1.5 M Tris, 0.4% SDS pH 8.8) 
ddH20 
10% APS 
TEMED
12 ml
9 ml (RGB : Resolving Gel Buffer) 
15 ml 
360 fil 
36 fil
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7.5% SDS-PAGE Resolving Gel
30% Acrylamide/ 0.8% Bisacrylamide 9 ml
4X RGB (1.5 M Tris 0.4% SDS pH 8 .8 ) 9 ml (RGB : Resolving Gel Buffer)
ddH20 18 ml
10% APS 360 m-I
TEMED 36 \i\
5% SDS-PAGE Stacking gel
30% Acrylamide/ 0.8% Bisacrylamide 2 ml
4X SGB (0.5 M Tris, 0.4% SDS pH 6.8) 3 ml (SGB : Stacking Gel Buffer)
ddH20 7 \i\
10% APS 200 [xl
TEMED 20 \i\
First the resolving gel buffer/Acrylamide mix was poured into the space between the plates up to 
the marked line on the plastic apparatus. Then H20-saturated butanol with was layered over the 
gel solution and the gel was left to set at room temperature. When gel was set the layer of H20- 
saturated butanol was washed extensively with water, the stacking gel solution was poured over 
the resolving gel and a 2mm-thick comb was inserted quickly and the gel was let to set at room 
temperature. After polymerisation was completed the comb was removed and the gel 
transferred to a gel tank containing 1X SDS-PAGE Running buffer (50 mM Tris, 1% Glycine, 
0.1% SDS). Protein was quantified as in 3.3.2. and samples were mixed with 2X SDS sample 
buffer (62.5 mM Tris pH 6.8, 2% SDS, 10% Glycerol, 0.1% Bromophenol blue, 4% p- 
Mercaptoethanol), boiled for 5 min at 100°C, cooled briefly on ice, and loaded onto the gel. An 
LKB powerpack (Bromma, Sweden) was used and gels were run overnight at 45 volts.
3.3.4.1. Low-Bisacrylamide SDS Polyacrylamide Gel Electrophoresis
This protocol was provided by Bill Clarck (Beatson Institute for Cancer Research). For the 
detection of phosphorylated forms of MEK-1 with a phosphospecific antibody a 30% low bis- 
Acrylamide solution in SDS-polyacrylamide electrophoresis was used. The low bis-Acrylamide
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solution contains 0.2% instead of 0.8% bis-Acrylamide. Low bis-Acrylamide containing gels have 
been used previously to separate phosphorylated proteins in their different isoforms by SDS- 
polyacrylamide gel electrophoresis (Marshall and Leevers, 1995). The solution was prepared in 
thefume hood to prevent Acrylamide and bis-Acrylamide toxicity and kept not more than two 
weeks at 4 °C due to the instability of its components.
SDS-PAGE, transfer to PVDF membranes and western immunoblotting was carried out 
as stated in 3.3.4., 3.3.5. and 3.3.6.1.
3.3.5. Semi-Dry Transfer of SDS-PAGE gels onto PVDF Membranes
After electrophoresis was completed the two plates were separated and the gel that remained in 
the surface of the one plate was submerged into Dry Blot Buffer (1X DBB: 60mM Tris, 50 mM 
Glycine, 1.6 mM SDS, 20% Methanol v/v). The Polyvinylidene Di-Fluoride membrane (PVDF, 
Immobilon-P) was submerged briefly to 100% v/v Methanol, to dd H20 for 3-5 minutes and then 
to 1X DBB. 12 pieces of Whatman paper were cut in a similar size to the size of the gel, and 
submerged into 1X DBB. The assembly of the dry blotter was as following: On the bottom of the 
apparatus six Whatman paper sheets followed by the PVDF membrane the gel and last six 
Whatman papers. The dry blotter was set to 200mA and 20V and electrotransfer proceeded for 
approximately for 1 -2 hours.
3.3.6. Western Immunoblotting
Immediately after transfer the membrane was blocked in blocking solution (PBS, 0.1% Tween- 
20, 5% Nonfat Dry Milk) for 1 -2 hours at room temperature or overnight at 4°C, shaking at an 
orbital shaker. Primary antibodies were incubated were in blocking solution overnight at 4°C 
After 16-18 hours incubation the membranes washed once with blocking buffer (PBS, 0.1% 
Tween-20, 5% Nonfat Dry Milk) for 15 minutes and 2 times with blocking buffer for 5 minutes at 
room temperature. After washes, a secondary Horse Radish Peroxidase-linked antibody (HRP- 
linked) diluted 1:5000 in blocking solution was employed for 1 hour at room temperature. Finally 
the membrane was washed two times with PBST (PBS, 0.1% Tween-20) for 10 minutes each at 
room temperature. The immunoreactive bands were detected with Enhanced 
Chemiluminecence system (Amersham), by submerging the membrane into reagent for 1
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minute followed by different exposures on Fuji RX medical film (FUJI Photo, UK Ltd, London, 
England). Films were developed in a Kodak X-OMAT 480 RA Processor.
3.3.6.1. Western Immunoblotting with phospho-specific antibodies
The western immunoblotting protocol with phospho-specific antibodies was according to the 
published procedure from New England Biolabs with minor modifications. Immediately after 
transfer the membrane was blocked in TBST blocking solution (20 mM Tris pH 7.6, 150 mM 
NaCI, 0.1% Tween-20, 5% Nonfat Dry Milk) for 2 hours at room temperature in a plastic box in 
an orbital shaker. Phospho-specific antibodies against MAP Kinases (ERK1 and ERK2) and 
MEK-1 were used in 1:10000 and 1:1000 respectively and incubated in TBST-5%BSA buffer (20 
mMTris pH7.6, 150 mM NaCI, 0.1% Tween-20, 5% BSA) at 4°C. After 16-18 hours incubation 
the membranes were washed 3 times with TBST (20 mM Tris pH 7.6, 150 mM NaCI, 0.1% 
Tween-20) for 5 minutes each at room termperature and secondary HRP-linked antibody was 
added diluted 1:5000 in TBST blocking solution (20 mM Tris pH 7.6, 150 mM NaCI, 0.1% 
Tween-20, 5% Nonfat Dry Milk). Incubation with the secondary antibody was carried for 1 hour 
at room temperature. Then the membrane was washed three time with TBST for 5 minutes at 
room temperature. The immunoreactive bands were detected as in 3.3.6.
3.3.6.2. Anti-phosphotyrosine Immunoblotting
After transfer the membrane was blocked in TBST-3%BSA blocking solution (20 mM Tris pH 
7.6, 150 mM NaCI, 0.1% Tween-20, 3% BSA) for 1 hour in a plastic box shaking in an orbital 
shaker at room temperature. The mambrane was incubated with PY-20 mouse monoclonal anti- 
phosphotyrosine serum was diluted 1:1000 or 1:3000 depending on the experiment in TBST- 
3%BSA solution for 1 hour at room temperature. After incubation the membrane was washed 3X 
at room termperature with TBST 10 minutes each, and secondary HRP-linked antibody (anti­
mouse 1:5000) was added diluted in TBST-3%BSA blocking solution. Incubation was carried out 
for 1 hour at room temperature. Finally the membrane was washed three times for 10 minutes 
each with TBST at room temperature. The immunoreactive bands were detected as in 3.3.6.
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3.3.7. Reprobing PVDF Membranes
For using the membranes second time the following protocol was used. The membrane was 
incubated in western pH 2.5 strip buffer (0.2 M Glycine, 1% SDS) for 1-2 hours at room 
temperature shaking at an orbital shaker, washed three times with TBST (20 mM Tris pH 7.6, 
150 mM NaCI, 0.1% Tween-20) 20 minutes each at room temperature, shaking at an orbital 
shaker and incubated in blocking solution according to each protocol. Western immunoblotting 
was carried out depending on the nature of the primary antibody.
3.3.8. Immunoprecipitation and ERK Kinase assay
The protocol was provided by Dr. Walter Kolch (Beatson Insitutte for Cancer Research). 10cm 
dishes were lysed in 1 ml of ice-cold ERK lysis buffer (20 mM Tris pH 7.4, 150 mM NaCI, 2 mM 
EDTA, 1% Triton X-100, 1 mM PMSF, 1 mg/ml leupeptin, 5 mg/ml Aprotinin, 1mM Benzamidine, 
1 mM sodium orthovanadate, 10 mM p-glycerophosphate, 2 mM sodium fluoride, 2 mM sodium 
pyrophosphate) and the lysates were cleared by centrifugation at 12000 g for 10 minutes at 4°C. 
The supernatant was transferred to a new eppendorf tube and protein concentration was 
determined as in 3.3.2. 1000 pig of soluble lysate was used per one immunoprecipitation 
reaction.
Gamma-Bind Plus beads were used for immunopreciptation (Pharmacia). The beads 
were washed three times with each 0.8 ml ice-cold ERK lysis buffer and aliquots of 25 nl of 
beads were adjusted to 200 pil with ERK lysis buffer and mixed with 5 pi! of ERK-1 anti-serum or 
with control serum for each immunoprecipitation reaction. The 800 pil of lysate was mixed with 
the 200 pil of beads and the reaction mix was incubated rotating for 16-18 hours at 4°C.
The immunopreciptates were washed three times with ice-cold ERK lysis buffer, three 
times in ice-cold RIPA buffer supplemented with inhibitors (20 mM Tris pH 7.4, 150 mM NaCI, 
1% Triton X-100, 0.5 % Sodium Deoxycholate, 0.1% SDS, 1 mM sodium orthovanadate, 10 mM 
p-glycerophosphate, 2 mM sodium fluoride, 2 mM sodium pyrophosphate) and 2 times with ice- 
cold kinase buffer (20 mM Tris pH 7.4, 20 mM NaCI, 10 mM MgCI2) and the volume of each 
sample was adjusted to 25 pil with kinase buffer. The reaction was initiated by adding of 6 pig of 
MBP, 5 piCi of [y-32P] ATP and 6 jxM ATP, per sample. Kinase reactions were incubated for 30
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minutes at 37 °C. The reactions were terminated with 20 [xl of 2X SDS sample buffer, boiling 5 
minutes at 100 °C and the samples were separated by 10% SDS-Polyacrylamide gel 
electrophoresis. After electrophoresis the proteins were transferred onto PVDF nitrocellulose 
membranes using Towbin Transfer.
To verify the efficence of the immunoprecipitation the membrane was immunoblotted 
with an the anti-ERK-1 serum to determine that equal levels of the enzyme were isolated 
(3.3.6.).
3.3.8.1. Transfer of SDS-PAGE gels in Towbin Solution
This method is carried at 4 °C overnight. The PVDF membrane was submerged to 100% 
Methanol, to dd H20 for 2-5 minutes and was immersed to Towbin transfer buffer pH 8.0 (25mM 
Tris, 192 mM Glycine, 20% Methanol). Four pieces of Whatman paper were cut in a larger size 
than the size of the gel, submerged to transfer buffer briefly, and placed two on the positive side 
of the tank and two in the negative. Then the membrane was placed in the and the gel in the. 
The assembly was placed in the tank (Bio-Rad Labs, CA, USA) and the proteins were 
transferred electrophoretically at 30mA.
After 12-18 hours of transfer the papers were separated from the membrane and the 
gel. The gel was discarded in a radioactive waste bin and the membrane was wrapped 
immediately in Saran Wrap in order not to dry, and exposed using intensifying screens at -70 °C 
for various lengths of time.
3.3.9. Immunoprecipitation and FAK anti-phosphotyrosine immunoblotting 
Quiescent or stimulated FBR or 208F cultures were washed twice with ice-cold PBS, placed on 
ice and 100 jxl of lysis buffer (20 mM Hepes, 5mM EDTA, 10mM EGTA, 5 mM NaF, 1 mM DTT, 
0.4 M KCL, 0.4% Triton-X100, 10% Glycerol, 5[xg/ml leupeptin, 1mM PMSF, 1mM Sodium 
Orthovanadate, 10mM p-Glycerophosphate, 1mM Benzamidine, 5 jxg/ml Aprotinin) was added 
immediately to the monolayer. Cells were scraped with disposable cell scraper [Costar] and the 
lysate was loaded to an eppendorf tube. The samples were incubated on ice for 30 minutes. 
Then lysates were cleared by centrifugation in an eppendorf microfuge for 20 min at 12000 g in 
4°C. The supernatant protein content was measured with the Bichinoninic Acid method and
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1000 pg of protein was diluted with ERK lysis buffer [3.3.8.] (20 mM Tris pH 7.4, 150 mM NaCI, 
2 mM EDTA, 1% Triton X-100, 1 mM PMSF, 1 mg/ml leupeptin, 5 pg/ml Aprotinin, 1mM 
Benzamidine, 1 mM sodium orthovanadate, 10 mM p-glycerophosphate, 2 mM sodium fluoride, 
2 mM sodium pyrophosphate) to give 800 pi final volume of solution.
Gamma-Bind Plus beads were used for immunopreciptation (Pharmacia). The Beads were 
washed three times, each with 1 ml ERK lysis buffer [3.3.8.] and aliquots of 45 pi of beads were 
adjusted to 200 pi with ERK lysis buffer [3.3.8.] and mixed with 5 pi of anti-FAK serum for each 
corresponding immunoprecipitation sample. The 800 pi of lysate was mixed with the 200 pi of 
beads and the mix was incubated rotating for 16-18 hours at 4°C. Next day the 
immunoprecipitates were washed 4 times with ERK lysis buffer [3.3.8.] and 40pl 2X SDS sample 
buffer was added and the samples were boiled for 5 minutes at 100°C in a boiling waterbath. 
After this step the samples were centrifuged in a eppendorf centrifuge briefly, the supernatant 
was carefully loaded to an 7.5% SDS-PAGE gel, electrophoresed overnight, transferred to 
PVDF membranes [3.3.5. semi-dry transfer] and blotted with the PY-20 anti-phosphotyrosine 
antibody at 1:3000 as in 3.3.6.2.
To verify equal amounts of FAK in the immunoprecipitates the membrane was stripped, washed, 
blocked in blocking solution (PBS, 0.1% Tween-20, 5% Nonfat Dry Milk) and probed with the 
anti-FAK mouse monclonal antibody at 1:5000 diluted in the blocking solution.
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RESULTS
CHAPTER 4. GENERATION OF FBR REVERTANT CELL LINES FOLLOWING 
TRANSFECTION OF THE DOMINANT NEGATIVE MUTANT OF c-jun TAM-67
4.1. The c-jun N-terminus is required for transformation
Full length human c-jun oncogene when it is transcriptionally driven under the strong signals of 
the Mo-MuSV LTR can transform established cell lines such as raf-1 as well as primary embryo 
cells when co-expressed with ras (Schutte e ta i, 1989a; 1989b).
Deletion analysis of c-jun showed that the N-terminus contains a transactivation domain 
(Angel et ai., 1989). A series of different deletion mutants of c-jun was constructed (Alani et 
ai, 1991) and the transactivation potential of these constructs was investigated in transactivation 
assays and in transformation assays. The results of these experiments demonstrated a direct 
correlation between c-y'un-induced transformation and its N-terminal transactivation domain. A 
similar N-terminal deletion mutant of the v-y'tvn oncogene reversed transformation by ras, src, 
Polyoma-mT, and fos oncogenes in tissue culture cells (Lloyd ef a/.,1991). This mutant efficiently 
suppressed transcriptional activation by oncogenes and phorbol esters and reduced the mRNA 
levels of cathepsin L.
These studies prompted us to use a dominant negative deletion mutant of c-jun termed 
TAM-67 to inhibit AP-1 activity in the FBR cells and to determine which attributes of the 
transformed phenotype in FBR cells are due to AP-1 function or which have arisen subsequently 
as a result of independent mutations. The TAM-67 dominant negative deletion mutant of c-jun 
protooncogene is identical to c-jun except that it lacks amino acids 1 to 123 which encode for 
the c-jun N-terminus transactivation domain. TAM-67 has been shown previously to suppress 
transformation by SV40 and ras and by ras and phorbol esters (Brown et ai., 1993 ; Brown et 
ai., 1994). This signifies a role for this truncated dominant deletion negative mutant of c-jun in the 
regulation of oncogenic transformation by the AP-1 transcription factor.
4.2. Transfection of TAM67 into FBR and to 208F fibroblasts
Lipofection was used to introduce p-CMV TAM-67 DNA into FBR and 208F cells. This vector 
contains the cDNA encoding the C-terminus of the c-jun protooncogene under the transcriptional
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signals of the cytomegalovirus promoter (Brown et a i, 1993). The p-CMV TAM-67 vector was 
transfected together with the pSV2neo, which confers G418 resistance as a means for selection 
of transfectants. Tissue culture dishes of approximate confluency 50-70 % were lipofected with 
the indicated amounts of plasmid DNA’s (Table 4.1). 24 hours after lipofection the dishes were 
split to three or four plates and 24 hours later G418 selection with 200 mg/ml was initiated. After 
approximately three weeks, stable cell clones were isolated by cylinder cloning for phenotypic 
analysis.
After selection with G418 the transfection dishes were stained with Giemsa to assess 
colony formation (Table 4.1). Transfection of TAM-67 into FBR cells results in a 2-fold reduction 
in the colony forming ability when compared with FBR cells transfected only with the pSV2neo 
vector (Table 4.1). In the case of the 208F c-Jun TAM-67 transfected cells a 2-fold reduction in 
the colony formation compared to the 208F cells transfected with the pSV2neo vector alone 
(Table 4.1). This suggests that TAM-67 reduces the colony forming ability of FBR and in 208F 
cells.
The expression of TAM-67 in transfected clones was analysed by western 
immunoblotting to assess the efficiency of the transfection protocol (Figure 4.1). From growing 
cultures in DMEM supplemented with 10% FCS total cell lysates were prepared using a Triton 
X-100-containing lysis buffer. The dishes were washed twice with ice-cold PBS and lysis buffer 
was added. Then the cells were scraped and the lysates were incubated on ice and clarified by 
centrifugation. The protein content of the different samples was normalised, 50 |xg of lysate was 
separated by 10% SDS-Polyacrylamide gel electrophoresis, transferred to PVDF membrane and 
blotted with an antibody specific for the Jun C-terminus. In the case of c-Jun TAM-67 the size of 
this protein (29 kD) allows its identification from the endogenous Jun protein (39 kD). TAM-67 
migrates on SDS-PAGE gels as a doublet as shown by western immunoblotting (Figure 4.1B, 
lanes 3,4,5,6,7,8 and 9).
The expression of the transforming FBR p75 v Fos oncoprotein was also analysed to 
ensure that it is still expressed and not lost during the selection process. The clones analysed by 
western immunoblotting for the expression p75 v Fos, all contained the transforming oncoprotein 
(Figure 4.1 A, lanes 3, 4, 5, 6, 7, 8 and 9) suggesting that the expression levels of the p75 v Fos 
and its posttranslational stability was not affected after introduction of the dominant negative 
deletion of c-Jun TAM-67. In these cell lines the expression of the c-Jun TAM-67 did not
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interfere with the expression of the endogenous viral oncoprotein. Therefore both the p75 v Fos 
and the dominant negative mutant TAM-67 are present in all cell lines that we examined.
208F TAM-67-transfected clones were also generated during this transfection 
experiment. 208F TAM-67 expressing cells exhibited a very flat phenotype. A representative 
clone of these transcfections is shown in Figure 4.2b. By western immunoblotting the presence 
of TAM-67 protein was identified in the 208F cells that have been selected for its expression with 
G418 (Figure 4.1C, lane 2).
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Table 4.1. Colony formation in 10cm tissue culture dishes after transfection of TAM-67 into FBR 
and to 208F cells. Cells were transfected with the indicated amounts of CsCI-purified plasmid 
DNA using lipofection. After 3-4 weeks colonies of selection with 200 mg/ml G418 were fixed in 
100% Methanol, washed with PBS, stained with 10% Giemsa solution (v/v in H20 ) and counted. 
[N D : Not Done].
Cell line Transfected plasmid Colony number
FBR neo 1 ng 150 colonies /1  n9
FBR TAM-67 /  neo 5 ng /1 n9 110 colonies /1  n9
FBR TAM-67 /neo 7 ng /1  n9 ND
FBR TAM-67 /neo 8 mg /1  n9 85 colonies /1  n9
208F neo 1 n9 110 colonies / 1 n9
208F TAM-67 / neo 10ng /1  n9 54 colonies/1 n9
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Figure 4.1. Expression of Fos and Jun proteins proteins in FBR, FBR TAM-67 
revertant cell lines, 208F cells and 208F TAM-67 expressing cells
Cells were grown in DMEM supplemented with 10% FCS. From subconfluent cultures 
lysates were prepared and proteins were separated by 10% SDS-PAGE, transferred to 
PVDF membranes and probed with an antibody specific for
A) p75 v-Fos (anti-gag MuLV, Dr. Alan Rein, Frederick, USA)
B) c-Jun (Oncogene Science) and for 208F TAM-67 cells C) c-Jun (Oncogene 
Science).
A) and B) 1) 208F cells; 2) FBR cells; 3-9) FBR TAM-67 revertant cell lines.
C) 1) 208F and 2) 208F TAM-67 tranfectant.
4.3. Morphological characteristics of FBR TAM-67 transfectants
FBR cells have a bipolar, retractile shape, which is typical of the appearance of cell lines 
transformed by several viral oncogenes (Figure 4.2c). In contrast to this the FBR TAM-67- 
positive cell clones isolated they demonstrated a flat phenotype as shown in the (Figure 4.2d, e, 
and f) with few rounded cells to appear in the cultures. The characteristics of the FBR TAM-67 
cells are reminiscent of revertant, and appeared after transfection of TAM-67 in FBR cells.
FBR TAM-67 clones demonstrated a flat morphology in approximately 70% of the 
clones isolated after transfection (Table 4.2). Also a number of FBR TAM-67 clones had a 
transformed morphology. This could be due to a genetic event that took place during the 
selection procedure that allowed individual clones to maintain the transformed phenotype and 
not to revert to a flat morphology. It is not known if this is related to a mutation in cellular genes 
or the p75v Fos suffered a point mutation which might act in a dominant fashion. FBR cell lines 
resistant to the marker pSV2neo were also isolated. All the G418-resistant FBR clones were 
morphologically transformed similarly to the parental FBR cells. The FBR neo clones isolated 
and expanded in to mass cultures had a transformed morphology which remained stable 
through passaging.
The revertant phenotype of the FBR TAM-67 cells was more evident in higher cell 
densities (Figure 4.3 c). FBR TAM-67 revertants in low density show some of the properties of 
the parental FBR v-/bs transformed fibroblasts, such as bipolar shape and extensions at the two 
edges of the cell (Figure 4.3a). In a higher cell density FBR TAM-67 display increased 
adherence to the substratum and form a monolayer in contrast to the parental FBR (Figure 4.2 
c).
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Figure 4.2. Morphology of FBR cells, 208F, FBR TAM-67 revertants and 208F cells 
transfected with TAM-67.
Phase-contrast pictures were taken with a Nikon camera attached to a Nikon 
inverted Diaphot microscope, a) 208F cells; b) 208F TAM-67 cells; c) FBR v-fos 
transformed fibroblasts; d) FBR TAM-67 revertant cloneT2-7-1; e) FBR TAM-67 
revertant clone T1-6; f) FBR TAM-67 revertant clone 2-10.
Table 4.2. Morphology of FBR neo and FBR TAM-67 transfected cells lines.
Cell lines were plated in DMEM containing 10% FCS at 10cm tissue culture dishes and allowed 
to grow for 48 hours in order to adhere to substratum to identify the individual cell morphologies.
Cell line Transfected plasmid Morphology
FBR neol neo transformed
FBR neo 2 neo transformed
FBR neo 3 neo transformed
FBR neo 4 neo transformed
FBR neo 5 neo transformed
FBR T1-2 TAM-67/neo flat
FBR T1-11 TAM-67/neo transformed
FBRT1-3 TAM-67/neo transformed
FBRT1-4 TAM-67/neo transformed
FBRT1-5 TAM-67/neo flat
FBRT1-6 TAM-67/neo flat
FBR T2-3 TAM-67/neo flat
FBR T2-4 TAM-67/neo flat
FBR T2-12 TAM-67/neo transformed
FBR T2-2 TAM-67/neo flat
FBR-T2-C2a TAM-67/neo transformed
FBR T2-2-1 TAM-67/neo flat
FBR T2-2-4 TAM-67/neo flat
FBR T2-5 TAM-67/neo flat
FBR T2-6 TAM-67/neo flat
FBR T-2-7a TAM-67/neo flat
FBR T2-7-1 TAM-67/neo flat
FBR T2-7-2 TAM-67/neo flat
FBR T2-7-3 TAM-67/neo transformed
FBR T2-7-5 TAM-67/neo transformed
FBR T2-15 TAM-67/neo flat
FBR T3-6 TAM-67/neo flat
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Figure 4.3 . Morphological reversion of FBR cells transfected with TAM-67 at 
different cell densities.
Cell lines were grown in DMEM supplemented with 10% FCS and photographed 
with a Nikon inverted Diaphot microscope.
4.4. TAM-67 inhibits FBR v-fos-induced anchorage independence
Flat revertants derived from RNA-containing Tumour Viruses do not grow efficiently in semi-solid 
medium (Ozanne and Vogel, 1974). Flat revertants isolated from FBJ-MuSV and FBR-MuSV 
transformed cell lines failed to form colonies in semi-solid medium and do not form tumours 
after injection in nude mice (Zarbl et a/., 1987; Wisdom and Verma, 1991). It is interesting that 
one class of FBJ revertants could be re-transformed by Polyoma middle T and the trk oncogene 
and not by ras, mos, abl and fos oncogenes (Zarbl et ai., 1987).
208F cells and 208F TAM-67 positive cells do not form colonies in semi-solid medium 
(Figure 4.4 a and b; Table 4.3) although in some cases the 208F cells line could form low 
numbers of small colonies under anchorage-independent conditions (not shown). The FBR cells 
formed colonies of a considerable size in the same assay (Figure 4.4 c; Table 4.3). The FBR 
TAM-67 revertant cells formed micro-colonies with reduced efficiency. When compared to the 
FBR-derived colonies the FBR TAM-67 colony forming ability was found to be 6- to 7-fold 
reduced (Figure 4.4, c and d; Table 4.3).
Another aspect of transformation that correlates with the oncogene suppression activity 
of TAM-67 is its ability to modulate invasion. Previously the invasiveness of FBR and 208F cells 
using an in vitro invasion assay was examined (Lamb et ai., 1997). In this assay 208F cells 
require growth factors, such as EGF or PDGF, to invade efficiently; while FBR cells invade in a 
growth factor-independent fashion. Expression of TAM-67 was found to suppress invasion of 
208F and of FBR cells (Lamb e ta i, 1997).
As shown in Figure 4.5 TAM-67 can suppress in vitro invasion of FBR cells. In this 
experiment FBR cells and FBR neo cells invade very efficiently the extracellular matrix whereas 
this property is severely impaired in FBR TAM-67 positive cells. This suggests that TAM-67 is 
involved through inhibition of AP-1 activity in growth factor and FBR v-/bs-dependent invasion 
(Hennigan 1993; Lamb efa/.,1997).
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Figure 4.4 . Growth in semi-solid medium of FBR, 208F, and FBR and 208F 
transfected with c-Jun TAM-67.
Cells were grown in methylcellulose containing 10% FCS for 28 days, and 
photographed with an inverted Nikon Diaphot microscope, a) 208F cells; b) 208F 
TAM-67 transfected cells; c) FBR cells and d) FBR TAM-67 cells.
Table 4.3. in vitro Anchorage-Independent growth of FBR and FBR TAM-67 cells.
2x104 cells from each cell line were plated in Ham’s media containing 1.5% Methylcellulose. 
Colonies were counted after 4 weeks. These results represent two independent experiments 
were duplicate samples were assayed.
Cell Line: FBR Experiment 1 Experiment 2
Colony Number
Mean
Ratio
14664-14444
14554
0.72
17610- 14352
15756
0.78
Cell L ine : 
FBRTAM-67
Experiment 1 Experiment 2
Colony Number
Mean
Ratio
2808-3120
2964
0.14
2184-2184
2184
0.10
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Figure 4.5. in vitro invasion assay of FBR and FBR TAM-67.
A) Migration of FBR , FBRneo and FBR TAM-67 above the filter in an in vitro 
invasion assay.
B) Relative invasion of FBR , FBR neo and FBR TAM-67 in an in vitro invasion 
assay.
Cells were allowed to attach to the underside of a transwell (Costar) and then 
chemoattracted across the 8 pm-pore-size filter. Cells were fixed, stained with 
propidium iodide and the nuclei visualised using a Bio-Rad MRC 600 Confocal 
illumination unit attached to a Nikon Diaphot inverted microscope.
Images of labelled cell nuclei were processed as tagged-image file format (TIFF) 
images, and pixels quantitated using a computer program described (Hennigan et 
al., 1994)
(This image is a representative of three experiments and was provided by Dr 
Richard Lamb and Prof. Brad Ozanne).)
4.5. FBR TAM-67 revertants are resistant to agonist-induced stress fiber formation 
One of the major changes observed in cells during ras transformation is a decrease in 
polymerised actin associated with stress fibres and the corresponding increase in new 
cytoskeletal structures such as membrane ruffles (Bar-Sagi and Feramisco, 1986). These 
alterations are mainly ascribed to activation of small GTPases of the ras superfamily such as 
rho„ rac and cdc42 (Qiu et a/., 1997).
Small GTPases do not only control the formation and distribution of actin in transformed 
but also in normal cells (Ridley and Hall, 1992). Adherent, serum-deprived Swiss 3T3 fibroblasts 
have a reduced actin content as shown by staining with Rhodamine-labelled Phalloidin (Ridley 
and Hall, 1992; Ridley et a i, 1992). Microinjection of the small GTPase Rho or incubation with 
serum or Lysophosphatidic acid (LPA) induces a rapid re-formation of actin stress fibres in 
quiescent Swiss 3T3 cells. Membrane ruffling activity is specifically induced by other agonists 
such TPA, di-butyril-cAMP or by microinjection of the small GTPase Rac (Ridley and Hall, 1992,
1994).
Revertant cell lines have a flat phenotype mainly due to alterations in cytoskeletal 
components (Weber et al., 1974; Pollack et a i, 1975). To identify if actin is involved in the flat 
phenotype of the FBR TAM-67 revertant cells, and to compare the actin content of the revertants 
with the parental FBR the cells were stained with Rhodamine-Phalloidin to visualise actin. The 
data were analysed using a Bio-Rad MRC Laser Confocal Illumination unit attached to Nikon 
Diaphot inverted microscope. This possibly would reveal a correlation between oncogenic 
transformation and the appearance of actin, and serve as an marker of reversion.
FBR cells growing in DMEM supplemented with 10% FCS were stained with 
Rhodamine-Phalloidin and processed for analysis with the confocal microscope. FBR cells 
cultured under these conditions have increased membrane ruffling at the leading end of the cells 
and the actin network is essentially lost except a very small number of stress fibres (Figure 4.6
a). In contrast 208F cells have multiple actin stress fibres with no evidence for membrane 
ruffling activity (Figure 4.6, b). The FBR v-fos TAM-67 revertants have a flat morphology quite 
similar to 208F cells with actin fibres present even when are cells are serum-deprived (Figure 
4.9 a). This shows that FBR TAM-67 cells have a different cytoskeletal organisation compared 
to the FBR cells and defined actin stress fibres at quiescence. Our results are similar with the 
results of Weber and co-workers who showed that revertants from DNA-tumour virus
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transformed cells have a flat morphology and contain stress fibres, although fewer compared to 
those found in normal fibroblasts (Weber et a/., 1974; Pollack e ta i, 1975).
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Figure 4.6. Actin distribution in FBR and 208F cells actively growing in DMEM 
supplemented with 10% FCS.
Cells were plated on coverslips, and grown in DMEM supplemented with 10% FCS. 
After 24 hours they were fixed, permeabilized and stained with TRITC-conjugated 
Phalloidin to visualise actin stress fibres.
a) FBR cells. The arrows point at the cell pseudopods were actin is concentrated 
locally.
b) 208F cells.
One question that appear interesting to ask after the landmark studies of Ridley and Hall (Ridley 
and Hall, 1992; Ridley et al., 1992) was whether stimulation of serum-deprived transformed 
fibroblasts with mitogens would have a direct effect on the reorganisation and distribution of 
actin. To our knowledge it has not been reported whether treatment with mitogens such as FCS 
induces actin stress fibres in serum-deprived oncogenically transformed cells.
When serum-deprived FBR cells stimulated with 10% FCS for 5 minutes they flatten out 
and the formation of peripheral actin and actin stress fibres becomes apparent (Figure 4.7 b). 
FBR cells also respond to other agonists by increased ruffling activity localised in the cell 
periphery in the case of treatment with 40 ng/ml phorbol ester TPA (Figure 4.7 c). Induction of 
quiescent FBR cells with 20 ng/ml LPA (Lysophosphatidic acid) results in the formation of a 
small number of stress fibres and membrane ruffling activity as shown in the Figure 4.7d. 
However it should be noted that the response of the FBR cells to LPA is clearly different from 
the response found in the 208F cells were the induction of abundant stress fibre formation is 
clear after stimulation with LPA.
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Figure 4.7. Actin reorganization in FBR by serum, TPA and LPA.
Cell lines were plated on coverslips and grown in DMEM supplemented with 10% FCS and after 
24 hours were serum deprived for 7 days. After this period of time, cells were stimulated for 5 
minutes with 10% FCS, 40ng/ml TPA, 20 ng/ml LPA or remain untreated. To visualise actin 
stress fibres cells were fixed, permeabilized and stained with TRITC-conjugated Phalloidin. 
Images were analysed and processed using a Bio-Rad MRC 600 confocal microscope, 
this experiment is a representative of four.
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208F cells responded also to treatment with FCS, TPA and LPA. Serum-deprived 208F cells 
stimulated with 10% FCS show an increased number of stress fibres, that appear mainly at the 
cell periphery (Figure 4.8b). TPA induces effectively membrane ruffling activity in quiescent 
208F cells (Figure 4.8c). Incubation of quiescent 208F cells with 20 ng/ml LPA acid resulted in 
the induction of stress fibres and also in cortical actin formation (Figure 4.8 d) which is similar to 
what observed in Swiss 3T3 cells (Ridley and Hall, 1992).
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Figure 4.8. Actin reorganization in 208F by serum, TPA and LPA.
Cell lines were plated on coverslips and grown in DMEM supplemented with 10% FCS and after 
24 hours were serum deprived for 7 days. After this period of time, cells were stimulated for 5 
minutes with 10% FCS, 40ng/ml TPA, 20 ng/ml LPA or remain untreated. To visualise actin 
stress fibres cells were fixed, permeabilized and stained with TRITC-conjugated Phalloidin. 
Images were analysed and processed using a Bio-Rad MRC 600 confocal microscope.
This experiment is a representative of three experiments.
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When quiescent FBR TAM-67 cells are induced with 10% FCS stress fibres form 
although less than those observed in serum-stimulated 208F cells. (Figure 4.9b). Treatment with 
40 ng/ml TPA induces some ruffling activity which again is decreased when compared to the 
FBR cells following this treatment (Figure 4.9c compare to Figure 4.7c). Incubation of serum- 
deprived FBR TAM-67 cells with 20 ng /ml LPA induces the formation of a low number of stress 
fibres with this response also restricted when compared to FBR and 208F cells (Figure 4.8d).
These data show that TAM-67 inhibits to a significant extent the effect of serum-, TPA-, 
and LPA- in the stimulation of the stress fibre formation and membrane ruffling in FBR cells. 
Similar are the recently published observations by Malliri et al. (1998) regarding the role of TAM- 
67 in the actin reorganisation in the A431 epidermoid carcinoma cell line.
Membrane ruffling has been found to be downstream of the small GTPase cdc42 (Qiu 
et al., 1997). cdc42 is also associated with anchorage-independent cell growth in semi-solid 
medium. It remains to be seen if these changes in the actin distribution in FBR TAM-67 cells are 
directly attributed to the stimulation of cdc42, and if the introduction of TAM-67 in the FBR cells 
and the inhibition the transcription factor AP-1 has a role in the signalling pathways controlled by 
the rho family of small GTPases
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Figure 4.9. Actin reorganisation in FBR TAM-67 revertants by serum, TPA and LPA.
Cell lines were plated on coverslips and grown in DMEM supplemented with 10% FCS and after 
24 hours were serum deprived for 7 days. After this period of time, cells were stimulated for 5 
minutes with 10% FCS, 40ng/ml TPA, 20 ng/ml LPA or remain untreated. To visualise actin 
stress fibres cells were fixed, permeabilized and stained with TRITC-conjugated Phalloidin. 
Images were analysed and processed using a Bio-Rad MRC 600 confocal microscope.
This experiment is a representative of three experiments.
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4.6. 208F TAM-67 transfectants are resistant to EGF-induced transformation 
The AP-1 transcription factor and the c-jun protooncogene function downstream of the ras signal 
transduction pathway (Karin, 1995). AP-1 is regulated by mechanisms that involve the upstream 
network of Tyrosine Kinases (Devary efa/.,1992) and small GTPases (Minden etal., 1995).
Members of the AP-1 transcription factor such as c-jun, play a role in the development 
of neoplasms. Disruption of the genomic integrity of the c-jun locus in ES cells results in less 
tumourigenic ES cell variants (Hilberg and Wagner, 1992) and fibroblasts lacking the c-jun gene 
have decreased proliferative capacity and reduced tumourigenic potential (Johnson etal., 1996)
The role of the dominant negative deletion mutant of c-jun TAM-67 has been well 
investigated in oncogene, growth factor and phorbol ester tumour promoter-induced 
transformation (Brown et al., 1993 -1994; Dong et al., 1994). Dong and co-workers have shown 
that EGF- and TPA-induced transformation of mouse epidermal cells could be suppressed by 
ectopic expression of TAM-67 (Dong etal., 1994).
It is well documented that high concentrations of serum (Peehl and Stanbridge, 1981; 
Gospodarowicz and Moran, 1974), transforming growth factors (de Larco and Todaro, 1978) 
and oncogenic viruses (Kaplan and Ozanne, 1983) are potent inducers of morphological 
transformation, anchorage independent growth, and dissolution of the stress fibre network 
(Ozanne etal., 1980). Such changes are mediated by a mechanism involving Receptor Tyrosine 
Kinases (RTK’s). More analytically, adaptor proteins such as GRB2 (Matuoka et al., 1993) and 
the rasGTPase Activating Protein, rasGAP (McGlade et al., 1993) that bind to 
autophosphorylated RTK’s mediate changes in the actin cytoskeleton implicating directly the 
growth factor receptors and their downstream effectors in EGF-induced transformation.
We hypothesised that if AP-1 and c-jun are downstream of an EGF-dependent 
signalling transforming mechanism then this mechanism could possibly be involved in regulating 
dissolution of the actin stress fibre network by transforming concentrations of EGF. This 
question was investigated in 208F cells and 208F TAM-67 transfectants by treating the cells with 
EGF and staining for Rhodamine-labelled Phalloidin to visualise actin cytoskeleton.
208F and 208F TAM-67 transfected cells were seeded in coverslips in DMEM 
supplemented with 10% FCS. 24 hours later in the plates 40ng/ml EGF was added and the 
cultures were incubated in 37 °C for an additional 24 hours. 208F cells growing in serum display 
a normal flat morphology with a significant number actin stress fibres extending throughout the
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cell (Figure 4.10a). When 208F cells treated with 40ng/ml EGF for 24 hours were stained with 
Phalloidin then the number of stress fibres was dramatically reduced, the cells became bipolar, 
spindle-like with actin localised in membrane ruffles (Figure 4.10 c).
208F TAM-67 cells have a flat morphology and they contain stress fibres as shown by 
staining with Rhodamine-labelled Phalloidin (Figure 4.10 b). 208F TAM-67 cells treated for 24 
hours with 40ng/ml of EGF did not show any evidence of morphological alterations in the actin 
cytoskeleton (Figure 4.10 d). This suggests that TAM-67 blocks downstream events of the EGF- 
induced signalling from the cell periphery to the nucleus through negative-regulation of AP- 
Itranscriptionl activity.
91
Figure 4.10. Inhibition of EGF-induced morphological transformation in 208F cells by TAM-67.
Cell lines were plated in DMEM supplemented with 10% FCS and after 24 hours they were 
incubated with 40 ng/ml of EGF for 24 hours or left untreated. To visualise actin stress fibres 
fixed, permeabilized and stained with TRITC-conjugated Phalloidin by indirect 
immunofluorescence microscopy.
a) 208F control cells serum; b) 208F cells induced with EGF for 24 hours; c) 208F TAM-67 
control; d) 208F TAM-67 cells induced with EGF for 24 hours 
This experiment is a representative of three experiments.
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4.7. Conclusion
The c-jun protoncogene is a downstream effector of Receptor Tyrosine Kinase signalling 
pathways that lead to AP-1 transcription activation (Karin, 1995). It is also involved in 
transformation by the FBR v-fos oncogene (Neuberg et al., 1991; Lloyd et al., 1991; Hawker et 
al., 1993). This evidence make the c-jun protooncogene an interesting candidate in cellular 
transformation by upstream oncogenes.
The effect of the dominant negative mutant of c-jun TAM-67 in v-/bs-induced 
transformation was tested. During this study several revertant cell lines were generated that 
might be useful to study transformation-relevant AP-1-mediated events during FBR v-/bs- 
induced oncogenesis.
TAM-67 reversed fos transformation and the isolated revertant cell lines showed a 
stability through passaging, both in their morphological characteristics and the expression of 
TAM-67. The oncogene-suppressor activity of TAM-67 is associated with various parameters of 
transformation, such as anchorage independent growth in semi-solid media (Shin etal., 1975), 
actin stress fibre formation (Weber etal., 1974; Pollack etal., 1975) and AP-1 mediated 
transcriptional regulation of certain genes (Johnston etal., 1998, submitted for publication).
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CHAPTER 5. DOWNREGULATION OF MAPK SIGNALLING IN FBR CELLS
5.1. Variations in the activation of the MAPK Pathway by oncogenes and growth factors 
Extracellular signals activate signalling mechanisms through Receptor Tyrosine Kinases (RTK) 
and small GTP-binding proteins. This mode of activation results in the stimulation of cell 
proliferation and in other cases the induction of cell differentiation (Marshall, 1995).
One of the main pathways through which growth factors stimulate cell proliferation is the 
growth factor - ras - MAP Kinase pathway, which functions downstream of RTK’s (Marshall,
1995). MAP Kinases were identified initially as insulin-stimulated kinases that phosphorylate 
microtubule-associated protein-2 and the translation-related Ribosomal S6 Kinase, (Ray and 
Sturgill, 1987; Sturgill et al., 1988). A number of MAP Kinase isoforms are known now, and the 
family of different genes that encode for homologous MAP Kinases includes enzymes such as 
the Extracellular Regulated Kinases ERK1 and ERK2 (Boulton etal., 1991), the Stress Activated 
Protein Kinases (SAPK) (Yan etal., 1994), and the inflammation-response related kinase p38 
(Han et al., 1994).
Evidence form various laboratories provides a role for MAP Kinase signal transduction 
pathway in cellular transformation. Studies with the Raf-1 Serine/Threonine Kinase helped in 
identifying elements of this signal transduction pathway. The Raf-1 kinase is a target of activated 
GTP-bound p21ras and initially was identified as the product of the gene of the transforming 
retrovirus MC 3611 (Rapp etal., 1983). Raf-1 can activate MEK-1, a MAP Kinase Kinase which 
phosphorylates and activates MAP Kinases on Tyrosine and Threonine residues (Dent et 
al., 1992; Howe et al., 1992; Kyriakis et al., 1992).
MEK-1 also has a role in cellular transformation by the oncogenes acting upstream of 
this enzyme. Introduction of a kinase-inactive, dominant negative MEK-1 was shown to suppress 
v-ras and v-src transformation and to revert the transformed phenotype (Cowley et al., 1994; 
Mansour et al., 1994). Conversely a contitutively active MEK-1 was shown to activate MAP 
Kinase signalling (Seger et al., 1994), to bypass growth factor-dependent proliferation and to 
induce transformation of NIH 3T3 cells (Cowley etal., 1994; Mansour etal., 1994). The activated 
mutant of MEK-1 was also shown to induce differentiation of PC12 cells, expanding the
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repertoire of biological roles of MEK-1 (Cowley etal., 1994). Collectively these data demonstrate 
that components of MAP Kinase pathway can be important modulators of cellular growth, 
mediating growth factor and oncogene stimulation of cell proliferation.
However in some cases there are variations from this paradigm, suggesting that 
oncogenic transformation is not necessarily associated with activation of MAP Kinase signalling. 
These findings emerge from studies with various oncogenes, mainly those located in the 
cytoplasm. In these studies oncogenes such as v-raf and activated raM  (Kizaka-Kondoh and 
Okayama, 1993; Samuels and McMahon, 1994), v-src (Stofega etal., 1997) and v-crk (Greulich 
etal.,1996) do not to induce activation of MAP Kinases as measured by a variety of methods.
5.2. Stimulation of MAPK signalling in FBR cells is not dependent on autocrine signals 
The role of the ras oncogenes in cell growth and oncogenesis is well established (Barbacid, 
1987). ras oncogenes can induce.cell proliferation, through the production of growth factors in 
the culture media, resulting in an activation of an autocrine loop which activates signalling 
through Receptor Tyrosine Kinases. Autocrine activity secreted by cells transformed by the v-Ki- 
ras oncogene (Ozanne et al., 1980) or a constitutively active MEK-1 (Cowley et al., 1994) has 
been reported to enable them to proliferate in the absence of serum, and to grow in anchorage 
independent conditions (Kaplan and Ozanne, 1983 ; de Larco and Todaro 1978).
Cells transformed by the FBJ-MuSV do not produce any growth factors and display a 
moderate ability to grow in soft agar compared to FBR-MuSV transformed cells (Kaplan , 1983). 
It is already known from previous studies in this laboratory that FBR cells do not incorporate 
tritiated thymidine when cultured in low serum media (Hawker et al., 1993; Hennigan, 1993), 
suggesting that these cells do not secrete any autocrine activity sufficient to stimulate DNA 
synthesis (Hennigan, 1993).
If an autocrine activity similar to transforming growth factor-a (Ozanne et al., 1980; 
Kaplan and Ozanne, 1983) is secreted by the FBR cells, this should induce MAP Kinase 
activation. Using western immunoblotting the induction of MAP Kinases by conditioned media 
prepared from serum-deprived FBR cells was examined. In this assay phosphorylation of MAP 
kinases was examined using a phospho-specific antibody which recognises only the dually 
phosphorylated forms of ERK1 and ERK2 MAP Kinases. To prepare conditioned medium 
subconfluent FBR and 208F cell monolayers were rendered quiescent by serum deprivation for
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48 hours and after this period of time the medium was collected and filtered through a 0.2 \i 
filter. The conditioned media were added directly to quiescent FBR and 208F serum-deprived 
cultures. The cells were washed with PBS; Triton X-100-containing lysis buffer was added and 
the cells were scraped and lysates clarified by centrifugation. The protein content was measured 
and 50 [xg of total cell lysate was separated by 10% SDS-Polyacrylamide gel electrophoresis, 
transferred to a PVDF membrane and blotted with the MAP Kinase phosphospecific antibody. 
As a control for identifying MAP Kinase activation, lysates prepared from serum-stimulated FBR 
and 208F cells were also included in these experiments.
The activation of MAP Kinase isoforms, ERK1 and ERK2 is indicated by the intensity of 
the bands in the autoradiogram (Figure 5.1). These bands represent phosphorylated ERK1 and 
ERK2 (Figure 5.1). In these experiments no phosphorylation of ERK1 and ERK2 from either 
FBR or 208F cells treated with conditioned media was found (Figure 5.1 A, lane 3 and 4 ; Figure 
5.1 B, lane 3 and 4). Stimulation with serum induces a 2-fold increase in MAPK phosphorylation 
in FBR cells and 10-fold in 208F cells (Figure 5.1 A2 and C2)
To ensure that equivalent amounts of protein were loaded to each sample the 
membrane was stripped and probed with an antibody that is specific for the C-terminus of 
ERK2.(Figure 5.1 B and D, lanes 1, 2, 3, and 4)
This experiment shows that activation of MAP Kinases as shown by the 
phosphoreactive bands is induced by serum in FBR and 208F cells. In contrast to this finding, no 
induction of phosphorylation of MAP Kinases using conditioned media derived from serum- 
deprived FBR and 208F cells was detected. The inability of the conditioned media to activate 
MAP Kinase phosphorylation in FBR cells suggests that MAP Kinase signalling in this cell type is 
dependent upon mitogenic stimulation with serum, and that FBR cells do not secrete any 
autocrine activity as measured by this method. This result further investigation of activation 
mechanisms of MAP Kinase phosphorylation in FBR compared to normal 208F cells.
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Figure 5.1 . Phosphorylation of MAP Kinases in FBR and 208F cells by serum and 
not by FBR- and 208F-derived conditioned medium.
Cells were grown in DMEM supplemented with 10% FCS followed by serum 
withdrawal for 48 hours (0.1% FCS). Stimulation was for 5 minutes with 10% FCS 
or with 10 ml of conditioned medium prepared from FBR and 208F cells. Cell 
lysates were prepared and proteins were separated by 10% SDS-PAGE, 
transferred to PVDF membranes and probed with an antibody specific for the 
phosphorylated ERK1 and ERK2 (MAPK*, Promega Corp., Wl, USA). Blots were 
stripped and probed with an antibody specific for ERK2 as a loading control 
(ERK2, Transduction Labs, KE, USA).
A) 1) FBR serum-deprived cells; 2) FBR serum-stimulated cells; 3) FBR cells 
stimulated with FBR derived conditioned medium; 4) FBR cells stimulated with 
208F derived conditioned medium.B) 1) 208F serum-deprived cells; 2) 208F 
serum-stimulated cells; 3) 208F cells stimulated with FBR derived conditioned 
medium; 4) 208F cells stimulated with 208F derived conditioned medium.
This experiment is a representative of two with identical results
5.3. Attenuated serum-induced MAPK signalling in FBR cells
To monitor activation of MAP Kinases in FBR and 208F cells by serum an immunocomplex- 
kinase assay. This assay is based on the isolation of ERK1 MAP Kinase from cultured cells by 
immunoprecipitation, followed by incubation with substrate Myelin Basic Protein and [y-32P] ATP 
as the source of phosphate. In this assay MAP Kinase activity is determined by autoradiography 
to detect phosphate incorporation into the substrate.
Cell lysates were prepared from serum-deprived and serum-stimulated FBR or 208F 
cells by using the ERK lysis buffer. 1000 ng of total cell lysate was incubated with a specific 
antibody for ERK1, or with pre-immune serum. The samples were incubated overnight and the 
following day the immunoprecipitates were washed and subjected to the in vitro kinase assay. 
The products of the kinase reaction were separated by 10% SDS-Polyacrylamide gel 
electrophoresis, transferred to PVDF membranes and exposed with intensifying screens to 
generate an autoradiograph. To verify the efficiency of the immunoprecipitation the membrane 
was subjected to western immunoblotting with an antibody to ERK1 to determine that equal 
levels of enzyme were immunoprecipitated (Figure 5.2 B).
This assay showed that phosphorylation of MBP was induced to a higher level in the 
immunoprecipitated samples from serum-induced 208F cells compared to the FBR serum- 
induced cells. (Figure 5.2 A lane 8 ; compare to lane 4 from serum-stimulated FBR fibroblasts). 
These data together with the results using the MAP Kinase phospho-specific antibody presented 
in Figure 5.1, show that there is a reduction in MAP Kinase activity in serum-stimulated FBR 
cells compared to the parental 208F non-transformed cells.
100
IP : ERK - MBP Kinase Assay
03azs
E
E
EcL
o
CLm
3*:oc
LLli
03
O
OC
CO
03c
=3
E
E
03
Cl
CO
o
+
00
CD
3*300
lljI
03
CO
o
+
00
CD
03C
13
E
E
03
Q .
LL
00O
C\J
3^
00
LLl
03
00O
C\J
03d
13
E
E
03
Cl
C/3
O
LL
O
+
COo
C\J
3^
00
LU
03
CO
O
LL
c£O
00o
CvJ
m •  •
B IP : ERK - b lo t: anti-ERK
- 11 •
MBP
ERK2
Figure 5.2. MAP kinase activity Assay.
Cells were plated in DMEM supplemented with 10 % FCS and when subconfluent 
serum-deprived for 48 hours (0.1% FCS). Stimulation was for 5 minutes with 10% FCS. 
Cell lysates were prepared and ERK1 activity was immunoprecipitated with an antibody 
against ERK1 (Transduction Labs, KY, USA). A) Kinase assay to determine ERK2 
activity from cultured cells was performed with Myelin Basic Protein as a substrate in 
the presence of [y-32P]ATP. The products of the assay were resolved in 10% SDS- 
PAGE and transferred to a PVDF membrane. The membrane was exposed using 
intensifying screens and the autoradiograph shown was the result of a 45 minute 
exposure. B) The membrane was probed with an antibody specific for the ERK1/2 
proteins (Transduction Labs) to verify immunoprecipitation of ERK2 activities.
1) Lysate from quiescent FBR immunoprecipitated with preimmune serum; 2) lysate 
from quiescent FBR f immunoprecipitated with ERK-specific serum; 3) lysate from 
stimulated FBR immunoprecipitated with preimmune serum; 4) lysate from stimulated 
FBR immunoprecipitated with ERK-specific serum; 5) lysate from quiescent 208F 
fibroblasts immunoprecipitated with preimmune serum; 6) lysate from quiescent 208F 
fibroblasts immunoprecipitated with ERK-specific serum; 7) lysate from stimulated 208F 
fibroblasts immunoprecipitated with preimmune serum; 8) lysate from stimulated 208F 
fibroblasts immunoprecipitated with ERK-specific serum
5.4. Induction of MAP Kinases in FBR and 208F cells by Growth factors 
To study phosphorylation of MAP Kinases by stimuli other than serum, growth factor induction of 
ERK1 and ERK2 activity was also investigated. This might yield insights into mitogenic signalling 
in these two distinct cells types and identify functional differences in the modes of MAP Kinase 
signalling and activation.
Serum deprived FBR and 208F cells were exposed for 5 minutes with 10% FCS, 100 
ng/ml EGF, 20ng/ml PDGF, 50ng/ml Insulin, or 100ng/ml IGF-I. Lysates were prepared using 
Triton X-100-containing buffer and the protein content was normalised to 50 pig per sample. The 
proteins were separated by 10% SDS-PAGE, transferred to PVDF membranes and blotted with 
the MAP Kinase phosphospecific antibody. To demonstrate the specificity of the actions of these 
growth factors and the reproducibility of the results in Figure 5.3 two independent experiments 
are shown, where serum, EGF, PDGF, Insulin and IGF-I were used to induce MAP Kinase 
phosphorylation. The results from densitometric scanning of the western blots are summarised 
in the Table 5.1. In FBR cells serum-induced total ERK activity was 3-fold over the basal (0.16+/- 
0.049, n=3, Significant at P <0.05). EGF activated well ERK’s (0.27+/-0.005, n=3, significant at 
P=0.0001). The response of FBR cells to Insulin and IGF-I was relatively low and not significant 
(0.03+/-0.03 for Insulin with P<0.6 and 0.08+/-0.02 for IGF-I with P<0.7). In this table the total 
ERK1 and ERK2 signal generated by western immunoblotting analysis is normalised for the 
ERK2 protein loading from the same autoradiographs.
Treatment of 208F cells with serum resulted in MAP Kinase activation approximately 10- 
fold over the basal levels (0.96+/-0.05, n=3 significant at P=0.006). EGF resulted in a similar 
mode and magnitude of activation in 208F cells when compared to serum (0.9+/-0.1, n=3, 
significant at P=0.0034). The response of 208F cells to Insulin was significant but very low 
(0.06+/-9'10, n=3, P=0.001) and this to IGF-I low but not significant ((0.1+/-0.04, n=1, P=0.3).
Other reports have shown activation of MAP Kinases by Insulin in fibroblasts over­
expressing the Insulin Receptor, using high concentrations up to 1000 ng/ml. After careful 
analysis of the literature, these concentrations are considered high for non-adipose like cells. 
The addition in high concentrations of growth factors to cultured fibroblasts could induce non­
specific effects and activate multiple pathways. Alessi et al. (1995) also have shown that the 
magnitude of MEK-1 and MAP Kinase activation in tissue culture cells is dependent on the 
concentration of added growth factors. Here, growth factors for stimulation experiments were
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administered at concentrations that by many groups have been shown to result in a specific 
response towards the activation of the MAP Kinase pathway.
The fact that in the case of induction with PDGF a similar response was observed in the 
FBR and 208F cells suggests a conserved mechanism for this particular growth factor and could 
be used as an internal standard. In the case of FBR cells the response to PDGF was 
approximately 5-fold over the basal (0.327+/-0.011, n=3, P=0.0007) and in the case of 208F 
cells approximately 3-fold over the basal (0.33+/-0.033, n=3, P=0.0034). The fact that the PDGF 
activation ERK1 and ERK2 is relatively conserved between transformed FBR and non­
transformed 208F cells suggests that there might be a signal transduction pathway which 
somehow is not affected by the process of transformation by the FBR fos oncogene. Future 
more detailed studies could address the levels, the activity and the role of effectors of the PDGF 
mitogenic signal such as the PLC and Phoshoinositide 3-Kinase (Valius and Kazlauskas, 1993) 
in the FBR and 208F cells.
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Figure 5.3. MAPK phosphorylation by serum in FBR and 208F cells by serum and purifed 
growth factors
Cells were grown in DMEM supplemented with 10% FCS and when subconfluent, serum- 
deprived for 48 hours (0.1% FCS) .Stimulation was for 5 minutes with 10% FCS, 
100ng/ml EGF, 20ng/ml PDGF , 50ng/ml Insulin or 100ng/ml IGF-1.
Cell lysates were prepared and proteins were separated by 10% SDS-PAGE, transferred 
to PVDF membranes and probed A)+B) with an antibody specific for phosphorylated 
ERK1/2 (MAPK*, Promega labs, Wl, USA).
Blots were stripped and reprobed with an antibody specific C) for ERK2 as a loading 
control (ERK2, Transduction labs)
1-6 : FBR cell lysates 1) serum deprived or stimulated with 2) 10% FCS, 3) EGF, 4) 
PDGF, 5), insulin, 6) IGF-1.
7-12 : 208F cells 7) serum deprived or stimulated with 8) 10% FCS, 9) EGF, 10) PDGF,
11), insulin, 12) IGF-1.
Two different exposure times of 1 and 2 minutes are shown.
These blots are representative of three different experiments.
Table 5.1. Activation of MAP Kinase by growth factors in FBR and 208F cells.
Quantification of the increase in phosphorylation of ERK1 and ERK2 was performed using 
scanning densitometry. The band of serum-stimulated 208F cells was taken as the maximal, 
100% activation. The values were normalised for control loading of ERK2 for each individual 
experiment. The values are the mean +/- SD (standard deviation) of three independent 
experiments.
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5.5. Induction of MAP Kinases in FBR and 208F cells by Lipid Singals
Apart from growth factors, phorbol esters such as TPA, a Protein Kinase C activator induces 
activation of ERK1 and ERK2 (de Vries Smits et al., 1992; Wood et al. ,1992; Thomas et 
a l, 1992). MAP Kinases also are activated in response to G protein-coupled Receptor activation. 
In this case the role of Lysophosphatidic Acid (LPA) is well documented (Van Corven et 
al., 1989). LPA can act as a mitogen for fibroblastic cells in culture by its ability to stimulate DNA 
synthesis via a pertussis toxin-sensitive pathway (Tokomura et al., 1994).
MAP Kinase phosphorylation after induction of quiescent FBR and 208F cells with TPA 
and LPA was examined. The results of these experiments are presented in Figure 5.4 and 
summarised in the table 5.2.
In the previous chapter, 20 ng/ml LPA were used to induce actin reorganisation in 
quiescent cells (Figure 4.7, 4.8, 4.9). Incubation of FBR cells with 20 ng/ml LPA did not enhance 
significantly phosphorylation of ERK1 and ERK2 MAP Kinases (0.07+/-0.06, n=3, P>0.05). Also 
stimulation with TPA of FBR cells resulted in a 2.8-fold increase of ERK phosphorylation, which 
was not significant (0.28+/-0.07, n=3, P>0.05). However a strong correlation between TPA 
stimulation and MAP Kinase phosphorylation was evident in 208F cells were a 3.2-fold activation 
over the basal levels appeared to be significant (0.46+/-0.05, n=3, P=0.01). It is apparent from 
the Figure 5.4 that in both FBR and 208F cells treatment with these low concentrations of LPA 
did lead to any significant activation of ERK1 and ERK2 phosphorylation. TPA was more potent 
in its role to activate MAP Kinase phosphorylation as shown in Figure 5.4 in the Experiments 
land 2, in lanes 10. Phorbol ester TPA is a potent activator of ERK’s in normal tissue culture 
fibroblasts (de Vries Smits et al., 1992; L’Allemain et al., 1992; Thomas et al., 1992; Wood et 
al., 1992).
The results presented in here regarding the effect of LPA in FBR and 208F cells did not 
lead to any identification of phosphorylated MAP Kinases. It is known that low concentrations 
LPA do not activate very well MAP Kinases in tissue culture cells (Cook and McCormick, 1996). 
Since LPA did not induce activation of MAPK Kinases at low concentrations, LPA was used at 
the concentration of 1 nM which has been shown to stimulate non-mitogenic MAP Kinase 
signalling in rat-1 cells (Cook and McCormick. 1996).
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Figure 5.4. MAPK phosphorylation in FBR, 208F by serum, EGF and activators 
of PKC and G-coupled receptors.
Cells were grown in DMEM supplemented with 10% FCS and when subconfluent 
serum-deprived for 48 hours (0.1% FCS). Stimulation was for 5 minutes with 10% 
FCS, 100ng/ml EGF, 100ng/ml TPA and 20 ng/ml LPA or left untreated. Lysates 
were prepared and proteins were separated by 10% SDS-PAGE, transferred to 
PVDF membrane and probed with an antibody specific for the phosphorylated ERK1 
and ERK2 (MAPK*, Promega Labs, Wl, USA).
Blots were stripped and probed with an antibody specific for ERK2 as a loading 
control (ERK2, Transdcution Labs, KY, USA).
1-6 : FBR cell lysates 1) serum deprived or stimulated with 2) 10% FCS, 3) EGF, 4) 
LPA, 5), TPA.
7-12 : 208F cells 6) serum deprived or stimulated with 7) 10% FCS, 8) EGF, 9) LPA, 
10), TPA.
Two different exposure times of 1 and 2 minutes are shown.
These blots are representative of three different experiments with similar results
Table 5.2. Activation of MAP Kinases by serum, EGF, LPA and TPA in FBR and 208F cells.
Quantification of the increase in phosphorylation of ERK1 and ERK2 was performed using 
scanning densitometry. The band of serum-stimulated 208F cells was taken as the maximal, 
100% activation. The values were normalised for control loading of ERK2 for each individual 
experiment. The values are the mean +/- S.D. (standard deviation) of three independent 
experiments
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5.6. Non-mitogenic doses of LPA induce MAP Kinases in 208F but not in FBR 
A maximal response in MAP Kinase activation occurs with LPA concentrations of approximately 
1 ^M. At the higher concentration of 100 iaM , LPA induces cell proliferation (Cook and 
McCormick, 1996). LPA levels in serum are between 1 and 5 jaM (Eicholltz e ta i, 1993).
While the use of 20ng/ml of LPA in the preceding experiments had no effect on MAP 
Kinase activation (Figure 5.4) LPA at this concentration is sufficient to elicit biological responses 
such as re-formation of actin stress fibre in 208F cells or membrane ruffling in FBR cells (Figure 
4.7 and Figure 4.8).
Basing further experiments on the results of Cook and McCormick (1996), the effect of 
1 jaM LPA was used to determine if this concentration is sufficient to induce MAP Kinase in 208F 
cells, a derivative of rat-1 cells and if similar signals can be elicited in FBR cells. Total cell 
lysates from FBR and 208F cells serum-deprived or stimulated with 10% FCS or 1 jaM LPA for 5 
minutes were prepared using the Triton X-100-containing lysis buffer. The proteins were 
separated by 10% SDS-PAGE, transferred to PVDF membranes and probed with the MAP 
Kinase phospho-specific antibody.
After treatment of 208F cells with 1 |aM LPA, densitometric scanning of the 
autoradiogram showed that the total ERK signal is similar to the results obtained with serum. In 
the case of serum the result was significant (0.83+/-0.04, n=4, P=0.0001) and with LPA a similar 
response was evident (0.925+/-0.08, n=4, P=0.0003). This result is somewhat different from 
what others have observed, where a serum gives a higher response compared to the treatment 
with LPA. When ERK1 activation was measured by an immunoprecipitation kinase assay, 10% 
FCS gave a higher response than LPA (Cook and McCormick, 1996). The slight difference 
observed here could be due to the fact that in the present study examined MAP Kinase 
activation after 5 minutes of LPA, whereas Cook and McCormick (1996) treated cells for 10 
minutes.
Consistently 1 jaM LPA failed to induce MAPK phosphorylation in the FBR cells 
(0.0375+/-0.005, n=4) as shown in the two independent experiments as shown in the Figure 5.5. 
That was significant result with a P=0.003.For this section the results from 4 independent 
experiments are summarised in Table 5.3.
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Figure 5.5. MAPK phosphorylation in FBR and 208F cells after induction with 
serum and 1 fiM LPA.
Cell lines were grown in DM EM supplemented with 10% FCS and when 
subconfluent, serum-deprived for 48 hours (0.1% FCS). Stimulation was for 5 
minutes with 10% FCS, 1pM LPA or remain untreated.
Cell lysates were prepared and proteins were separated by 10% SDS-PAGE, 
transferred to a PVDF membrane and probed with an antibody specific for 
a), b), c) and d) phosphorylated MAPK* (Promega Labs , Wl, USA), 
e) and f) Blots were striped and probed with an antibody specific for ERK2 to 
verify equal loading (ERK2, Transduction Labs, KY, USA).
Two different exposures are shown for 1 and 3 minutes.
These blots are representative of four different experiments were similar results 
were obtained.
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Table 5.3. Activation of MAP Kinases by serum and 1 jxM LPA.
Quantification of the increase in phosphorylation of ERK1 and ERK2 was performed using 
scanning densitometry. The band of LPA-stimulated 208F cells was taken as the maximal, 
100% activation. The values were normalised for control loading of ERK2 for each individual 
experiment. The values are the mean +/- standard deviation of four independent experiments.
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5.6. Activation of MEK-1 in FBR and 208F cells
MEK-1 is the major activator of MAP Kinases in mammalian cells. Activation of MEK-1 in FBR 
and 208F cells is detected by western immunoblotting with antibodies that specifically recognise 
the major phosphorylation sites by Raf-1, Serines 217 and 221 (Alessi et a/., 1994).
From quiescent and serum induced FBR and 208F cells, lysates were prepared using 
the standard Triton X-100-containing lysis buffer. The lysates were clarified by centrifugation, the 
protein content was normalised and 300 ng of total cell lysate was separated by 10 % SDS- 
Polyacrylamide gel containing a low concentration of bis-Acrylamide (Marshall and Leevers, 
1995). The reduction in the percentage of bis-Acrylamide has been found to be critical for the 
identification of phosphorylated protein iso-forms by western immunoblotting (Marshall and 
Leevers, 1995).
In the Figure 5.6 a representative experiment is shown where activation of MEK-1 by 
serum in FBR and 208F cells was investigated by western immunoblotting of total cell lysates 
with phospho-specific antibodies. By scanning densitometry the relative levels of 
phosphorylation MEK-1 were identified. Phosphorylation of MEK-1 was enhanced by 5-fold in 
serum-stimulated compared to serum-starved 208F cells. In the serum-stimulated FBR lysates, 
MEK-1 was activated 2-fold. Also the basal phosphorylation levels of MEK-1 in FBR and 208F 
were examined and found to be 4-fold higher in quiescent 208F cells compared to quiescent 
FBR cells (Figure 5.6 lanes 1 and 3).
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Figure 5.6. MEK-1 phosphorylation by serum in FBR and 208F cells.
Cells were grown to subconfluence in DM EM supplemented with 10% FCS and 
serum deprived for 48 hours (0.1% FCS). Stimulation was for 5 minutes with 
10% FCS. Cell lysates were prepared and proteins were separated by 10% 
SDS-PAGE, transferred to a PVDF membrane and probed A) with an antibody 
specific for the phosphorylated MEK-1 (MEK-1*, New England Biolabs, MA, 
USA)
To confirm equal loading the blot was stripped and probed B) with an antibody 
specific for MEK-1 as a loading control (MEK-1, Santa Cruz Bio., CA, USA)
Using scanning densitometry the relative phosphorylation of MEK-1 in blot A 
was assessed. The protein content was normalised for the levels of MEK-1 
using data presented in the blot 2. This experiment is a representative of two 
with similar results.
5.7. Conclusion
It is known that cells transformed by raf, src and ras oncogenes display an increase in MAP 
Kinase activity (Dent et al., 1992 ; Gallego etal. 1992 ; Leevers and Marshall, 1992). Also cellular 
transformation by v-ras and v-src requires MEK-1 (Cowley et at., 1994), and by v-raf requires 
MAP Kinases (Kortenjann et al. 1994). This evidence shows that MAP Kinase signalling is 
involved in transformation by oncogenes that function in upstream pathways from AP-1.
In this chapter evidence was presented which argued that MAP Kinase phosphorylation 
in FBR cells by various agonists is reduced compared to the parental 208F cells. This was an 
unexpected finding since in most cell lines transformed by viral oncogenes, MAPK signalling is 
enhanced and associated with transformation (Gallego et al. 1992; Troppmair et al., 1994) and 
proliferation (Kerkoff and Rapp, 1997 , 1998).
This suggests that FBR fos could transform cells without being dependent on any 
upstream component of the ras pathway such as Raf-1 and MEK-1 protein kinases. To 
investigate this further we have transfected dominant negative mutants of Raf-1 and MEK-1 in 
FBR cells and generated stable cell lines. The results of these transfections are presented in the 
two following chapters of results.
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RESULTS 
CHAPTER 6. GENERATION OF FBR REVERTANT CELL LINES 
FOLLOWING TRANSFECTION OF THE DOMINANT NEGATIVE MUTANT OF 
MEK-1, A221
6.1. MAP Kinase Kinase, MEK-1 is required for cellular transformation
A major pathway involved in the transmission of signals from the extracellular environment to 
the nucleus is the MAP Kinase pathway. Stimulation of cultured cells with mitogens results in 
activation of MAP Kinase (Anderson et al., 1990a) by dual phosphorylation on Tyrosine and 
Threonine residues (Ray and Sturgill, 1988). MAP Kinases have multiple substrates including 
transcriptional activators, such as members of the transcription factor AP-1 (Karin, 1995; Gruda 
et al., 1994).
The activation of this pathway involves the small GTP-binding protein p21ras , which is 
activated by receptor tyrosine kinases and G-protein coupled receptors (Wood et al., 1992; 
Gallego et al., 1992). The activated GTP-p21ras binds to the N-terminus of the Raf-1 protein 
kinase (Vojtek et al., 1993) and this event accounts for the activation of the MAP Kinase 
pathway. Raf-1 kinase initially was identified as a retroviral oncogene (Rapp et al., 1983) and 
has been reported to activate a MAPK Kinase Kinase known as MEK-1 (Kyriakis et al., 1992; 
Dent et al., 1992; Howe., et al., 1992). MEK-1 is a kinase with dual specificity, phosphorylating 
MAP Kinases on threonine and serine residues (Alessi etal., 1994).
Experiments with oncogenes that lie upstream of MEK-1 showed that MEK-1 could 
indeed be at a convergent point of oncogene action. In these experiments the dominant negative 
kinase inactive MEK-1 A221 was shown to inhibit growth factor stimulation of MAP Kinase 
signalling (Cowley et al., 1994). The same mutant when microinjected reversed transformation 
of v-ras and v-src transformed NIH 3T3 mouse fibroblasts. Conversely constitutively active 
MEK-1 has been shown to activate MAP Kinase signalling in the absence of growth factors and 
to induce cellular transformation in NIH 3T3 fibroblasts and differentiation of PC12 cells (Cowley 
etal., 1994).
The AP-1 transcription factor and its components are regulated by extracellular signals. 
Here we have examined the role of the MEK-1, MAP Kinase Kinase Alanine 221 point mutant in
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the context of transformation by the FBR v-fos oncogene, a member of the transcription factor 
AP-1.
Identification of serum-induced isoforms of MEK-1 in FBR by a phospho-specific 
antibody shows that phosphorylation of MEK-1 is low in FBR. This result makes MEK-1 an 
unattractive candidate for regulating fos-transformation. However since recently its function has 
been implicated in oncogenic growth we thought that it would still be interesting to test its role in 
fos-induced transformation, by examining the role of MEK-1 A221 in fos-induced anchorage 
independent growth. To investigate this we used a transfection approach by introducing an 
expression vector containing the MEK-1 A221 dominant negative cDNA into FBR. The cell lines 
that we have isolated had properties resembling those of revertants which indicated that some 
aspect of MAP Kinase signalling downstream of MEK-1 is important in transformation by v-fos 
oncogene.
6.2. Transfection of MEK-1 A221 into FBR and 208F cells
Lipofection was used to transfect FBR with pBABE puro expression vectors encoding wild type 
MEK-1 and MEK-1 A221. One day after transfection the cultures were divided into four 10cm 
dishes and 24 hours later selection with puromycin started. The results of this transfection assay 
are shown in Table 6.1. The number of puromycin resistant colonies is an indication of the effect 
of the transfected A221 and wild type MEK-1 on the growth of FBR and 208F cells. As a control 
a pBABE empty vector was transfected to FBR and 208F cells.
Transfection of 1 ng of wild type MEK-1 to FBR cells gave rise to a 1.5-fold increased 
number of colonies compared to FBR transfected with the empty pBABE puro vector. When 
FBR were transfected with 5 ng of wild type MEK-1 vector then a 3-fold decrease in the number 
of colonies was observed. This suggests that the wild type MEK-1 may confer a growth 
advantage to FBR in a low concentration but when the amount of the transfected plasmid was 
increased then this resulted in an inhibition of puromycin-resistant colony formation in FBR and 
in 208F. It is likely that an increase in the amount of the transfected wild type MEK-1 could result 
in cellular toxicity. This could be responsible for the appearance of low colony numbers after 
transfection of wild type MEK-1 into FBR cells.
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When FBR were transfected with 1 ng of the pBABE MEK-1 A221 vector it was noticed 
that the number of puromycin resistant colonies was decreased 3-fold compared to an empty 
vector. When the amount of plasmid was increased to 5 ng, there was a 2-fold decrease in the 
amount of puromycin-resistant colonies suggesting a modest reduction of colony number of 
FBR after transfection of A221.
These transfection assays in FBR gave rise to a limited number of puromycin-resistant 
colonies after selection in DMEM supplemented with 10% FCS. This stringent selection process 
could probably be attributed to a specific effect of puromycin in FBR since in the same 
transfection assays in 208F cells we observed that puromycin did not limit the number of 
colonies after the selection process was completed and the plates were stained with Giemsa to 
identify individual colonies. In control experiments we have found that FBR are very sensitive to 
puromycin compared to 208F cells when concentrations of the antibiotic are higher than 2 ng/ml 
in the selection media.
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Table 6.1. Colony formation in 10cm tissue culture dishes after transfection of of pBABE puro, 
pBABE MEK-1 wt and pBABE MEK-1 A221 into FBR and to 208F cells.
Cells were transfected with the indicated amounts of CsCI-purified plasmid DNA using 
lipofection. Colonies were counted after 3-4 weeks during selection with 2 ng/ml puromycin for 
the puro and wt MEK-1 vectors and 2.5 ng/ml puromycin for MEK-1 A221 vector followed by 
fixation in 100% Methanol, washed with PBS, stained with 10% Giemsa solution (v/v in H20). 
[ND : Not Determined].
Cell line Transfected plasmid Colony formation efficiency
FBR puro 1 24 colonies /1  ng
FBR MEKwt 1 ng 36colonies/ 1ng
FBR MEKwt 5 ng 56 colonies / 5ng
FBR MEKA221 1 ng 7 colonies /  1 ng
FBR MEKA221 5ng 17colonies / 5 ng
208F puro 1 ng 220 colonies /1  ng208F MEKwt 1 ng 66 colonies /1  ng208F MEKA221 1 ng 150 colonies /1  ng
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6.2. Morphological characteristics of FBR MEK-1 A221 transfectants
To investigate the morphological characteristics of FBR A221 clones, we isolated several cell 
lines by cylinder cloning. These clones were expanded into cultures and the morphology was 
scored by phase contrast microscopy.
Of the 17 FBR MEK-1 A221 revertant clones isolated by cylinder cloning, 14 clones had 
a flat morphology and this accounted for approximately 80 per cent of total colonies isolated 
from this experiment, designated Experiment 1 (Table 6.2). These pyromycin-selected FBR 
A221 clones maintained their morphological characteristics during passaging. In the control FBR 
transfectants with the vector pBABE puro alone, 7 of the 9 colonies isolated were transformed 
and 2 had a non-transformed morphology, resulting in 77% transformed colonies in the 
Experiment 1 (Table 6.2, first nine cell lines).
In a another transfection experiment, termed Experiment 2, with identical plasmid 
analogies as those in the Table 6.1, similar reversion data were obtained as those presented in 
Table 6.2. Table 6.3 summarises the morphological characteristics of the clones isolated from 
the Experiment 2. The percentage of reversion was 74%, with 17 out of 23 FBR A221 clones 
having a flat morphology. This result along with the results presented in Table 6.2 demonstrated 
that reversion after transfection of MEK-1 A221 into FBR is not a random, selection-dependent 
event but rather is related to the effect of this dominant negative mutant reversing fos-mediated 
transformation. When the phenotype of the revertant cells at different densities was examined, it 
was found that reversion occurred in FBR MEK-1 A221 transfectants at different densities. This 
is similar to that reported in FBR TAM-67 revertants (Figure 6.1). FBR appear to be bipolar in 
shape when growing in the presence of 10% FCS, and also a large number of cells appear to be 
rounded (Figure 6.1, a). In contrast to this 208F cells are flat when attached to plastic in the 
tissue culture dish, maintaining this property in higher densities and very rarely rounded cells 
appear in the cultures (Figure 6.1 b). FBR A221 clones 19 and 23 are two revertant clones we 
have isolated after transfection of MEK-1 A221 (Figure 6.1 c, d, e and f) which have a spindle­
like morphology at low density which is reminiscent of FBR, whereas in a higher density they are 
flat (Figure 6.1 c and e ; and d and f respectively). Also the percentage of rounded cells which 
are present in FBR cultures (Figure 6.1, a) is reduced in the FBR A221 clones 19 and 23 (see 
Figure 6.1 d and f).
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Table 6.2. Experiment 1. Morphological characteristics of FBR transfected with pBABE puro 
and pBABE MEK-1 A221.
FBR cells were transfected with 1 n9 of pBABE puro and 5 ng of pBABE MEK-1 A221 using 
lipofection. The clones were selected with puromycin at a final concentration of 2 ng/ml and 2.5 
ng/ml for the pBABE puro and pBABE MEK-1 A221 vectors respectively and maintained in 
culture using the same concentration.
Cell line Transfected plasmid Morphology
FBR puro 2 pBABE puro transformed
FBR puro 3 pBABE puro transformed
FBR puro 4 pBABE puro transformed
FBR puro 5 pBABE puro transformed
FBR puro 9 pBABE puro flat
FBR puro 10 pBABE puro transformed
FBR puro 11 pBABE puro flat
FBR puro 14 pBABE puro transformed
FBR puro 15 pBABE puro transformed
FBR A2 MEK-1 A221 flat
FBR A3 MEK-1 A221 flat
FBR A4 MEK-1 A221 flat
FBR A5 MEK-1 A221 flat
FBR A6 MEK-1 A221 flat
FBR A8 MEK-1 A221 transformed
FBR A10 MEK-1 A221 flat
FBR A11 MEK-1 A221 flat
FBR A14 MEK-1 A221 transformed
FBR A16 MEK-1 A221 transformed
FBR A17 MEK-1 A221 flat
FBR A19 MEK-1 A221 flat
FBR A20 MEK-1 A221 transformed
FBR A21 MEK-1 A221 flat
FBR A22 MEK-1 A221 flat
FBR A23 MEK-1 A221 flat
FBR A28 MEK-1 A221 flat
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Table 6.3 . Experiment 2. Morphological characteristics of FBR transfected with pBABE puro 
and pBABE MEK-1 A221.
FBR cells were transfected with 1 of pBABE puro and 5 ng of pBABE MEK-1 A221 using 
lipofection. The clones were selected with puromycin at a final concentration of 2 fxg/ml and 2.5 
ng/ml puromycin for the pBABE puro and pBABE MEK-1 A221 vectors respectively and 
maintained in culture using the same concentration.
Cell line Transfected plasmid Morphology
FBR puro 1 pBABE puro transformed
FBR puro 2 pBABE puro transformed
FBR puro 6 pBABE puro transformed
FBR puro 9 pBABE puro flat
FBR puro 10 pBABE puro transformed
FBR puro 15 pBABE puro transformed
FBR puro 19 pBABE puro transformed
FBR puro 23 pBABE puro transformed
FBR A221 1 MEK-1 A221 flat
FBR A221 2 MEK-1 A221 flat
FBR A221 3 MEK-1 A221 flat
FBR A221 4 MEK-1 A221 transformed
FBR A221 6 MEK-1 A221 transformed
FBR A221 7 MEK-1 A221 transformed
FBR A221 8 MEK-1 A221 flat
FBR A221 9 MEK-1 A221 flat
FBR A221 10 MEK-1 A221 flat
FBR A221 11 MEK-1 A221 transformed
FBR A221 12 MEK-1 A221 transformed
FBRA221 13 MEK-1 A221 flat
FBR A221 14 MEK-1 A221 flat
FBR A221 15 MEK-1 A221 flat
FBR A221 16 MEK-1 A221 flat
FBR A221 18 MEK-1 A221 flat
FBR A221 19 MEK-1 A221 flat
FBR A221 20 MEK-1 A221 flat
FBR A221 21 MEK-1 A221 flat
FBR A221 22 MEK-1 A221 flat
FBR A221 26 MEK-1 A221 transformed
FBR A221 27 MEK-1 A221 flat
FBR A221 28 MEK-1 A221 flat
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Figure 6.1. Morphological reversion at different cell densities.
Morphology of FBR, 208F and FBR transfected with the dominant negative mutant of 
MEK-1, MEK-1 A221 at low and high cell density.
Cell lines were plated in DMEM supplemented with 10% FCS, allowed to attach for 24- 
48 hours and photographed with a Nikon inverted Diaphot microscope, a) FBR; b) 
208F; c) FBR A221 revertant dome 19 in low density; d) FBR A221 revertant dome 19 
in high density; e) FBR A221 revertant dome 23 in low density; f) FBR A221 revertant 
dome 23 in high density.
6.3. MEK-1 A221 inhibits v-fos-induced anchorage independence
After isolation of FBR A221 clones these clones were tested for the ability to grow in 
methylcellulose, that is under anchorage-independent conditions. Cells from parental cell and 
from three revertant clones FA6 , FA19 and FA23, were plated in Ham’s media containing 1.5% 
methylcellulose and allowed to grow for 20 days. After this period of time colonies were 
observed using the light microscope. Clones FA6  and FA19 showed no colonies (Figure 6.2) 
and clone FA23 showed few colonies reduced in size compared to the parental FBR fibroblasts 
(Figure 6.2). The FBR cell line maintained under the same conditions gave rise to a high number 
of colonies of large size (Figure 6.2,a) and the 208F resulted in no colonies (Figure 6.2,b). As a 
positive control another transformed cell line Ki-Mu-SV transformed 208F cells (208F v-Ki-ras) 
was included. These cells formed colonies in methylcellulose with high efficiency of larger size 
than the FBR colonies (Figure 6.2,c). The data from three different experiments are summarised 
in Table 6.4. In this table it is shown that FBR cells form colonies with high efficiency but the 
FBR A221 6  and FBR A221 19 clones do not form any colonies in the semi-solid medium after 
approximately 3-4 weeks of growth in these media. FBR A221 23 clone formed colonies of 
decreased size and approximately 4-fold decreased in number when compared to FBR cells.
Previous reports highlight the role of a constitutively active form of MEK-1 in 
morphological transformation (Cowley et al., 1994; Mansour et al., 1994). In these published 
reports there is little evidence for MEK-1 A221 in oncogene-induced anchorage-independent 
growth (Cowley et al., 1994). By transfection of the dominant negative mutant MEK-1 A221 into 
FBR cells we demonstrate that MEK-1 A221 has a role, in semi-solid media growth of FBR , as 
a parameter of cellular transformation in vitro.
Since the expression vectors for the wild type and A221 MEK-1 do not contain an 
epitope tag to identify the expressed proteins by western analysis or by immunoprecipitation 
experiments, a functional approach was employed to obtain evidence for biochemical activity of 
the mutant MEK-1 A221, as an indication of its presence in FBR A221 transfectants.
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FBR 208F
FBR A221 c 23 
  -------
Figure 6.2. G rowth in sem i-so l id  med ium  of FBR, 208F  and FBR transfected  with 
wild type and dom inan t negative  mutant of MEK-1 A221.
Cells grown in m ethy lce l lu lose  conta in ing 10% FCS fo r 20 days and photographed
with a Nikon D iaphot m ic roscope , a) FBR cells; b) 208F cells; c) v-K i-ras
trans fo rm ed 208F cells; d) FBR MEK-1 A221 revertan t clone 6; e) FBR MEK-1
A221 revertan t c lone 19; f) FBR MEK-1 A221 revertan t c lone 23; g )FBR  MEK-1
A221 c lone wt2; h) FBR wild type MEK-1 c lone wt7.
Table 6.4. in vitro Anchorage-Independent growth of FBR and FBR A221 cells.
Cell lines were passaged in DMEM supplemented with 10% FCS, trypsinized, counted with a cell 
chamber counter and 2x104  cells were plated in Ham’s media containing 1.5% Methylcellulose. 
Colonies were counted after 3-4 weeks by phase contrast microscopy. Three independent 
experiments are shown were duplicate samples were assayed
Cell line Experiment 1 Experiment 2
FBR 12672- 12096 12320 14227
Average 12384 13273
ratio 0.61 0 . 6 6
Ceil line Experiment 1 Experiment 2
FBR A221 23 3600 - 3264 ND
Average 3432 ND
ratio 0.17 ND
Cell line Experiment 3
FBR 14784- 12936
Average 13860
ratio 0.69
Cell line Experiment 3
FBR A221 23 2669 - 4006
Average 3337
ratio 0.16
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6.4. MEK-1 A221 suppresses serum-induced MAP-Kinase activation in FBR 
MEK-1 mutants that have an Alanine substitution in the position of the Serine 221 have a 
reduced ability to phosphorylate MAP Kinase (Alessi et al., 1994). Here the ability of MEK-1 
A221 to suppress MAP Kinase activation by extracellular agonists was examined using 
phosphospecific antibodies in western immunoblotting experiments. Since the pBABE MEK-1 
A221 vector (Cowley et al., 1994) is not tagged, this method was chosen to demonstrate the 
function of the dominant negative MEK-1 in our cell lines. In previous experiments RT-PCR was 
not able to detect the MEK-1 A221 mutant. This could have been possibly due to the high 
homology at the nucleic acid level between the transfected rabbit enzyme (Ashworth et al., 
1992) and the endogenous rat MEK-1.
To test MEK-1 A221 the phospho-specific antibody that has affinity for the dually 
phosphorylated forms of MAP Kinases was used, ERK1 and ERK2 as it was used in the 
previous chapter to compare MAP Kinase phosphorylation between FBR and 208F cells. From 
quiescent and serum stimulated for 5 minutes cultures of FBR, 208F and FBR A211 clones 6  , 
19 and 23 cell lysates were prepared using the standard Triton X-100 lysis buffer. The proteins 
were separated by 10% SDS-PAGE, transferred to PVDF membranes and blotted with the 
phosphospecific antibody.
208F cells induced with 10% foetal calf serum show a significant activation of MAP 
kinase phosphorylation approximately 1 0 -fold over basal levels (maximal activation taken as 1 , 
n=3, P=0.04; Table 6.5; Figure 6.3A, lane 8 ). In the case of FBR this response is 5-fold reduced 
(0.2+/-0.09, n=4 P<0.05; Figure 6.3A, lane 3). In the FBR cells the immunoreactivity of phospho- 
reactive MAP Kinase after serum stimulation showed reproducible decreased levels compared 
to the activation ERK1 and ERK2 in 208F cells.
In the FBR A221 clones 6 , 19 and 23 after serum induction, a 2 to 3-fold decrease in 
the phosphorylation of MAP Kinases was observed when compared to FBR cells (Figure 6.3A 
lane 11 compare with lane 3/ and Figure 6.3B lanes 7 and 11 compare with lane 3). In clone 19 
presented in the Table 6.5 the response to serum induction was approximately 2-fold reduced 
compared to FBR cells (In the FBR the response to serum was maximal at 0.2+/-0.05, n=3 , 
P<0.05, approximately 2 fold over the basal of FBR control and in clone 19 0.15+/-0.04, n=3, 1.3 
fold reduced compared to FBR control, significant at P<0.05/ also look Table 6.5).
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Other stimuli will also induce MAP kinase phosphorylation in fibroblasts. Stimulation for 
example with sodium orthovanadate, a general inhibitor of protein tyrosine phosphatases 
potentiates activation of ERK’s possibly by enhancing the basal autophosphorylation activity of 
Receptor Tyrosine Kinases and by inhibiting the dual-specificity Tyrosine-Threonine 
phosphatases involved in MAP Kinase signalling. Recently there is evidence to support a 
positive role of vanadate in the activation of the MAP Kinase pathway (Zhao et al., 1996) and the 
role of orthovanadate in ERK stimulation in Rat-1 fibroblasts has been well studied (Cook etal., 
1997).
The activation of MAP Kinases by orthovanadate in FBR, 208F and FBR A221 revertant 
cells was next addressed. As shown in Figure 6.4 the data are similar with the results of serum 
stimulation presented in Figure 6.3. In FBR serum induces MAPK phosphorylation whereas 
orthovanadate does not (Figure 6.4A lanes 2 and 3 and Figure 6.4B lanes 3 and 4, for serum 
and orthovanadate respectively; 0.6+/-0.2 activation for serum-treated FBR cells, n=3 not 
significant at P>0.05 and in FBR treated with orthovanadate activation was 0.09+/-0.01, n=3, not 
significant, P>0.05). In contrast, in 208F cells orthovandate stimulates a similar response to 
serum in activating ERK’s which is significant (Figure 6.4A lanes 5 and 6  / 6.4B lanes 6  and 8  for 
serum and orthovanadate respectively; 208F serum treated activation was taken as maximal 1 
and in the orthovanadate 208F treated samples 0.92+/-0.16, n=3, P<0.05). In the FBR A221 
revertants the response to stimulation by orthovanadate was not significant (Figure 6.4A, lanes 9 
and 12 and 6.4B lane 11; activation for clone 6  0.065+/-0.015, n=3, P>0.05; activation for clone 
19 0.1+/-0.005, n=3, P>0.05; activation for clone 23 0.07+/-0.01, n=3, P>0.05). The serum 
induction in the FBR A221 clones was maintained in lower levels compared to FBR as shown in 
the Figure 6.3 (The activation by serum in FBR A221 clones was 2-3 fold reduced compared to 
FBR parental cells. More specifically for clone FBR A221 6  activation by serum was 0.15+/-0.04, 
n=3, P<0.05, for clone FBR A221 19 activation was 0.21+/-0.03, n=3, P<0.05 and for clone FBR 
A221 23 activation 0.33+/-0.011, n=3, P<0.051).
These data suggest that MEK-1 A221-induced reversion of FBR possibly does sensitise 
the response to MAP Kinases to this inhibitor of protein tyrosine phosphatases. The 
phosphorylation of ERK’s in response to this compound was maximal in 208F cells, a derivative 
of Rat-1 cells, but remained in lower levels in the FBR cells.
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From these experiments is not possible to assess the expression of the MEK-1 
dominant negative mutant A221, an alternative approach was used to try to identify its 
expression and function. This was to subject lysates prepared from FBR A221 derived clones 
and from control FBR and 208F cells to low bis-Acrylamide SDS-Polyacrylamide gel 
electrophoresis followed by western immunoblotting. In this experiment the phosphorylatable 
endogenous MEK-1 could be possibly distiguished from the transfected A221 mutant MEK-1 by 
mobility shift of the phosphorylated MEK-1. In the Figure 6.4a such an experiment is shown 
where the phosphorylation of MEK-1 in 208F cells is clearly indicated by the double band that 
appears after immunoblotting with the phospho-specific antibodies (Figure 6.4a A, lane 4). This 
pattern is several-fold less intense in the parental serum-induced FBR cells (Figure 6.4a A, lane
2). In the case of the FBR A221 clones 19 and 23 there is staining of MEK-1 that is shifting after 
western immunoblotting although majority of the MEK-1 is retained in the non-phosphorylated 
lower isoform. This experiment which is rather difficult to interpret suggests that the this 
approach although powerful did not gave clear evidence for the expression of the MEK-1 A221.
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Figure 6.3 . Phosphorylation of MAPK by serum in FBR, 208F and FBR transfected 
with a dominant negative mutant of MEK-1 A221.
Cell lines were grown in DMEM supplemented with 10% FCS and when sub-cofluent 
serum-deprived for 48 hours (0.1% FCS).
Stimulation was for 5 minutes with 10% FCS. The pre-treatment with the MEK-1 
inhibitor PD 98059 was for 30 minutes at a final concentration of 50pM. Cell lysates 
were prepared and proteins were separated by 10% SDS-PAGE, transferred to 
PVDF membranes and probed with an antibody specific for phosphorylated ERK1 
and ERK2 (MAPK*, Promega labs, Wl, USA).
Blots were stripped and probed with an antibody specific for ERK2 as a loading 
control (ERK2) (Trasnduction labs, KY, USA). The indicated times are the exposing 
times that the blots were exposed to the FUJI X-mat film after the ECL reagent was 
added to the membranes. This experiment is representative of two independent 
experiments.
FBR lysates 208F lysates FBR A221 6 lysatesFBR A221 19 lysates
S Od''
>o >o >o >o
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b lo t: anti- MEK-1
b lo t: anti-ERK2
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FBR lysates 208F lysates FBR A221 23 lysates
>o o o
blot :anti- MAPK
b lo t: anti- MEK-1
b lo t: anti-ERK2
10 11
Figure 6.4. Phosphorylation of MAPK by serum, sodium orthovandate, and their 
comibination in FBR, 208F and FBR transfected with the dominant negative mutant 
of MEK-1 A221.
Cell lines were grown in DMEM supplemented with 10% FCS and when 
subconfluent serum-deprived for 48 hours (0.1% FCS).
Stimulation was for 5 minutes with 10% FCS, 100 |iM sodium orthovanadate, their 
combination or the cells were left untreated. The pretreatment with the MEK-1 
inhibitor PD 98059 was for 30 minutes at a final concentration of 50 fiM. Cell lysates 
were prepared and proteins were separated by 10% SDS-PAGE, transferred to 
PVDF membranes and probed with an antibody specific for the phosphorylated 
ERK1 and ERK2 (MAPK*, Promega labs, Wl, USA).
Blots were stripped and probed with an antibody specific for ERK2 as a loading 
control (ERK2, Transduction labs, KY, USA).
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Figure 6.4a. Identification of MEK-1 phosphorylated isoforms by low-bisAcrylamide 
SDS-Polyacrylamide electrophoresis in lysates of -quiescent and serum-stimulated 
FBR, 208F and FBR transfected with a dominant negative mutant of MEK-1 A221.
Cell lines were grown to subconfluence in DMEM supplemented with 10% FCS and 
they were serum deprived for 48 hours (0.1% FCS). Stimulation was for 5 minutes with 
10% FCS.
Cell lysates were prepared and the proteins were separated by 10% SDS-PAGE,, 
transferred to PVDF membrane and probed A) with an antibody specific for the dually 
phosphorylated MEK-1 (MEK-1*) (New England Bio., MA, USA). The same blot was 
stripped and probed with B) an antibody for MEK-1 (MEK-1) (Santa Cruz Bio., CA, 
USA) to verify equal loading.
A) and B) 1) FBR serum deprived cells; 2) FBR serum stimulated cells; 3) 208F serum 
deprived cells; 4) 208F serum stimulated cells; 5) FBR MEK-1 A221 revertant clone 19 
serum deprived; 6) FBR MEK-1 A221 revertant clone 19 serum stimulated; 7) FBR 
MEK-1 A221 revertant clone 23 serum deprived; 8) FBR MEK-1 A221 revertant clone 
23 serum stimulated.
This is a representative experiment of two with similar results
Table 6.5. Modulation of MAP Kinase by serum in FBR, 208F and FBR clone 19 transfected with
MEK-1 A221.
The cells were pre-treated with 50 pM of PD98059 for 30 minutes and then left untreated or 
serum stimulated with 10% FCS for 5 minutes.
Quantification of the increase in phosphorylation of ERK1 and ERK2 was performed using 
scanning densitometry. The band of serum-stimulated 208F cells was taken as the maximal, 
100% activation. The values were normalised for control loading of ERK2 for each individual 
experiment. The values are the mean of three independent experiments.
0.8
0.6
0.4
0.2
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- 0.2
1) FBR serum-deprived cells
2) FBR cells treated with 50 jaM of PD98059
3) FBR serum-stimulated cells
4) FBR cells pre-treated with 50 jxM of PD98059 and serum-stimulated for 5 minutes
5) 208F serum-deprived cells
6 ) 208F cells treated with 50 jaM of PD98059
7) 208F serum-stimulated cells
8 ) 208F cells pre-treated with 50 pM of PD98059and serum-stimulated for 5 minutes
9) FBR A221 clone 19 serum-deprived cells
10) FBR A221 clone 19 treated with 50 nM of PD98059
11) FBR A221 clone 19 serum-stimulated cells
12) FBR A221 clone 19 treated with 50 nM of PD98059 and serum-stimulated for 5 minutes
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6.5. Growth factor activation of MAPK in FBR, 208F and FBR A221 revertants 
To examine the effect of a purified growth factor on MAP Kinase activation, lysates of FBR, 
208F and FBR A221 cells treated with EGF were analysed by western immunoblotting with the 
MAPK phosphospecific antibody. Activation was again determined by the intensity of the ERK1 
and ERK2 in the autoradiograms. As shown in Figure 6.5, stimulation of FBR cells with 100 
ng/ml EGF gave rise to a modest stimulation of MAP Kinase phosphorylation (Figure 6.5 lane 3; 
activation 0.15+/-0.02 , n=3, P<0.05/ Table 6 .6 ). In the case of 208F cells, induction of ERK’s 
with 100 ng/ml EGF resulted in maximal activation of ERK1 and ERK2 (Figure 6.5 lane 7; 
maximal activation taken as 1, n=3, P<0.05/ Table 6 .6 ). FBR MEK-1 A221 revertants are 
sensitive to induction by serum of MAP kinases and the effect of serum is suppressed, as 
shown in Figures 6.3 and 6.4. However stimulation of quiescent FBR A221 revertant clones 6 , 
19 and 23 with 100 ng/ml EGF resulted in activation of ERK1 and ERK2 phosphorylation of 
approximately 2 to 3-fold over the response observed in the FBR cells (Figure 6.5A lane 11 and 
6.5B lanes 7 and 11/ For the FBR A221 clone 6  activation was 0.4+/-0.02, n=3, P<0.05/ For 
clone FBR A221 19 activation was 0.23+/-0.07, n=3, P<0.05 and for clone FBR A221 23 
activation 0.46+/-0.05, n=3, P>0.05/ look also Table 6 .6 ).
Identical results were obtained by treating FBR A221 revertants with 100ng/ml EGF as 
shown in an independent experiment in Figure 6 .6 . Again there an induction of MAPK 
phosphorylation in the FBR A221 revertant clones by EGF was observed. A plausible 
explanation for the effect of EGF, according to the studies of Krebs and co-workers (Seger et 
al., 1994) is that 100 ng/ml EGF is saturating concentration, and despite the presence of the 
inactive kinase the pathway is efficiently activated. These investigators have shown in 
transfection experiments that at 100 ng/ml EGF a maximal response in all the MEK-1 subtypes 
(wild type, dominant negative and constitutively active MEK-1 isoforms) occurs in NIH 3T3 cells. 
Marshall and co-workers also have suggested that the mutants of MEK-1 are effective in low 
concentrations of EGF, of approximately 0.2 nM (Cowley et al., 1994). According to these 
investigators the MEK-1 A221 mutant at low concentrations of EGF is able to confer maximal 
92% inhibition as a response to this particular growth factor in the activation of MAP Kinases.
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Figure 6.5. Phosphorylation of MAPK by EGF in FBR, 208F and FBR transfected 
with the dominant negative mutant of MEK-1 A221.
Cell lines were in DMEM supplemented with 10% FCS, and when subconfluent 
serum-deprived for 48 hours (0.1% FCS).
Stimulation was for 5 minutes with 100 ng/ml EGF. The pretreatment with the MEK- 
inhibitor PD 98059 was for 30 minutes at a final concentration of 50fiM. Cell lysates 
were prepared and proteins were separated by 10% SDS-PAGE, transferred to 
PVDF membranes and probed with an antibody specific for phosphorylated ERK1 
and ERK2 (MAPK*, Promega labs, Wl, USA).
Blots were stripped and probed with an antibody specific for ERK2 as a loading 
control (ERK2, Transduction labs, KY, USA).
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Figure 6.6. Phosphorylation of MAPK by EGF in FBR, 208F and FBR transfected 
with the dominant negative mutant of MEK-1 A221.
Cell lines were grown in DMEM supplemented with 10% FCS and when 
subconfluent serum-deprived for 48 hours (0.1% FCS).
Stimulation was for 5 minutes with 100 ng/ml EGF. The pre-treatment with the 
MEK-inhibitor PD 98059 was for 30 minutes at a final concentration of 50 pM. Cell 
lysates were prepared and proteins were separated by 10% SDS-PAGE, 
transferred to PVDF membranes and probed with an antibody specific for 
phosphorylated ERK1 and ERK2 (MAPK*, Promega Labs, Wl, USA).
Blots were stripped and probed with antisera specific for ERK2 as a loading control 
(ERK2, Transduction labs, KY, USA). This experiment is a representative of two 
independent experiments.
Table 6 .6 . Modulation of MAP Kinase activation by 100 ng/ml of EGF FBR, 208F and FBR 
clones A221 6 , 19 and 23 transfected with dominant negative MEK-1 A221.
The cells were pre-treated with 50 nM of PD98059 for 30 minutes and then left untreated or 
stimulated with 100 ng/ml of EGF for 5 minutes.
Quantification of the increase in phosphorylation of ERK1 and ERK2 was performed using 
scanning densitometry. The band of serum-stimulated 208F cells was taken as the maximal, 
100% activation. The values were normalised for control loading of ERK2 for each individual 
experiment. The values are the mean of three independent experiments.
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1) FBR serum-deprived cells
2) FBR cells treated with 50 jaM of PD98059
3) FBR EGF-stimulated cells
4) FBR cells pre-treated with 50 [aM of PD98059 and EGF-stimulated for 5 minutes
5) 208F serum-deprived cells
6) 208F cells treated with 50 jaM of PD98059
7) 208F EGF-stimulated cells
8 ) 208F cells pre-treated with 50 piM of PD98059and EGF-stimulated for 5 minutes
9) FBR A221 clone 6  serum-deprived cells
10
11
12
13
14
15
16
17
18
19
20
FBR A221 clone 6 treated with 50 jaM of PD98059 
FBR A221 clone 6  EGF-stimulated cells
FBR A221 clone 6  pre-treated with 50 jaM of PD98059 and EGF-stimulated for 5 minutes
FBR A221 clone 19 serum-deprived cells
FBR A221 clone 19 treated with 50 |aM of PD98059
FBR A221 clone 19 EGF-stimulated cells
FBR A221 clone 19 treated with 50 jaM of PD98059 and EGF-stimulated for 5 minutes
FBR A221 clone 23erum-deprived cells
FBR A221 clone 23treated with 50 jaM of PD98059
FBR A221 clone 23 EGF-stimulated cells
FBR A221 clone 23 treated with 50 jaM of PD98059 and EGF-stimulated for 5 minutes
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6.6. PD98059 negatively regulates MAPK signalling in FBR
In this series of experiments (Figure 6.3, Figure 6.5, Figure 6 .6 ) the recently described MEK-1 - 
specific inhibitor PD 98059, developed by Alan Saltiel and co-workers (Dudley etal., 1995) was 
also used. This inhibitor has been shown to be selective towards MEK-1, and acts to prevent 
extracellular stimulation of MAPK by growth factors (Dudley etal., 1995 ; Alessi etal., 1995).
Serum-starved FBR, 208F and FBR A221 revertant cells were treated with 50 jiM PD 
98059 for 30 minutes before the addition of 10% FCS serum or 100 ng/ml EGF. When FBR are 
pre-treated with PD 98059, then stimulated with 10% FCS, phosphorylation of MAP Kinases was 
abolished as shown in the western immunoblots. Statistical analysis showed that was a 
significant response (Figure 6.3A lane 4, Figure 6.3B lane 4; FBR activation 0.2+/-0.09 , n=3, 
P<0.05; and FBR pretreated with the PD98059 0.063+/-0.005, n=3, P>0.05).
A similar response was seen for PD 98059-pre-treated-FBR cells after induction with 
100 ng/ml EGF (Figure 6.5A lane 4, Figure 6.5B lane 4 ; Figure 6 .6 A lane 4, Figure 6 .6 B lane 4; 
activation of FBR MAP Kinases by EGF was 0.15+/-0.02, n=3, P<0.05 ; inhibition by PD98059 of 
MAP Kinases in FBR treated with EGF was 0.13+/-0.05, n=3, not significant with P>0.05). These 
data suggest that in FBR, MAP Kinase phosphorylation is not very sensitive to pharmacological 
inhibition by the MEK-1 inhibitor PD 98059 although as it appears in the western immunoblotting 
experiments the levels of phosphorylated ERK’s return to basal if FBR are treated with PD 
98059 and then stimulated with serum or EGF.
In the case of 208Fcells there was a different pattern of response to the treatment with 
the PD 98059, both when treated with serum or EGF. 208F cells are more resistant to treatment 
with PD 98059, since after pretreament with PD 98059 and stimulation with serum the MAP 
Kinase phosphorylation is reduced 2 which was significant (Figure 6.3 A lane 7 maximal 
activation was taken as 1, n=3, P<0.05; compare to lane 8 , activation 0.59+/-0.02, n=3, P<0.05). 
PD98059 reduces only by 20% the appearance of phosphorylated MAP Kinases in 208F cells 
after induction with 100 ng/ml EGF (significant with P<0.05, see Figure 6.4A lane 8  and Figure 
6.5A lane 8 , activation for 208F pre-treated with PD 98059 and treated with EGF: 0.79+/-0.04, 
n=3, P<0.05).
FBR A221 clones 6 , 19 and 23 pre-treated with PD 98059 then stimulated with 10% 
FCS exhibited a reduction in the levels of phosphorylated ERK’s (Figure 6.3A lane 12 ; Figure 
6.3B lanes 8  and 12, e.g. clone 19, P<0.05). This suggests that: in the case of serum the FBR
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A221 revertant clones are sensitive to the inhibition by PD 98059. When PD*98059-pretreated 
FBR A221 clones were stimulated with 100 ng/ml of EGF there was not a complete inhibition 
and still phosphorylated ERK1 and ERK2 bands appear in clones 6  and 19 (Figure 6.5A lane 12, 
Figure 6.5B lanes 8 / For example in the FBR A221 clone 6  the activation after pre-treatment with 
PD 98059 and subsequent EGF induction was 0.11+/-0.01, n=3, P<0.05; in the FBR A221 clone 
19 the activation was 0.24+/-0.5, n=3, P>0.05 and in the FBR A221 clone 23 the activation was 
0.21+/-0.01, n=3, P<0.05). These data show some similarities with the results from the 208F
cells pre-treated with PD 98059 and stimulated with EGF where there is not an inhibition in the
MAP Kinase phosphorylation (Figure 6.5A lane 8  ; Figure 6 .6 A lane 8 )
The experiments with the MEK-1-specific inhibitor PD 98059 in 208F cells suggested 
that EGF and serum can activate MAP Kinase phosphorylation in the presence of the MEK-1 
inhibitor PD 98059. This effect could be partially mediated by a non-MEK-1 signalling 
mechanism. When activation of MAP Kinases is measured by phosphospecific antibodies it was 
found to be increased inraf-1 fibroblasts compared to other cell lines such as NIH 3T3 and Hela 
cells (Yung etal., 1997). Using MAP Kinase phosphospecific antibodies this group also showed 
that activation of the MAP Kinase pathway in raf-1 fibroblasts is elevated, sustained and 
maximally activated by purified growth factors such as EGF. Others have suggested that there 
might be alternative ways to activate MEK-1. These studies have demonstrated the existence of 
MEK-1 activators other than Raf-1 kinase (Zheng etal., 1994; Pang et al., 1995; Pritchard etal., 
1995). Saltiel and co-workers have identified an alternative regulator of MEK-1 although have so 
far been unable to clone this kinase (Zheng et al., 1994). McMahon and co-workers have 
identified that different forms of the Raf-1 kinase exert diverse responses in fibroblasts to the 
activation of MAP Kinases and the induction of DNA synthesis (Pritchard et al., 1995), which
may account for the results presented here.
6.7. FBR A221 revertants have increased content of F-actin
Cells transformed by oncogenic viruses have a decreased content of F-actin resulting from the 
reduction of number of stress fibres detected by staining with Rhodamine-labelled Phalloidin or 
actin-specific antibodies (Weber et al., 1974; Pollack etal., 1975).
To gain insight into the possible involvement of the dominant negative mutant of MEK-1 
A221 into the reversion of /bs-induced transformation, the actin distribution and actin content of
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FBR A221 revertants in comparison to the parental FBR cells was investigated. In order to 
pursue this question a fluorescent immunostaining approach was used and the results analysed 
using a Bio-Rad MRC Laser Confocal Illumination unit attached to a Nikon Diaphot inverted 
microscope.
208F cells when actively growing in media with 10% FCS are well attached and they 
have actin stress fibres. Upon serum deprivation actin stress fibres in 208F cells do not 
disappear completely and the cells remain well attached to the plastic substratum (Figure 6.7a). 
Immunostaining with an monoclonal antibody for phosphotyrosine (P-tyr) to visualise focal 
adhesions showed that focal adhesions were detectable in 208F cells when starved and these 
are localised to the cell periphery (Figure 6.7a).
In contrast to 208F cells, FBR have a spindle-shaped morphology in monolayer culture 
and contain few actin stress fibres. Actin in these cells is disorganised (Figure 6.7c). FBR have a 
very small number of focal adhesions when quiescent, although these can still be detected by 
staining with the monoclonal antibody specific for phosphotyrosine (Figure 6.7c). In FBR focal 
adhesions are found in the cell periphery and actin is found concentrated to the end of the cell in 
the area of the pseudopod.
Treatment of quiescent 208F with 10% FCS results in a rapid reorganisation of the actin 
components into well defined actin stress fibres as shown in Figure 6.7b after immunostaining 
with Rhodamine-Phalloidin. Serum contains a component, most probably the lipid LPA, which is 
a potent inducer of actin reorganisation (Ridley and Hall, 1992).
In FBR the activation of MAPK by LPA is poor but serum and LPA are potent in their 
ability to induce actin filament redistribution upon stimulation for a short time (Figure 6.7d). This 
conserved function between normal and transformed fibroblasts suggest that serum might have 
a role in the anchorage-dependent growth, which might be dissociated from activation of MAP 
Kinase signalling.
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Figure 6.7. Serum-induced Actin reorganisation in FBR and 208F cells.
Cell lines were plated in DMEM with 10% FCS and after 24-48 hours were serum deprived for 7 
days. After this period of time cells were stimulated with 10% FCS for 5 minutes, fixed, 
permeabilized and stained with TRITC-conjugated Phalloidin to visualise actin and with a 
monoclonal antibody against phosphotyrosine to visualise focal adhesions. This is an 
experiment representative of at least three independent experiments.
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In FBR A221 revertants the phalloidin-detectable F-actin filaments are increased, and the 
cytoskeleton is organised in a similar manner to 208F cells where actin is present in a large 
number of stress fibres (Figure 6 . 8  a and c). Staining for phosphotyrosine (P-tyr) to visualise 
focal adhesions showed that these structures are localised to the cell periphery and are 
abundant compared to 208F cells (Figure 6 . 8  a and c). Stimulation with serum resulted in a 
redistribution of F-actin to the periphery and an increased number of fibres (Figure 6 . 8  picture b 
and d) similar to 208F fibroblasts (Figure 6 . 8  b). In the FBR A221 revertant cells the focal 
adhesion components are reorganised by serum stimulation as shown by indirect 
immunofluoresence (Figure 6 . 8  c and d)
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Figure 6.8. Serum-induced Actin reorganisation in FBR A221 transfectants
FBR A221 clones 19 and 23 were plated in DMEM with 10% FCS and after 24-48 hours were 
serum deprived for 7 days. After this period of time cells were stimulated with 10% FCS for 5 
minutes fixed, permeabilized and stained with TRITC-conjugated Phalloidin to visualise actin 
and with a monoclonal antibody against phosphotyrosine to visualise focal adhesions. This is an 
experiment representative of at least three independent experiments.
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6.8. Serum-dependent actin reorganisation in FBR A221 revertants
In an attempt to identify mechanisms of actin reorganisation, Ridley and Hall (1994) have 
examined the role of various activators of pathways involved in mitogenic signalling. Instead of 
serum and growth factors, they used activators of PKC and PKA to investigate changes in the 
actin distribution in Swiss 3T3 cells. Their data suggest that a requirement for a tyrosine kinase 
signal is important in the reorganisation of the actin component. Activators of PKA such as 
forskolin do not inhibit the formation of new stress fibres by LPA or by activated V14rho proteins. 
This suggests that although PKA signals disrupt stress fibre formation in Swiss 3T3 cells they do 
not lead to the prevention of formation of new actin fibres.
Incubation of serum-deprived 208F cells with 2 jaM dibutyril-cAMP for 30 minutes to 
enhance endogenous PKA activity resulted in a dramatic reorganisation of the cytoskeleton in 
the form of peripheral actin resembling the effect of PDGF or Insulin on Swiss 3T3 cells (Figure 
6.9b). Incubation of serum-starved 208F cells with 10% FCS resulted in the formation of stress 
fibres and new focal adhesions (Figure 6.9c). When these cells were pre-treated with dibutyril- 
cAMP and subsequently with 10% FCS for 5 minutes, the membrane ruffling activity due to PKA 
activation was to a large extent overcome by the effect of serum (Figure 6.9d) suggesting that 
serum was responsible for the formation of new stress fibres, in accordance with Ridley and Hall 
(1994).
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Figure 6.9. Actin reorganisation in 208F cells by cAMP and serum.
Cells lines were plated in DMEM supplemented with 10% FCS and after 24 hours were serum 
deprived for 7 days. After this period, cells stimulated with 10% FCS, 2 [xM dbcAMP, their 
combination or remained untreated. Cells were fixed, permeabilized and stained with TRITC- 
conjugated Phalloidin to visualise actin stress fibres and with a monoclonal antibody against 
phosphotyrosine to stain Focal Adhesions. This is an experiment representative of three 
independent experiments.
a) 208F fibroblasts in 0.1% FCS ; b) 208F fibroblasts stimulated for 5 minutes with 10% FCS ; c) 
208F fibroblasts stimulated for 30 minutes with 2 |xM of dbcAMP ; d) 208F fibroblasts stimulated 
for 20 minutes with 2 |xM of dbcAMP and treated then with 10% FCS.
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Treatment of quiescent FBR with dibutyril-cAMP did not lead to the induction of membrane 
ruffling and surprisingly induced the appearance of few stress fibres and an increase in cell 
volume, effects that are induced by the addition of foetal calf serum to the media. This treatment 
did not lead to the formation of new focal adhesions suggesting that the increase of the 
intracellular cAMP which opposes LPA and Rho signalling is not sufficient to mediate this event 
(Ridley and hall, 1992; Ridley and hall, 1994). Treatment with 10% FCS induced the 
reorganisation of the actin cytoskeleton and the reappearance of new focal adhesions (Figure 
6.10c). Pre-treatment with dibutyril-cAMP for 30 mimutes and subsequent treatment with 10% 
FCS for 5 minutes lead to a similar situation to that observed in 208F’s where focal adhesions 
and actin stress fibres reform, suggesting that the activation of PKA is not sufficient to lead to 
the dissolution of the reformed actin network and that the serum-induced response is sufficient 
for this effect (Figure 6.10d)
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Figure 6.10. Actin reorganisation in FBR cells by cAMP and serum.
Cells lines were plated in DMEM supplemented with 10% FCS and after 24 hours were serum 
deprived for 7 days. After this period, cells stimulated with 10% FCS, 2 ^M dbcAMP, their 
combination or remained untreated. Cells were fixed, permeabilized and stained with TRITC- 
conjugated Phalloidin to visualise actin stress fibres and with a monoclonal antibody against 
phosphotyrosine to stain Focal Adhesions. This is an experiment representative of three 
independent experiments.
a) FBR in 0.1% FCS ; b) FBR stimulated for 5 minutes with 10% FCS ; c) FBR stimulated for 20 
minutes with 2 jiM of dbcAMP ; d) FBR stimulated for 30 minutes with 2 nM of dbcAMP and 
treated then with1 0 % FCS.
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Tthe induction of actin reorganisation in the FBR A221 revertants by cAMP activation of PKA 
was also examined. Serum deprived FBR A221 cells display a flat morphology and have stress 
fibres (Figure 6.11a). Treatment with dibutyril-cAMP does not have any dramatic effect in the 
actin distribution neither nor on the formation of focal adhesions (Figure 6.11b). Treatment with 
10% FCS results in reorganisation of the cytoskeleton and focal adhesions in the cell periphery 
(Figure 6.11c). This suggests that the pathway of serum induction of stress fibres remains 
unaltered by the transfection of the MEK-1 A221 expression vector. In the FBR A221 cells there 
is a constitutive appearance of actin stress fibres. This might be related to the presence of the 
dominant negative mutant MEK-1 A221.
These data suggest that A221 is somehow related to the reversion of the transformed 
morphology through the induction of the microfilament network, but the presence of this 
dominant negative mutant does not prevent reorganisation of the actin network as in the case of 
FBR TAM-67 cells.
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Figure 6.11. Actin reorganisation in FBR A221 cells by cAMP and serum.
Cells lines were plated in DMEM supplemented with 10% FCS and after 24 hours were serum 
deprived for 7 days. After this period, cells stimulated with 10% FCS, 2 jaM dbcAMP, their 
combination or remained untreated. Cells were fixed, permeabilized and stained with TRITC- 
conjugated Phalloidin to visualise actin stress fibres and with a monoclonal antibody against 
phosphotyrosine to stain Focal Adhesions. This is an experiment representative of three 
independent experiments.
a) FBR A221 clone 19 in 0.1% FCS ; b) FBR A221 clone 19 stimulated for 5 minutes with 10% 
FCS ; c) FBR A221 clone 19 stimulated for 30 minutes with 2 jiM of dbcAMP ; d) FBR A221 
clone 19 stimulated for 20 minutes with 2 jxM of dbcAMP and treated then with10% FCS.
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6.9. PD98059 modulates formation of actin stress fibres in FBR
FBR A221 revertant cell lines have an increased stress fibre content. Here the effect of the 
MEK-1 specific inhibitor PD98059 on the actin filament distribution and the reversion of the 
transformed phenotype was tested.
This inhibitor has been shown to reverse of v-ras transformation after treatment of ras- 
transformed cells for 24 hours with 50 of the inhibitor (Dudley et al., 1995). Incubation of v- 
Ki-ras transformed cells growing in 10% FCS with PD98059 resulted in a time-dependent 
reversion of morphological transformation, as shown by Rhodamine-labelled Phalloidin staining 
of the actin stress fibres (Figure 6.12 d and f).
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Figure 6.12. Actin reorganisation in v-Ki-ras transformed cells by PD98059.
Cells were plated in DMEM supplemented with 10% FCS for 24 hours, and subsequently treated 
for 24 or 48 hours hours in the presence of 10% FCS with the MEK-1 inhibitor PD 98059 at a 
final concentration of 50 p,M. To visualise actin stress fibres cells were fixed, permeabilized and 
stained with TRITC-conjugated Phalloidin by indirect immunofluorescence microscopy. This is a 
representative experiment of 2 independent experiments.
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FBR cells growing in 10% FCS were incubated with PD98059, a partial reversion and reduction 
of the membrane ruffling activity in the pseudopodes of FBR was observed (Figure 6.13 c and e, 
compared to control FBR picture a). Use of this inhibitor at a higher concentration resulted in an 
increase of the F-actin content (Figure 6.14 c and d) as well as a reduction in the membrane 
ruffling.
As shown previously in this chapter, FBR A221 revertant show a decreased membrane 
ruffling activity (Figure 6.8). This is in agreement with the results observed here, since a 
decrease in membrane ruffling after treatment of the FBR with the MEK-1-specific inhibitor 
PD98059 was seen.
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Figure 6.13. Actin reorganisation in FBR by PD98059.
Cells were plated in DMEM supplemented with 10% FCS for 24 hours, and subsequently treated 
for 24 or 48 hours hours in the presence of 10% FCS with the MEK-1 inhibitor PD 98059 at a 
final concentration of 50 jaM. To visualise actin stress fibres cells were fixed, permeabilized and 
stained with TRITC-conjugated Phalloidin by indirect immunofluorescence microscopy. This is a 
representative experiment of at least three independent experiments.
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Figure 6.14. Concentration-dependent actin reorganisation in FBR by PD98059.
Cell lines were plated in DMEM supplemented with 10% FCS for 24 hours and treated for the 
indicated periods of time with the MEK-1 inhibitor PD 98059. All treatments took place in cells 
growing in DMEM supplemented with 10% FCS. To visualise actin stress fibers, cells were fixed, 
permeabilized and stained with TRITC-conjugated Phalloidin by indirect immunofluorescence 
microscopy. This experiment is a representative of three independent experiments, 
a) FBR control in 10% FCS; b) FBR treated with 50 nM PD 98059 for 24 hours; c) FBR treated 
with 100 nM PD 98059 for 24 hours; d) FBR treated with 100 fiM PD 98059 for 48 hours.
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6.10. Conclusion
Dominant negative MEK-1 abrogates v-ras and v-src induced transformation (Cowley et al., 
1994) and constitutively active MEK-1 transforms NIH 3T3 cells (Cowley et al., 1994 ; Mansour 
et al., 1994 ; Alessandini et al., 1996 ; Greulich eta!., 1997). From this evidence it is apparent 
that the role of MEK-1 is not very well established for other types of oncogenes and its role in 
anchorage independence has not been investigated (Cowley et al., 1994).
In this study a transfection approach was used to examine the role of a dominant 
negative MEK-1 in FBR v-fos-induced transformation. After transfection of a vector encoding a 
dominant negative MEK-1 with an Alanine substitution in the regulatory Serine residue 221 it 
was found that anchorage independence growth of FBR cells was suppressed and 
phosphorylation of MAP Kinases by serum was reduced.
It has been reported that MEK-1 A221 inhibits partially MAP Kinase phosphorylation by 
the neuropeptide bombesin in Swiss 3T3 cells and this induction could be effectively reduced by 
PD98059 (Seufferlein etal., 1996). MEK-1 A221 and A217 had also a negative regulatory role in 
the induction of DNA synthesis by bombesin in Swiss 3T3 cells but not in the combination of 
bombesiin with an additional growth factor such as Insulin (Seufferlein etal., 1996).
The MEK-1-specific inhibitor PD98059 can effectively abolish phosphorylation of MAP 
Kinases by serum and EGF in FBR cells, but not completely in 208F cells. This indicates the 
existence of another putative MEK isoform in 208F since PD98059 inhibits MEK-1 by binding to 
its activation site. Another possibility in the case of 208F cells is that the response to EGF- 
induced signalling is maintained at high levels and thus a higher amount of PD 98059 is required 
to abolish MAP Kinase induction.
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RESULTS
CHAPTER 7. GENERATION OF FBR REVERTANT CELL LINES FOLLOWING 
TRANSFECTION OF THE DOMINANT NEGATIVE MUTANT OF Raf-1 KINASE, NA 
Raf-1
7.1. Raf-1 kinase is a major constituent of the Growth Factor- ras- AP-1 pathway 
A major signal transduction pathway that is stimulated by growth factors involves the small GTP- 
binding oncoprotein p21ras which belongs to a family of small GTP-binding proteins. p21ras is 
also a frequently mutated target protein in different types of human cancer (Barbacid, 1987).
A requirement for p21ras in signalling downstream of Receptor Tyrosine Kinases and 
upstream of the c-raf-1 protooncogene was first shown in microinjection experiments (Smith et 
a l, 1986). The product of the c-raf-1 protooncogene, which is the cellular homologue of the v-raf 
oncogene (Rapp etal., 1983), encodes the Serine/ Threonine Kinase Raf-1. The v-raf oncogene 
induces cellular transformation of established cell lines, and microinjection of a mutant c-Raf-1 
protein results in cellular transformation of NIH 3T3 cells (Smith etal., 1990).
GTP-bound p21ras forms complexes with Raf-1 and MEK-1, a dual specificity threonine/ 
tyrosine kinase MAP Kinase Kinase (Moodie et al., 1993). Raf-1 kinase activates MEK-1 by 
phosphorylation (Kyriakis et al., 1992; Dent et al., 1992; Howe et al., 1992). MEK-1 
phosphorylates MAP Kinases resulting in activation of their catalytic activity. MAP Kinases have 
multiple targets such as nuclear transcription factors and cytoplasmic signalling molecules 
(Treisman, 1996). Raf-1 also is required for transcriptional activation of AP-1 and regulation of 
AP-1-dependent genes (Bruderetal., 1992).
Taken together these results suggest that Raf-1 kinase might indeed be a central point 
of the ras-growth factor signalling pathway. Raf-1 kinase as mentioned already functions as a 
positive regulator of MAP Kinase signalling and AP-1 transcriptional activity, but also can serve 
other functions. These include involvement in cellular transformation (Samuels etal., 1993), cell 
cycle (Lovric and Moelling, 1996), cell proliferation (Kerkhoff and Rapp, 1997) and cell growth 
(Kerkhoff and Rapp, 1998).
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In this study a dominant negative mutant of Raf-1 kinase, NARaf-1, was used to 
investigate an involvement of Raf-1 in v-/bs transformation. To approach this question FBR cells 
were transfected with the NARaf-1 and stable transfectants were generated. These cell lines 
have the properties of the revertant and a possible role of ANRaf-1 in reversion is discussed.
7.2. Transfection of NA Raf-1 in FBR and 208F cells
In order to continue the study of the MAP Kinase pathway in FBR cells, Raf-1 kinase activity was 
inhibited by transfection of the an expression vector encoding for a C-terminally truncated Raf-1 
kinase NA Raf-1 (Schaap et al., 1993). This mutant lacks the catalytic domain of Raf-1 kinase 
and has been shown to be a negative regulator of MAP Kinase signalling in mammalian cells by 
blocking activation of MAP Kinases by EGF and TPA (Schaap etal., 1993).
The pEXV-NA Raf-1 vector was transfected together with the pSV2neo, which confers 
G418 resistance as a means for selection of transfectants. After selection in G418 for 
approximately three weeks, stable cell clones expressing NA Raf-1 were isolated for phenotypic 
and biochemical analysis.
After selection with G418 was completed the transfection dishes were stained with 
Giemsa to assess relative colony formation. A reduction of approximately 0.7-fold in total colony 
number was observed for FBR cells after transfection of NARaf-1 when compared with FBR 
cells transfected only with the pSV2neo control vector alone (Table 7.1). Therefore introduction 
of NARaf-1 did not result in inhibition of colony formation in FBR in contrast to the transfections 
with the dominant negative Jun TAM-67 mutant and the kinase-inactive MEK-1 A221. The 
NARaf-1 mutant was also introduced in the 208F cells. In this case a slight increase in the 
colony number by 1.2-fold was observed.
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Table 7.1. Colony formation after transfection of NA Raf-1 into FBR and 208F cells.
Cells were transfected with the indicated amounts of CsCI-purified plasmid DNA using 
lipofection. After 3-4 weeks post-transfection and selection in DMEM/10% FCS containing 400 
jxg/ml G418 the colonies were fixed in 100% Methanol, washed with PBS, and stained with 10% 
Giemsa solution (v/v in H20). The approximate number of G418 resistant colonies is indicated.
Cell Line Transfected Plamsid Number of G418-Resistant colonies
FBR neo 1 [xg 155 colonies
FBR NA Raf-1/neo 5^g/1 |xg 122 colonies
208F neo 1 jxg 150 colonies
208F NA Raf-1/neo 5jxg/1 jxg 200 colonies
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From this series of transfections revertant cells lines were isolated demonstrating a flat 
morphology. After the isolation of these revertants the expression of the NARaf-1 and the 
endogenous Raf-1 protein levels were analysed, to assess the efficiency of the transfection in 
FBR cells.
Cultures growing in DMEM supplemented with 10% FCS were washed twice with ice- 
cold PBS and lysed with standard Triton X-100 lysis buffer. The lysates were normalised for 
protein content and 100 ng of total cell lysate was separated by 10% SDS-polyacrylamide gels 
electrophoresis (Figure 7.1). The proteins were transferred to a PVDF membrane and blotted 
with a monoclonal antibody specific for the Raf-1 N-terminus. In the FBR, 208F cells and also in 
the 6 FBR NA raf-1 revertant cell lines a c-Raf-1-specific immunoreactive band of 70 kD 
corresponding to endogenous kinase was observed (Figure 7.1 A, lanes 1, 2, 3, 4, 5, 6, 7, 8). In 
the FBR ANRaf-1 revertant 1, 4, 5, 7,10, and 12 clones a band of approximately 30kD which 
corresponds to the transfected NA Raf-, was also observed (Figure 7.1 A, lanes 3, 4, 5, 6, 7 ,8) 
according to the previous published reports (Schaap etal., 1993).
These revertant clones were also examined for expression of the p75 v Fos transforming 
oncoprotein to ensure that it is still expressed at sufficient levels and that is not lost during the 
process of selection. To confirm p75 v Fos expression the same membrane shown in the Figure 
7.1 A was stripped and probed with the K-25 antibody which identifies p75 v Fos and also broadly 
reacts with different Fos proteins (Figure 7.1 B). p75 v Fos protein was seen in parental FBR cells 
(Figure 7.1B lanel) and in the FBR NARaf-1 revertant 1, 4, 5, 7, 10, and 12 cell lines (Figure 
7.1B, lanes 3, 4, 5, 6, 7, 8). Therefore the transfection process did not affect significantly the 
expression of the transforming p75v Fos oncoprotein.
In an attempt to look for differences in /bs-effector genes, at the levels of the Fra-1 
protein, a known v-/bs-effector which is an AP-1 component (Cohen and Curran, 1988; Bergers 
et al., 1995). Transformation by v-/bs and fosB increases the levels of fra-1 mRNA and protein 
(Bergers etal., 1995; Mechta etal., 1997). The filter in Figure 7.1 B and was stripped and probed 
with the N-17 antibody specific for the Fra-1 protein. As shown in Figure 7.1 C, in FBR 
immunoreactive bands were observed which migrated at the expected size of the Fra-1 proteins 
on an 10% SDS-polyacrylamide gel (Franza etal., 1987). The Fra-1 protein expression appears
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to be greately reduced in lysates prepared from cycling 208F fibroblasts (Figure 7.1C lane 2). 
Expression of Fra-1 protein was also detected in the lysates prepared from cycling FBR NA 
Raf-1 revertants (Figure 7.1 C lanes 3, 4, 5, 6, 7 , 8). In four out of the six FBR NA Raf-1 
revertant clones (Figure 7.1C lanes 5, 6, 7, 8 ) we found that Fra-1 protein levels were 
approximately 2-fold reduced compared to the parental FBR cells as determined by scanning 
densitometry (Figure 7.1C lane 1).
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Figure 7.1. Expression patterns of p75vFos, Raf-1 and NA Raf-1 and Fra-1 proteins 
in FBR, 208F cells and FBR transfected with the dominant negative C-terminal 
deletion mutant of Raf-1 Kinase, ANRaf-1.
Cell lines were grown in DMEM supplemented with 10% FCS and when sub­
confluent, cell lysates were prepared. 100pg of total cell lysate was separated on 
10% SDS-PAGE, transferred to PVDF membrane, and blotted with an antibody 
against A) Raf-1 (Transduction Labs, KY, USA). The same membrane was stripped 
and blotted with antibodies against B) Fos (K-25, Santa Cruz, Bio) and C) fra-1 (N- 
17, Santa Cruz, Bio.) to visualise the expression of Fos and Fra-1 proteins.
1) FBR cells 2) 208F cells; 3) FBR NA Raf-1 revertant clone 1; 4) FBR NA Raf-1 
revertant clone 4; 5) FBR NA Raf-1 revertant clone 5; 6) FBR NA Raf-1 revertant 
clone 7; 7) FBR NA Raf-1 revertant clone 10; 8) FBR NA Raf-1 revertant clone 12.
In the panel C the integrated and normalised OD values after scanning 
densitometry of the Fra-1 western are shown.
7.3. Morphological Characteristics of FBR NARaf-1 transfectants
FBR cells have a transformed morphology when maintained in 10% FCS (Figure 7.2 a). In 
contrast the cell lines that were isolated after transfection of NARaf-1 into FBR cells have a flat 
morphology (Table 7.2). As shown in the Figure 7.2 (c, d, e, e, f, d, h) transfection of FBR cells 
with NA Raf-1 reverted v-/bs-induced transformation. The FBR NA Raf-1 expressing cell lines 
showed a flat morphology when grown in cycling conditions (Figure 7.2).
It was also observed that the morphological reversion of FBR NARaf-1 revertants was 
density dependent and the flat phenotype was more pronounced in higher cell densities. One of 
the clones was chosen to demonstrate the appearance of the revertant phenotype at low and a 
higher cell density. As illustrated in Figure 7.3, FBR NARaf-1 clone 4 showed an increased 
ability to revert at a higher density.
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Figure 7.2. Morphology of FBR, 208F cells and FBR AN Raf-1 revertants.
Cell lines were grown in DMEM supplemented with 10% FCS for 24 hours and 
photographed with am inverted Nikon Diaphot microscope.
a) FBR cells ; b) 208F cells ; c) FBR NA Raf-1 revertant clone 1 ; d) FBR NA Raf-1 
revertant clone 4 ;e) FBR NA Raf-1 revertant clone 5 ; f) FBR NA Raf-1 revertant 
clone 7 ; g) FBR NA Raf-1 revertant clone 10 ; h) FBR NA Raf-1 revertant clone 
12 .
Table 7.2. Morphology of FBR neo and FBR NA Raf-1 transfected cells lines.
Cell lines were plated in DMEM containing 10% FCS and 400 i^g/ml G418 on 10cm tissue 
culture dishes and were allowed to attach for 48 hours to the plastic substratum to identify 
individual cell morphologies.
Cell line Transfected plasmid Morphology
FBR neo 1 neo transformed
FBR neo 2 neo transformed
FBR neo 3 neo transformed
FBR neo 4 neo transformed
FBR NA 1 NA Raf-1 / neo flat
FBR NA 2 NA Raf-1 / neo flat
FBR NA 4 NA Raf-1 / neo flat
FBR NA 5 NA Raf-1 / neo flat
FBR NA 7 NA Raf-1 / neo flat
FBR NA10 NA Raf-1 / neo flat
FBR NA 12 NA Raf-1 / neo flat
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FBR NA Raf-1 clone 4
Figure 7.3. Morphological reversion at different cell densities.
Morphology of FBR NA Raf-1 revertant clone 4 shown at two different cell 
densities a) low density and b) high density.
Cell lines were grown in DMEM supplemented with 10% FCS and 
photographed with a Nikon inverted Diaphot microscope.
7.4. A/A Raf-1 inhibits v-fos-induced anchorage independence
The parental FBR, 208F and the FBR NARaf-1 revertants were tested for their ability to grow in 
methylcellulose, that is under anchorage-independent conditions. Cells from the 6 revertant 
clones: FBR NA1, FBR NA4, FBR NA5, FBR NA7, FBR NA10, and FBR NA12, were trypsinized 
from cultures growing in DMEM supplemented with 10 % FCS and resuspended in serum-free 
media. Cell number was determined and 2x104 cells plated in Ham’s medium supplemented 
with 10% FCS containing 1,5% methylcellulose. The cells were allowed to grow for a period of 
20 days. Colonies were observed using a light microscope (Figure 7.4 c, d, e, e, f, d, h) and 
counted to measure the approximate number present in each plate.
208F cells do not grow in anchorage-independent conditions (Figure 7.4b), however 
FBR cells showed a high colony-forming ability in semi-solid medium (Figure 7.4 a). A decrease 
in the colony formation efficiency (measured by the relative number of colonies formed per 
10cm2 dish and this number divided by the number of cells plated initially) was seen for the 
clones expressing the dominant negative NA Raf-1 mutant. Table 7.3 summarises the results of 
this experiment.
These results suggest a correlation between the expression of NA Raf-1 and a 
decrease in the colony forming ability in semi-solid medium of the FBR NA Raf-1. These data 
suggest a role for the NA Raf-1 kinase mutant in suppression of v-/bs-induced transformation.
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Figure 7.4. Growth in semi-solid medium of FBR, 208Fand FBR transfected with 
the dominant negative C-terminal deletion mutant of Raf-1 Kinase, NA Raf-1.
Cells were grown in methylcellulose containing serum for 20 days an 
photographed with a Nikon inverted Diaphot microscope, a) FBR cells ; b) 208F 
cells ; c) FBR NA Raf-1 revertant clone 1 ; d) FBR NA Raf-1 revertant clone 4 ; e) 
FBR NA Raf-1 revertant clone 5 ; f) FBR NARaf-1 revertant clone 7 ; g) FBR NA 
Raf-1 revertant clone 10 ; h) FBR NA Raf-1 revertant clone 12.
Table 7.3. Anchorage-Independent growth of FBR and FBR NA Raf-1 revertants.
2x104 cells from each cell line were plated in Ham’s media containing 1.5% Methylcellulose. 
Colonies were counted after 3 weeks. These results represent two independent experiments, 
where triplicate samples were assayed.
Cell Line Average Colony Number Mean Ratio
FBR 8064 - 8256 8160 0.4
FBR NA 1 806.4 - 672 739 0.03
FBR NA 4 144 -380 262 0.01
FBR NA 5 768 - 960 864 0.04
FBR NA 7 921 -816 868 0.04
FBR NA 10 48 - 240 144 0.007
FBR NA 12 144 -96 120 0.006
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7.5. The role of NA Raf-1 in serum-induced MAP-Kinase activation
Previously it has been shown that the NA Raf-1 has inhibits activation of MAP Kinases by EGF 
and TPA (Schaap etal., 19930. Here the ability of NA Raf-1 to prevent MAP Kinase activation by 
serum in the FBR NA Raf-1 expressing cells was examined, compared to the activation in the 
parental FBR cells. To test this an antibody specific for the phosphorylated forms of MAP Kinase 
isoforms ERK1 and ERK2 was used for western analysis. Cell lysates were prepared from 
quiescent and serum-stimulated cells total using the standard Triton X-100 lysis buffer. Lysates 
were cleared by centrifugation, normalised for protein content, and 50 pg of lysate were 
separated by 10% SDS-Polyacrylamide gel electrophoresis, transferred to a PVDF membrane 
and blotted with the MAPK phospho-specific antibody.
Serum induces strong MAP Kinase phosphorylation in 208F as shown in Figure 7.5 lane 
4 compared to FBR cells. In the FBR NA Raf-1 clones 1 and 4 activation of MAP Kinases ERK1 
and ERK2 was 1.5-fold reduced compared in FBR cells (Figure 7.5A lanes 6 and 8, 0.29+/- 
0.13,n=3, P>0.05 in FBR cells and 0.17+/-0.005, n=3, P>0.03 in FBR NA Raf-1 clone 1 and 
0.16+/-0.03, n=3 P<0.05 in FBR NA Raf-1 clone 4). These two clones express higher levels of 
the transfected mutant NA Raf-1 compared to FBR NA Raf-1 clone 10 (Figure 7.1C lanes 3 and 
4). The relative inhibition of serum-induced MAP Kinase phosphorylation in FBR NA Raf-1 clone 
1 was found to be reduced not very significantly compared to serum-stimulated FBR cells 
(P>0.05). In the FBR NA Raf-1 clones 4 and 10 the inhibition of ERK activation was found to be 
significant (P<0.05) and the activation state of MAP Kinases remained and similar to FBR as 
determined by scanning densitometry (Figure 7.5 lane 10). This particular clone contains 
reduced levels of NA Raf-1 mutant (Figure 7.1 C lane 7). For the same experiment when ERK1 
activation was measured using scanning densitometry it was found that in all three clones was 
reduced to approximately 2-fold compared to the FBR untransfected control cells (Figure 7.5 top 
panel above A, lanes 6,8 and 10). The differences in the activation status of ERK1 might reflect 
the potency of NA Raf-1 to reduce the phosphorylation of this isoform.
van Blitterswijk and co-workers (van Dijk et al., 1997) have shown that the activation of 
MAP Kinases in Rat-1 cells transfected with the NA Raf-1 mutant stimulated with EGF or PDGF
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is reduced by 2-fold. A similar result is seen with the FBR NA Raf-1 clones, suggesting a 
functional response to serum when the NA Raf-1 mutant is present in the FBR cells.
Since the inhibition of ERK1 and ERK2 phosphorylation in the FBR NA Raf-1 clones 1 
and 4 is not striking the effect of NA Raf-1 in the suppression of FBR /bs-induced transformation 
could be ascribed to another function of this dominant negative mutant.
It is known that the NA Raf-1 is an inhibitor of p21ras function in mammalian cells (Kolch 
et al., 1991). The putative inhibition of ras function by NA Raf-1 in FBR NA Raf-1 cells could be 
associated with the suppressor effect of this mutant in the MAP Kinase pathway or another 
pathway downstream of p21ras . The ability of p21ras to control also the Phosphoinositide 3- 
Kinase, PI3K (Rodriguez-Viciana et al., 1994, 1997; Khwaja et al., 1997) and the Ral-GDS 
pathways (Urano et al., 1996) in regulating cellular transformation is well established. Such a 
pathway could be involved in the transformation-suppressor function of NA Raf-1 in FBR cells. 
To addresssuch a question pharmacological inhibitors or dominant negative mutants could be 
used to identify a possible role of PI3K or Ral-GDS in FBR /bs-induced transformation and 
anchorage independence.
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Figure 7.5. Serum-induced MAPK phosphorylation in FBR, 208F and FBR 
transfected with the dominant negative mutant of Raf-1 kinase, NA Raf-1.
Cell lines were grown to subconfluence in DMEM supplemented with 10% FCS 
and serum-deprived for 48 hours (0.1% FCS). Stimulation was for 5 minutes with 
10% FCS. Cell lysates were prepared and 50 pg of total cell lysate was separated 
by 10% SDS-PAGE, transferred to PVDF membranes and probed with an 
antibody specific for A) the phosphorylated MAP Kinases ERK1 and ERK2 
(MAPK*, Promega Labs, Wl, USA).
Blots were stripped and probed with an antibody specific for B) ERK-2 as a 
loading control (ERK-2) (Transduction Labs, KY, USA) and for C) Raf-1 
(Transduction, Labs, KY, USA).
Quantification was performed using scanning densitometry. In the case of 
quantification of the total ERK1 and ERK2 signal by densitometry the OD values 
presented are derived from automatic subtraction of the backround using the Pdi 
software. In the case of the quantification of the ERK1 signal the OD values 
presented are derived from subtraction of the total backround from the film.
Table 7.4 The effect of the dominant negative mutant of Raf-1, NA Raf-1 in the serum- 
stimulated MAP Kinase phosphorylation in FBR, 208F and FBR NA Raf-1 revertants.
Quantification of the increase in phosphorylation of ERK1 and ERK2 was performed using 
scanning densitometry. The band of serum-stimulated 208F cells was taken as the maximal, 
100% activation. The values were normalised for control loading of ERK2 for each individual 
experiment. The values are the mean +/- standard deviation of three independent experiments.
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7.6. FBR NARaf-1 revertants have increased F-Actin content
It has been shown that an inverse correlation exists between morphological transformation and 
the cellular content of actin stress fibres (Weber etal., 1974; Pollack et al., 1975; Ozanne et al., 
1980; Lamb etal., 1997). FBR cells have a reduced number of actin stress fibres and also have 
a fraction of actin which is soluble and diffuse (Hennigan, 1993). In contrast, 208F cells have 
stress fibres when grown in the presence of serum and maintain a number of stress fibres when 
are serum-deprived.
The distribution of F-actin in FBR, 208F and FBR NARaf-1 revertant cell lines was 
examined by staining with Rhodamine-labelled Phalloidin and fluorescence microscopy. Cels 
grown in serum were fixed, permeabilised and stained with Rhodamine-Phalloidin to visualise 
actin.
FBR cells appear bipolar, contain a small number of actin stress fibres and have 
extensive membrane ruffling activity localised at the cell extensions (Figure 7.6 a). 208F cells 
are flat and contain actin stress fibres in large numbers extending from one side of the cell to the 
other.
When the actin distribution was examined in the FBR NAaf-1 revertants, the actin 
content was significantly increased and the cells contained stress fibres (Figure 7.6 c, d, e, e, f, 
g, h). Careful examination showed that the cells were morphologically reverted but a significant 
number of membrane ruffling activity was still present. The ability of NARaf-1 to revert fos- 
induced transformation and to induce stress fibre formation but not inhibit membrane ruffling is 
associated with the role of Raf-1 in transformation pathways (Khosravi-Far etal., 1996; Joneson 
etal., 1996).
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Figure 7.6. Actin filament distribution in FBR, 208F and FBR transfected with the dominant 
negative mutant of Raf-1 kinase, NARaf-1.
Cell lines were plated on coverslips, and grown in DMEM supplemented with 10% FCS. To 
visulaise actin stress fibres, cells were fixed, permeabilised and stained with TRITC-conjugated 
Phalloidin. Images were analysed and processed using a Bio-Rad MRC 600 Confocal 
microscope. These figures are representative from two independent experiments,
a) FBR cells; b) 208F cells; c) FBR NARaf-1 revertant clone 1; d) FBR NARaf-1 revertant clone 
4; e) FBR NARaf-1 revertant clone 5; f) FBR NARaf-1 revertant clone 7; g) FBR NARaf-1 
revertant clone 10; h) FBR NARaf-1 revertant clone 12.
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7.7. The effect of Raf-1 inhibitor L-779 450 in serum-induced MAPK phosphorylation 
Recently, L-779 450, a novel Raf-1 Kinase-specific inhibitor has been described. This compound 
inhibits Raf-1 kinase activity in vivo at a low micromolar range. L-779 450 inhibits also in vitro the 
enzymatic activity of Raf-1 kinase.
In experiments similar to those in the previous chapter where MEK-1 inhibitor PD98059 
was used, here L-779 450 was used to study serum-induced MAP Kinase phosphorylation in 
FBR, 208F and v-Ki-ras transformed cells. In serum-treated quiescent FBR there is a 2-3 fold 
increase in MAPK phosphorylation (Figure 7.7. lane 3). This induction can be inhibited by 2-fold 
with pre-treatment of the quiescent FBR with 3 |xM L-779 450 for 30 minutes (Figure 7.7 lane 3 
and 4). In serum treated 208F cells a strong induction of MAP Kinase phosphorylation could be 
reduced 3-fold by pre-treatment with L-779 450 of serum-stimulated 208F cells (Figure 7.7 lane 
7 and lane 8). These data show that L-779 450 can inhibit the induction of MAP Kinases in FBR 
and 208F cells by serum.
In v-Ki-ras transformed 208F cells MAP Kinase phosphorylation basal levels were 
higher compared to FBR and 208F serum-starved cells (Figure 7.7 lane 9), suggesting that the 
pathway is efficiently activated by the presence of the oncogenic ras (Howe et al., 1992; Kyriakis 
etal., 1992; Dent etal., 1992). Also in v-Ki-ras cells MAP Kinase phosphorylation did not change 
significantly after serum stimulation (Figure 7.7A lane 11). This correlates with evidence from 
others where ras oncogenes did not contribute to the enhancement MAP Kinase activation after 
serum stimulation (Samuels and McMahon, 1994; Pritchard et al., 1995; Olson et al., 1998). In 
these experiments it was found that the basal and also the serum-induced phosphorylation of 
MAP Kinases in ras- transformed cells was sensitive to inhibition by L-779 450 (Figure 7.7 lanes 
10 and 12). In contrast to this the phosphorylation of MEK-1 was not inhibited in serum- 
stimulated v-Ki-ras cells (Figure 7.7B, lane 12) suggesting the existence of an alternative MEK-1 
activator.
In addition to MAPK activation the activation state of MEK-1 was examined in FBR, 
208F and v-Ki-ras cells. The blot shown in Figure 7.7A was stripped and probed with the MEK-1 
phosphospecific antibody (Figure 7.7B). In this case phosphorylated MEK-1 was induced 
dramatically by serum in 208F (Figure 7.7B; lane 7). In the case of 208F cells as in the v-Ki-ras 
cells the phosphorylation of MEK-1 is not completely alleviated by L-779 450 (Figure 7.7B; lane
8). Serum-deprived v-Ki-ras cells also contain high levels of phosphorylated MEK-1 (Figure 7.7
185
B lane 9) which are elevated in response to serum (Figure 7.7 B 11). MEK-1 phosphorylation is 
sensitive to inhibition of Raf-1 activity by L-779 450 in the ras transformed cells (Figure 7.7 B 
lane 10). This shows a direct dependence of MEK-1 activation on the presence of the 
transforming ras oncogene, a potent activator of Raf-1 kinase (Howe etal., 1992; Kyriakis etal., 
1992; Dent etal., 1992). In FBR cells, the magnitude of MEK-1 activation was much weaker and 
inhibited 2-fold by L-779 450 (Figure 7.7 B lane 3 and 4 respectively) showing a similar pattern 
for MEK-1 activation to MAP Kinase activation in this cell type (Figure 7.7 panel A lanes 3 and
4).
Phosphorylation of the Raf-1 C-terminus, through a MAPK-dependent mechanism 
results in a decrease in its electrophoretic mobility in SDS-polyacrylamide gels (Williams et al., 
1992, 1993; Ferrier et al., 1997). L-779 450 treatment of cells resulted in a diminished 
phosphorylation-dependent activation of Raf-1 kinase in FBR, 208F and v-Ki-ras cells (Figure 
7.7 C, lanes 4, 8 and 12 respectively), compared to its activation by serum (Figure 7.7 C, lanes 
3, 7 and 11 respectively). This shows that phosphorylation of Raf-1 detected by mobility shift is 
MAP Kinase-dependent Raf-1 specific. Previously MAP Kinase activation has been correlated 
with mobility shift assays in western immunoblotting experiments (Posada and Cooper, 1992; 
Leevers and Marshall, 1992) and with phosphospecific antibodies (Olson etal., 1998).
The Table 7.5 summarises data from experiments with the L-779 450 and its effect in 
the inhibition of MAPK phosphorylation in FBR, 208F and v-Ki-ras cells. In the case of FBR cells 
the activation by serum (0.24+/-0.02, n=2, P=0.01) was inhibited by L-779 450 and this was a 
significant response (0.12+/-0.01, n=3, P=0.0032), although in the Figure 7.7A, lane 3 there is 
some ERK1 and ERK2 specific immunoreactive band. Also in 208F cells the Raf-1 inhibitor was 
effective and inhibited the serum-induced MAP Kinase phosphorylation (serum activation 1+/- 
0.00, n=3, P=0.001 and the inhibition was significant with activation reaching 0.28+/-0.02, n=3, 
P=0.0005). In the v-Ki-ras transformed 208F cells the induction by serum was not very 
significant (0.24+/-0.04, n=3, P>0.05), which this correlates from the results reported by Marshall 
and co-workers (Olson et al., 1998). The response to serum of v-Ki-ras cells was significant, and 
this was inhibited approximately by 1.5-fold by L-779 450 (activation 0.15+/-0.02, n=3, significant 
at P=0.02). The results presented in the Table 7.5 show that the Raf-1-specific inhibitor L-779 
450 is an effective inhibitor of MAP Kinase phosphorylation in FBR and 208F cells after 
stimulation with serum (10% FCS).
186
FBR lysates 208F lysates v-Ki-ras lysates
E E E
Z5 Z! ZJ
<5 a5 q3
CO CO CO
+ + +
O O O o o o
LO LO £> LO lo  lo^
cx-MAPK
(X-ERK2
a-Raf-1
1 2 3 8 9 10 11 12
Figure 7.7. The role of the Raf-1 kinase inhibitor L-779 450 in the phosphorylation 
of MAPK and MEK-1 in FBR cells, 208F cells and v-Ki-ras transformed 208F cells.
Cells were grown in DMEM supplemented with 10% FCS and when sub-confluent, 
serum-deprived for 48 hours. Cells were stimulated with 10% FCS for 5 minutes or 
untreated and immediately cell lysates were prepared and 50 pg of total cell lysate 
was separated by 10 % SDS-PAGE, transferred to PVDF membrane and blotted 
with an antibody specific for A) activated MAPK (Promega Labs, Wl, USA), B) 
activated MEK-1 (New England Biolabs, USA) C) ERK2 (Transduction Labs, KY, 
USA) .
D) 80 pg of total cell lysate separated in 7.5% SDS-PAGE, transferred to PVDF 
membrane and blotted with an antibody specific for Raf-1 (Transduction Labs, KY, 
USA).
FBR cell lysates in 1) 0.1% FCS 2) 0.1% FCS treated with L-779 450 for 30 
minutes 3) treated with 10% FCS for 5 min 4) pre-treated with 3 pM L-779 450 for 
30 min and with 10% FCS for 5 min
208F cell lysates in 5) 0.1% FCS 6) 0.1% FCS treated with 3 pM L-779 450 for 30 
minutes 7) treated with 10% FCS for 5 min 8) pre-treated with 3 pM L-779 450 for 
30 min and with 10% FCS for 5 min
v-Ki-ras cell lysates in 9) 0.1% FCS 10) 0.1% FCS treated with 3 pM L-779 450 
for 30 minutes 11) treated with 10% FCS for 5 min 12) pre-treated with 3 pM L-779 
450 for 30 min and with 10% FCS for 5 min.
The experiment shown is a representative of three experiments with very similar 
results.
Table 7.5. The effect of L-779 450 in serum-stimulated MAP Kinase phosphorylation in FBR,
208F and v-Ki-ras transformed 208F cells.
Quantification of the increase in phosphorylation of ERK1 and ERK2 was performed using 
scanning densitometry. The band of serum-stimulated 208F cells was taken as the maximal, 
100% activation. The values were normalised for control loading of ERK2 for each individual 
experiment. The values are the mean +/- standard deviation of three independent experiments.
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1) FBR serum-deprived cells
2) FBR cells treated with 3 jxM of L-779 450
3) FBR serum-stimulated cells
4) FBR cells pre-treated with 3 of L-779 450 and serum-stimulated for 5 minutes
5) 208F serum-deprived cells
6) 208F cells treated with 3 piM of L-779 450
7) 208F serum-stimulated cells
8) 208F cells pre-treated with 3 piM of L-779 450 and serum-stimulated for 5 minutes
9) v-Ki-ras serum-deprived cells
10) v-Ki-ras cells treated with 3 piM of L-779 450
11) v-Ki-ras serum-stimulated cells
12) v-Ki-ras cells pre-treated with 3 of L-779 450 and serum-stimulated for 5 
minutes
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7.8. L-779 450 modulates actin filament distribution
In order to investigate the relationship of activation of Raf-1 kinase by serum and v-fos 
oncogene, the effect of L-779 450 in membrane ruffling and morphological transformation was 
investigated.
FBR cells growing in medium supplemented with 10% FCS display a characteristic 
bipolar shape with increased actin-containing structures in the leading edge of the cells when 
stained with Rhodamine-Phalloidin (Figure 7.8a). Since MEK-1 is downstream of Raf-1 the Raf- 
1 inhibitor L-779 450 was used to examine the effect on actin organisation in FBR cells.
Treatment with 3 jiM L-779 450 for 24 hours resulted in partial morphological reversion 
of FBR and reduction of peripheral membrane ruffling. We found that the actin fibres increased 
compared to the untreated FBR cells and the cells appeared flatter (Figure 7.8b). When FBR 
cells were incubated with L-779 450 for 48 hours surprisingly the inhibitor did not induce 
reversion. The actin distribution of the treated cells was more similar to untreated FBR cells 
(Figure 7.8c). This experiment suggests that L-779 450 does not reverse very efficiently fos- 
induced morphological transformation as the PD 98059 inhibitor shown in experiments 
presented in the previous chapter.
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Figure 7.8 . Actin filament distribution in FBR fibroblasts treated with the inhibitor of 
Raf-1 kinase L-779450.
Cells were grown in DMEM supplemented with 10% FCS for 24 hours, and treated 
with the Raf-1-specific inhibitor L-779450 for an additional 24 or 48 hours. To 
visualise actin, cells were fixed, permeabilized and stained with TRITC-conjugated 
Phalloidin. Images were analysed and processed using a Bio-Rad MRC 600 confocal 
microscope.
a) FBR in 10% FCS ; b) FBR treated for 24 hours with 3 pM of the Raf-1 kinase- 
specific inhibitor L-779450 ; c) FBR treated for 48 hours with 3 pM of the Raf-1 
kinase-specific inhibitor L-779450.
To test the specificity of L-779 450, v-Ki-ras 208F transformed fibroblasts were treated under 
the same conditions used for FBR cells (Figure 7.9). In fibroblasts transformed by ras Raf-1 
kinase is strongly activated (Howe et al., 1992). Inhibition of Raf-1 activity by L-779 450 could 
potentially modulate different responses of oncogenic ras such as actin reorganisation and 
membrane ruffling.
v-Ki-ras cells have a characteristic asteroid morphology when maintained in DMEM 
supplemented with 10% FCS, and are not bipolar like FBR cells when attached to plastic (Figure 
7.9 a). When stained with Rhodamine-Phalloidin the v-Ki-ras cells show extensive membrane 
ruffling and have a decreased number of stress fibres (Figure 7.9 a).
v-Ki-ras cells responded differently from FBR after treatment with L-779 450. Incubation 
of v-Ki-ras cell with 3nM L-779 450 for 24 hours resulted in morphological reversion and the 
suppression of membrane ruffling activity (Figure 7.9b). L-770 450 reverts ras transformation 
even after more prolonged treatment for 48 hours (Figure 7.9 c). In this case reversion was 
stable and the cells had a characteristic pentagonal, flat fibroblastoid shape. However despite 
the morphological reversion of ras-transformed cells after incubation with L-779 450, reformation 
of stress fibres was not observed in contrast to studies with the MEK-1 inhibitor PD 98059 
(Results Chapter 6, Figure 6.12 b and c).
Reversion of morphological transformation is mainly associated with the appearance of 
the actin and microfilament network in mammalian cells. In the case of reversion of ras 
transformation with L-779 450, a dissociation from this principle was revealed. This suggests 
that the reversion of the transformed morphology in ras cells by a Raf-1 kinase specific inhibitor 
might be independent of the formation of the actin stress fibre network and also that Raf-1 might 
be involved in the reversion through other mechanisms.
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Figure 7.9. Actin filament distribution in v-Ki-ras 208F transformed fibroblasts treated 
with the Raf-1 kinase inhibitor L-779450.
Cells were grown in DMEM supplemented with 10% FCS for 24 hours, and treated 
with the Raf-1-specific inhibitor L-779450 for an additional 24 or 48 hours. To 
visualise actin, cells were fixed, permeabilized and stained with TRITC-conjugated 
Phalloidin. Images were analysed and processed using a Bio-Rad MRC Confocal 
microscope.
a) v-Ki-ras 208F transformed fibroblasts in 10% FCS ; b) v-Ki-ras 208F transformed 
fibroblasts treated for 24 hours with 3 pM of the Raf-1 kinase-specific inhibitor L- 
779450; c) v-Ki-ras 208F transformed fibroblasts treated for 48 hours with 3 pM of the 
Raf-1 kinase-specific inhibitor L-779450
7.9. Conclusion
In this chapter the role of Raf-1 kinase was investigated in the context of /os-induced 
transformation. Raf-1 kinase is upstream of fos in the growth factor - ras signalling pathway and 
this makes Raf-1 an interesting candidate for mediating signals to downstream effectors and 
ultimately to AP-1 (Bruder et al., 1992).
Introduction of the dominant negative C-terminally truncated mutant of Raf-1 kinase 
ANRaf-1 into FBR cells resulted in morphological reversion of /bs-induced transformation. It was 
also observed that the anchorage independent growth of FBR NARaf-1 revertant cells was also 
suppressed compared to parental FBR cells.
When the FBR NARaf-1 cells were tested for activation of MAP Kinases using 
phosphospecific antibodies, it was found that the AN Raf-1 mutant suppresses MAP Kinase 
activation by 2-fold. This is in agreement with transfection experiments in COS cells where the 
NARaf-1 mutant has been reported to confer a concentration-dependent reduction of MAP 
Kinase activation by growth factors (van Dijk et al., 1997). It should also be noted that we have 
not been able to demonstrate activation of Raf-1 by MEK-1 substrate phosphorylation in in vitro 
kinase assays due mainly to technical obstacles.
Actin organisation is altered by NARaf-1 when it is stably expressed in FBR cells. The 
FBR NARaf-1 revertant cells isolated show an increase in the formation of actin stress fibres, a 
characteristic of normal fibroblasts, but retain membrane ruffling a characteristic of transformed 
fibroblasts. Thus Raf-1 could possibly regulate anchorage independent growth that is associated 
with actin formation (Pollack et al., 1975) but not membrane ruffling which is controlled by other 
ras-dependent mechanisms (Nobes and Hall, 1995; Qiu etal., 1997).
Pharmacological intervention in FBR cells using the Raf-1 inhibitor L-779 450 resulted in 
partial time-dependent reversion of /bs-transformation. In contrast in the case of v-Ki-ras cells 
transformed cells reversion was evident in morphology, since these cell became very flat and 
lost the membrane ruffles but without any re-formation of the actin stress fibre network.
These data suggest that Raf-1 kinase activity is present in FBR cells and its inhibition by 
the introduction of the NARaf-1 reverses the transformed phenotype in these cells and inhibits 
the serum-induced MAP Kinase phosphorylation.
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CHAPTER 8. STUDIES IN THE FOS-RELATED ANTIGEN-1 IN FBR AND 
REVERTANT CELL LINES
8.1. Fos-related antigen-1 is positively regulated during fos-induced transformation 
The induction of c-fos expression is associated with important biological processes such as 
mitogenesis (Greenberg and Ziff, 1984; Muller et al., 1984) and differentiation (Muller and 
Wagner, 1984). Transcriptional activation of c-fos by growth factors is very rapid (Greenberg 
and Ziff, 1984) and the p55 c Fos protein accumulation is maximal after 30 minutes of induction. 
These observations place c-fos in a signal transduction pathway that couples short term signals 
elicited on the cell surface by growth factors to the induction of gene expression in the nucleus.
p55c Fos is complexed in resting and stimulated fibroblasts with a 39 kD protein (Curran 
et al., 1984, 1985; Franza et al., 1987; Sassone-Corsi et al., 1988b). In addition, p55 c Fos is 
complexed with other polypeptides as shown by immunoprecipitation of [^Sj-methionine labeled 
lysates from quiescent and induced PC12 cells followed by two-dimensional gel electrophoresis 
(Franza et al., 1987). These proteins appear to be recognized directly by Fos-specific antibodies 
(Franza et al., 1987) and represent modified forms of the Fos-Related antigens Fra-1 and Fra- 
2. The Fra-1 protein appeared to be the major Fos-related antigen identified from PC12 cells 
induced by NGF or from serum-stimulated 208F fibroblasts (Cohen and Curran, 1988).
The fra-1 mRNA and Fra-1 protein are also up-regulated during oncogenic 
transformation. Rat-1 cells expressing the FBJ fos or fosB transforming genes show elevated 
levels of fra-1 mRNA (Bergers et al., 1995). fra-1 message and Fra-1 protein is also up- 
regulated in ras-transformed NIH 3T3 cells (Mechta et al., 1997), and transfection of fra-1 
contributes positively to transformation by ras (Mechta et al., 1987) and jun oncogenes (Bergers 
etal., 1995), suggesting that fra-1 might act co-operatively with other nuclear oncogenes. There 
is evidence also in epithelial cells for fra-1 in malignant progression and cellular transformation. 
In the metastatic cell line CSML100, that represents a an in vitro cell line model of epithelial 
tumour progression, increased expression of fra-1 correlates with elevated AP-1 binding activity, 
invasiveness and metastatic properties of this cell line (Kustikova et al., 1998). Moreover 
expression of exogenous fra-1 in non-malignant CSMLO cells (of this epithelial progression
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model) resulted in increased metastatic potential, morphological alterations resembling 
fibroblastoid conversion and expression of a number of a genes associated with late stages of 
tumour development (Kustikova et al., 1998).
The regulation of Fra-1 protein in FBR cells or 208F cells has been under analysed in 
this laboratory, mainly by western immunoblotting. Nuclear cell lysates prepared from 
exponentially growing FBR cells contain high levels of Fra-1 protein compared to 208F cells 
(Kim Hawker and Lynn McGarry, unpublished data).
In an attempt to look for any possible relationship between morphological reversion and 
the expression of Fra-1 in the revertant cell lines. Therefore the expression pattern of Fra-1 
protein in FBR, 208F cells and in FBR MEK-1 A221 and FBR TAM-67 revertant cell lines was 
analysed by western immunoblotting.
8.2. Fra-1 protein expression in FBR and revertant cell lines
Fos-Related Antigens are up-regulated during mitogenic stimulation of fibroblasts by serum 
(Franza etal., 1987; Cohen and Curran, 1988; Cohen etal., 1989). In addition to their induction 
by serum and growth factors, Fra-1 and Fra-2 proteins are positively regulated at the 
transcriptional and post-translational level by different transforming oncogenes such as v-ras 
(Mechta etal., 1997), v-jun (Liz Black and David Gillespie, unpublished observations) and v-fos 
(Kim Hawker and Lynn McGarry, unpublished observations). These data highlight a role for 
these proteins in cell proliferation and possibly transformation.
The Fra-1 protein is present in high levels in cycling FBR cells grown in 10% FCS, but at 
very low levels under the same conditions in non-transformed parental 208F cells. In contrast, in 
NIH 3T3 cells the major protein which is detected under cycling conditions is the Fra-2 protein 
whereas the Fra-1 and c-Fos proteins are not detected (Lallemand etal., 1997)..
The levels and the variation of the Fra-1 protein in FBR and the revertant cell lines was 
examined by western analysis, to identify any possible relationship between the expression of 
Fra-1 protein and morphological reversion. To address this, lysates from exponentially growing 
cultures of FBR and revertant cell lines were prepared followed by western immunoblotting with 
Fra-1-specific antibodies. The result of such an experiment is shown in Figure 8.1. In the FBR 
cells multiple protein species of 46 and 32-35 kDa are recognized by commercially available 
anti-Fra-1 rabbit serum (Figure 8.1 A lane 1). In contrast, in 208F cell lysates a Fra-1
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immunoreactive band which represents the Fra-1 protein is reduced 15-fold compared to Fra-1 
protein from FBR lysates (Figure 8.1 A lane 2). In the FBR MEK-1 A221 revertant cells (Figure 
8.1 A lanes 3, 4, and 5), approximately a 60% reduction in FBR A221 clone 6 and FBR A221 
clone 19 in Fra-1 levels was found, but only a 20% reduction in FBR A221 clone 23. In the FBR 
TAM-67 lysates, a 60% reduction in the levels of Fra-1 protein was found compared to the FBR 
cells (Figure 8.1 lane 6 compare to lane 1).
In ras transformed fibroblasts Yaniv and co-workers have observed a dramatic increase 
in Fra-1 protein levels. This parallels the studies of Bergers et al. (1995) where it was shown that 
the expression of the fra-1 gene is controlled by an AP-1-dependent mechanism and is under 
positive control by AP-1 family members. In Figure 8.1 B, a second experiment is shown, in 
which lysates from v-Ki-ras transformed 208F cells were also included as a positive control. 
Scanning densitometry revealed that the levels of Fra-1 protein in ras transformed 208F cells is 
2-fold elevated over FBR cells.
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Figure 8.1. E xpression  of Fra-1 prote in  in FBR , 208F, v -K i-ras  trans fo rm ed  
208F ce lls  and revertan t cell lines.
Cells w ere grow n in DM EM  supp lem en ted  w ith 10%  FCS to sub-con fluence , 
cell lysates w ere prepared and pro te ins w ere separa ted  by 10%  SDS- 
PAGE, trans fe rred  to PVD F m em brane  and probed  w ith an an tibody 
specific  fo r Fra-1 prote in . (N -17 rabbit antibody, S anta C ruz Bio., CA, USA).
A) 1) FBR cells; 2) 208F  cells; 3) FBR A221 clone 6; 4) FBR A221 clone 19;
5) FBR A221 c lone 23; 6) FBR T A M -67  ce lls.
B) 1) FBR ce lls; 2) 208F  ce lls; 3) FBR A221 clone 19; 4) FBR A221 c lone 
23; 5) v -K i-ra s  208F  trans fo rm ed  cells.
The expe rim en ts  are representa tive  o f three a t least s im ila r expe rim en ts
8.3. Inducibility of Fra-1 in FBR cells after extracellular stimulation
Previously Curran and co-workers have examined the patterns of Fra-1 induction in quiescent 
208F cells treated with serum (Franza et al., 1987 ; Cohen et al., 1989) and PC12 cells treated 
with benzodiazepines and NGF (Franza et al., 1987). The induction of Fra-1 is slower compared 
to p55c Fos protein in fibroblasts, reaching a peak after 2 -2 V2  hours after the addition of 20% FCS 
in 208F cells (Franza etal., 1987) and in NIH 3T3 fibroblasts (Lallemand etal., 1997). This lag 
period of Fra-1 induction suggests that it could be regulated by AP-1 components, such as Fos 
and FosB which are induced earlier in the cell cycle.
While the regulation of Fra-1 expression in normal cells is documented, little is known of 
Fra-1 inducibillity in v-fos transformed cells. The induction of Fra-1 protein in FBR cells and 208F 
cells in a short term response of 60 minutes was examined. This time point was chosen to 
demonstrate any rapid changes in the induction of Fra-1 that exist in FBR that will allow to 
distinguish this response to the previously identified 2 V2  hour induction in 208F cells (Franza et 
al., 1987).
When FBR cells are serum-deprived, Fra-1 protein levels are still detectable, suggesting 
that the fra-1 gene escapes transcriptional silencing at quiescence, during /bs-induced 
transformation. Fra-1 proteins consist of multiple bands that migrate between 30 to 46 kD as 
shown in SDS-polyacrylamide gels and western immunoblotting (Figure 8.2A lane 1). Using 
scanning densitometry and normalising for ERK2 as a control a 3-fold reduction in the protein 
levels of Fra-1 was observed in serum-deprived 208F cells (Figure 8.2A lane 5).
During mitogenic stimulation of fibroblasts by serum the Fra-1 protein appears as a 
smear in SDS-polyacrylamide gels. This mainly is attributed to post-translational modifications of 
the protein such as phosphorylation (Cohen et al., 1989; Gruda et al., 1994). Stimulation of 
FBR cells with 10% FCS for 60 minutes induced approximately 2-fold the expression of Fra-1 
(Figure 8.2A lane 3) and had no detectable effect on Fra-1 induction in 208F cells (Figure 8.2A 
lane 7). The patterns of fos protooncogene and Fos protein expression after serum stimulation, 
are well investigated in 208F cells and other established cell lines (Muller et al., 1984; Kruijer et 
al., 1984; Sassone-Corsi et al., 1988a). c-fos mRNA is induced rapidly within minutes and its 
protein synthesis is maximal between 30 and 60 minutes after the addition of mitogens (Muller 
et al., 1984). To identify if in this experiment the p55 c Fos protein is induced in 208F cells the
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membrane of the Figure 8.2A was stripped and probed with the K-25 antibody which recognizes 
the p55c Fos protein and the p75v Fos protein also.
The result of this attempt is shown in the Figure 8.2 Panel B. There was a dramatic 
induction of p55c Fos protein in the 208F cells after treatment with 10% FCS (Figure 8.1 B lane 7). 
In FBR cells the inducibility of c-Fos protein is dramatically impaired (Figure 8.1 B lane 3). These 
data suggested that induction of Fos and Fra-1 proteins in response to mitogenic stimulation by 
serum in FBR and 208F cells is altered, and Fos compared to Fra-1 shows a differential pattern 
which allows to distinguish their post-translational modifications.
Mitogenic stimulation with serum induces post-translational modifications in Fra-1 and 
Fos proteins (Curran et al., 1984; Cohen et al., 1989). The mobility patterns by SDS- 
Polyacrylamide gel electrophoresis of Fra-1 and Fos after induction are easily distinguished, 
although was not clear whether this was the result of phosphorylation or another type of 
modification. Molecular Biology Grade Alkaline Phosphatase has been used previously to 
confirm whetther such mobility shifts are the result of phosphorylation (Barber and Verma, 1987; 
Lin et al., 1992; Gruda et al., 1994; Lallemand et al., 1997). In such experiments Alkaline 
Phosphatase was used to investigate if phosphorylation accounts for the appearance of higher 
molecular weight species of Fra-1 after SDS-polyacrylamide electrophoresis (Figure 8.2A lanes 
2, 4, 6 and 8).
Lysates prepared with the standard Triton X-100 lysis buffer were normalized for their 
protein content and treated with alkaline phosphatase and then processed as usual for SDS 
polyacrylamide electrophoresis. In samples from FBR cells treated with phosphatase a reduction 
in the formation of the higher migrating Fra-1 bands was observed, suggesting that these are 
phosphorylated. Similarly in lysates from FBR cells induced with serum, Fra-1 protein was found 
to be phosphorylated (Figure 8.2A lanes 2 and 4). After phosphatase treatment an accumulation 
of Fra-1 immunoreactivity in protein species of 35 kD was observed in FBR cells (Figure 8.2A 
lanes 2 and 4). However in 208F cells this effect was negligible (Figure 8.2A lanes 6 and 8) 
which was expected, as the Fra-1 protein levels are low in the 208F cells is at low levels 
compared to FBR cells. The effect of the phosphatase treatment in the differential modification 
of the p 55 c Fos protein is shown in the Figure 8.2B. In this case the phosphatase altered the 
mobility of the induced 55 kD c-Fos protein only in 208F cells (Figure 8.2B lane 7 ; compare to 
lane 8) but not in the FBR cells, were is undetectable (Figure 8.2B, Lane 3) (Hawker et al.,
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1994). These changes in mobility of Fra-1 protein in FBR cells suggest that kinase is able to 
modify the protein at quiescence. When FBR cells are stimulated with serum this effect is more 
pronounced resulting in elevation of the Fra-1 protein as well as in its post-translational 
modification by phosphorylation.
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Figure 8.2. Induction of Fra-1 and Fos pro te ins by serum  in FBR and 208F cells 
and the e ffect o in v itro  incubation  w ith A lka line  Phosphatase.
C ells w ere grow n in D M EM  supp lem en ted  w ith 10% FCS and w hen subcon fluen t, 
se rum -deprived  fo r 48 hours (0.1%  FCS). S tim u la tion  was fo r 60 m inu tes w ith 10% 
FCS. C ell lysates w ere prepared  and incubated fo r 2 hours at 37° C w ith a lka line  
phospha tase  or rem ain un trea ted .
P rote ins were separa ted  by 10% S D S -P A G E , trans fe rred  to PVD F m em brane  and 
p robed w ith an an tibody spec ific  fo r  A) Fra-1 prote in (N -17 rabbit antibody, Santa 
C ruz Bio.). B lots w ere stripped  and probed w ith an an tibody spec ific  B) fo r FOS- 
p ro te ins  and FO S -re la ted  an tigens (K-25 rabbit antibody, S anta C ruz B io.). As 
contro l fo r prote in loading, the m e m branes  w ere p robed w ith an an tibody to ERK2 
(T ransduction  Labs, KY, USA).
Lane 1) Lysate from  FBR se rum -dep rived  cells; 2) Lysate from  FBR se rum - 
deprived  cells incubated in vitro w ith A lka line  P hosphatase to dephosphory la te  
lysate prote ins; 3) Lysate from  FBR se rum -s tim u la ted  cells; 4) Lysate from  FBR 
se rum -s tim u la ted  cells incubated  in vitro w ith A lka line  P hospha tase  to 
dephosphory la te  lysate p ro te ins; 5) Lysate from  208F se rum -deprived  ce lls 6) 
Lysate from  208F se rum -dep rived  ce lls incubated  in vitro w ith A lka line  
P hospha tase  to dephosphory la te  lysate pro te ins; 7) Lysate from  208F se rum - 
s tim u la ted  cells; 8) Lysate from  208F  se rum -s tim u la ted  cells incubated in vitro w ith 
A lka line  P hosphatase to dephosphory la te  lysate pro te ins.
8.4. Fra-1 is phosphorylated in FBR
The levels of Fra-1 protein in cycling FBR cells growing in 10% FCS are high compared to 208F 
cells (Figure 8.1). These forms of Fra-1 protein accumulate in the higher migrating forms of 
approximately 40-46 kD after SDS-polyacrylamide electrophoresis. These forms might represent 
modified forms of this protein since early studies have showed that this protein is heavily 
modified in cultured fibroblasts (Cohen et al., 1989).In order to analyse and possibly correlate 
Fra-1 phosphorylation state with cells either at quiescence or after mitogenic stimulation, 
alkaline phosphatase was again used to identify Fra-1 phosphorylation.
Phosphatase treatment of FBR lysates prepared from cycling cells growing in 10% FCS 
resulted in a mobility shift of this band from 45 kD to approximately 35 kD (Figure 8.3B Iane2). 
This demonstrates that the majority of Fra-1 in FBR cells exists in a phosphorylated form in the 
case that these cells are growing in the presence of 10% FCS.
Stimulation with EGF or phorbol ester for 2 hours (Figure 8.3B, lanes 5 and 7) resulted 
in the induction of the higher migrating forms of Fra-1 proteins, as in FBR cycling cells (Figure 
8.3A lane 1 and Figure 8.3B lane 1). To demonstrate that these higher migrating forms of Fra-1 
caused by EGF or TPA were the result of phosphorylation the samples were treated with 
phosphatase (Figure 8.3B, lanes 6 and 8). Phosphatase treatment resulted in the 
disappearance of the higher migrating forms of these proteins and all the Fra-1 immunoreactive 
bands accumulated the 35kD molecular weight species (Figure 8.3B lanes 6 and 8) (Franza et 
al., 1987). This shows that the induction of Fra-1 proteins by agonists other than serum results 
in phosphorylation of Fra-1. A similar observation had been shown (Gruda et al., 1994). 
Treatment of Swiss 3T3 cells with Insulin and TPA results in the accumulation of phosphorylated 
forms of Fra-1 (Gruda et al., 1994).
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Figure 8.3. Induction of Fra-1 proteins by EGF and TPA in FBR and the effect of in 
vitro incubation with Alkaline Phopshatase.
Cells were grown in DMEM supplemented with 10% FCS and when to subconfluent 
serum-deprived for 48 hours (0.1% FCS). Stimulation was for 2 hours with 100 ng/ 
ml EGF, 100 ng/ml TPA or the cells left untreated. Cell lysates were prepared and 
incubated for 2 hours at 37° C with alkaline phosphatase or left untreated.
Proteins were separated by 10% SDS-PAGE, transferred to PVDF membrane and 
probed with an antibody specific for A) Fra-1 protein (N-17 rabbit antibody, Santa 
Cruz Bio.). Blots were stripped and probed with an antibody specific B) Fra-1 protein 
(N-17 rabbit antibody, Santa Cruz Bio.). For a loading control the blot was probed C) 
with an antibody specific for ERK2 (Transduction Labs).
A) lane 1) FBR growing in 10% FCS ; 2) 208F cells growing in 10% FCS.
B and C) lane 1) Lysate from FBR growing in 10% FCS; 2) Lysate from FBR 
growing in 10% FCS incubated in vitro with Alkaline Phosphatase; 3) Lysate from 
FBR serum-deprived cells; 4) Lysate from FBR serum-deprived cells incubated in 
vitro with Alkaline Phosphatase; 5) Lysate from FBR TPA-stimulated cells 6) Lysate 
from FBR cells TPA-stimulated incubated in vitro with Alkaline Phosphatase; 7) 
Lysate from FBR EGF-stimulated cells; 8) Lysate from FBR EGF-stimulated cells 
incubated in vitro with Alkaline Phosphatase.
8.5. Fra-1 induction in FBR, 208F and revertant cell lines
There is evidence that the MAPK pathway is responsible for the changes in the Fra-1 
phosphorylation during mitogenic stimulation. Stimulation with growth factors results in 
phosphorylation of Fra-1 by MAP Kinases and stimulation of its transcriptional activity (Skinner 
et al., 1997). Here the inducibilty and phosphorylation of Fra-1 in FBR, 208F and revertant cell 
lines was examined, in order to correlate Fra-1 phosphorylation state with the ras signaling 
pathway in normal and transformed cells.
For these experiments subconfluent cultures were incubated in DMEM supplemented 
with 0.1 % FCS to induce quiescence. After 48 hours of serum deprivation, the cultures were 
incubated with 10% FCS for 2 V2  hours and cell lysates were prepared under standard 
conditions. The lysates were separated by SDS-PAGE and blotted with the Fos-specific antibody 
K-25 (Figure 8.4A). In this case a strong induction of the p55c Fos protein (Figure 8.4A, lane 4). In 
samples prepared from FBR and revertant cells no Fos-specific bands were identified (Figure 
8.4; lanes 2, 6, 8, 10 and 12). Using the K-25 antibody in the samples prepared from stimulated 
FBR , 208F and revertant cells a serum-inducible band of approximately 30-45 kD was also 
identified. This protein could potentially represent a novel Fos-Related Antigen since it is of a 
similar molecular weight to Fra-1. However further investigation is required to confirm this. It is 
also of interest that its expression also found to be reduced in the revertant cell lines (Figure 
8.4A, lanes 6, 8, 10, and 12 compare to lane 3 and 4).
To examine if the inducibility of the Fra-1 protein is affected by the introduction of 
dominant negative mutants, the western immunoblot in Figure 8.4A was probed with the N-17 
Fra-1-specific antibody. In FBR serum-deprived cultures, low levels of Fra-1 protein are present, 
as previously documented (Franza et al., 1987; Cohen et al., 1989).
Stimulation of FBR cells with 10% FCS for 2 V2  hours resulted in the induction of Fra-1 
protein 3-4 fold as determined by scanning densitometry (Figure 8.4B, lane 1 and 2). In the case 
of 208F cells the magnitude of induction of Fra-1 protein was 2-fold reduced compared to FBR 
cells (Figure 8.4B, lane 4). In the FBR A221 revertant clones 6 and 19, and in one clone of FBR 
TAM-67 cells examined here, there was a 1.5-fold reduction in the inducibility of the Fra-1 
protein levels when compared to FBR (Figure 8.4B, lane 6, 8, and 12). It should be noted that in
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the case of FBR A221 23 clone the induction in response to serum was similar in that of FBR 
cells (Figure 8.4B, lane 10).
Together these data suggest that there could be a biological correlation between 
reversion and the mechanism of reduction of Fra-1 protein levels in the revertant cell lines.
The MEK-1 inhibitor PD98059 was used to establish a possible molecular relationship 
between the dominant negative MEK-1 A221, Fra-1 induction and FBR reversion. In this 
experiment the MEK-1-specific inhibitor PD 98059 was used to mimic the conditions of a 
transfection with the dominant negative MEK-1 A221 in order to examine the role of MEK-1 in 
Fra-1 protein inducibility (Figure 8.5).
Serum-deprived cultures of FBR cells were incubated for 60 minutes with 50 |i,M of PD 
98059 and then induced for 2 V2  hours with 10% FCS. Cell lysates were prepared, proteins were 
separated by 10% SDS-PAGE and transferred to PVDF membranes. Western immunoblotting 
with the Fra-1-specific antibody showed that there was potent induction of Fra-1 protein (Figure 
8.5A, lane 3). FBR cells were incubated with PD 98059 and treated with 10% FCS for 2 V2  
hours. Scanning densitometry of the western immunoblot revealed that there was a 2-fold 
reduction of Fra-1 protein levels suggesting a requirement of MEK-1 and MAP Kinase in the 
induction of Fra-1 protein expression.
To determine total Fra-1 protein content of the cells, lysates were incubated with 
phosphatase for a prolong period to dephosphorylate all Fra-1 protein to allow estimation of the 
total protein content as one 35 kD band (Figure 8.5B). In the samples from quiescent FBR cells 
or treated with the inhibitor there was no major difference in the amount of Fra-1 protein levels 
(Figure 8.5B lanes 1 and 2). In the samples treated with 10% FCS a clear induction of Fra-1 
protein was observed (Figure 8.5B lane 3) which was reduced approximately 2-fold as 
determined by scanning densitometry (Figure 8.5B, lane 4). This experiment supports the data 
presented in the Figure 8.5A which suggest that a MEK-1-dependent mechanism is involved in 
the serum induction and post translational modification of Fra-1 protein in FBR cells.
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Figure 8.4. Regulation of Fra-1 and Fos proteins by serum in FBR, 208F and FBR 
transfected with dominant negative mutant MAPKK A221 and FBR transfected with 
a dominant negative deletion mutant of c-Jun TAM-67.
Cell lines were grown in DMEM supplemented with 10% FCS and when sub­
confluent serum-deprived for 48 hours (0.1% FCS) Stimulation was for 2 1/2 hours 
with 10% FCS. Cell lysates were prepared and 50 pg of total cell lysate was 
separated in 10% SDS-PAGE, transferred to PVDF membrane and probed with an 
antibody specific for A) Fos protein (K-25, Santa Cruz Bio., CA, USA) stripped and 
probed with an antibody specific for B) Fra-1 proteins (N-17, Santa Cruz Bio., CA, 
USA)
1) serum-deprived FBR; 2) serum-stimulated FBR; 3) serum-deprived 208F cells ;
4) serum-stimulated 208F cells; 5) serum-deprived FBR A221 revertant clone 6; 6) 
serum-stimulated FBR A221 revertant clone 6; 7) serum-deprived FBR A221 
revertant clone 19; 8) serum-stimulated FBR A221 revertant clone 19; 9) serum- 
deprived FBR A221 revertant clone 23; 10) serum-stimulated FBR A221 revertant 
clone 23; 11) serum-deprived FBR TAM-67 revertant clone 10; 12) serum- 
stimulated FBR TAM-67, revertant clone 23
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Figure 8.5 . Post-translational regulation of Fra-1 protein in FBR cells by the 
MEK-1 specific inhibitor PD 98059.
Cells were grown in DMEM supplemented with 10 % FCS and when sub­
confluent serum-deprived for 48 hours. The pre-treatment with the MEK-1 
inhibitor PD 98059 was for 60 minutes at a final concentration of 50pM. 
Serum stimulation with 10% FCS was for 2 Vfe after the addition of the MEK-1 
inhibitor. Cell lysates were prepared and incubated with alkaline phosphatase 
or left untreated. Proteins were separated by 10% SDS-PAGE, transferred to 
PVDF membrane and probed with an antibody specific for the fra-1 proteins 
(N17, Santa Cruz Bio., CA, USA)
To confirm equal loading the blots were stripped and probed with an antibody 
specific for ERK2 (Transduction Labs, KY, USA).
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8.6. Conclusion
The Fos-Related Antigen 1, Fra-1 is a protein with extensive similarities in primary structure with 
p5 5 c F°s  ^ mp NA and protein is induced by serum and mitogens in fibroblasts. This induction 
is AP-1 dependent due to an AP-1 responsive element in the 5’ end of the fra-1 gene (Bergers et 
al., 1995).
Transformation by oncogenes that activate and regulate AP-1 such as ras and fos lead 
to induction of fra-1 gene transcription (Bergers et al., 1995) and to up-regulation of the Fra-1 
protein (Mechta etal., 1997). By western analysis Fra-1 protein levels are elevated in FBR cells 
during cycling conditions. In contrast, Fra-1 protein levels are dramatically reduced in 208F cells. 
In quiescent FBR cells expression of Fra-1 protein is induced after stimulation with 10% FCS. 
This suggests that the inducibility of Fra-1 protein in FBR cells has a similar pattern of induction, 
but the magnitude of induction is greater in FBR cells as a result of transformation with the FBR 
v-fos oncogene.
Fra-1 expression was examined in FBR MEK-1 and FBR TAM-67 revertant cell lines 
isolated. In most revertant cell lines there was a reduction in the levels of Fra-1 protein. This 
event was independent of culture conditions. Revertant cell lines cycling in serum or serum- 
stimulated had reduced levels of Fra-1 protein when compared to the parental FBR Fra-1 levels. 
This suggests that the dominant negative mutants might act in an antagonistic manner and limit 
the levels of AP-1 effectors such as the Fra-1 gene and protein, resulting in an inhibition of 
morphological transformation. It is also known that in all the revertant cell lines the p75vFos 
oncoprotein is expressed. This might reduce the reversion potential of the dominant negative 
mutants resulting in clones that are selected for the expression of the mutant by retaining 
morphological properties of the transformed phenotype in vitro.
This data and published observations from others argue for a ras - MEK-1 - AP-1 
dependent regulation of Fra-1 expression in FBR cells. The role of the Fra-1 protein is not very 
well established in transformation by the fos oncogene. It potentially represents a downstream 
effector of AP-1-dependent transformation. This makes its transactivation properties important 
in the context of transcriptional regulation by fos and jun oncogenes. A study that could shed 
some light in the role of fra-1 gene would be to manipulate it genetically to identify its role in 
regulation of specific genes. The use of fra-1 null cells for example could be an important tool to 
identify AP-1 target genes in a fibroblast model of gene regulation. Such cells could be re-
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transformed by fos, ras or other oncogenes and a differential display protocol could be carried 
out to search for candidate AP-1 targets.
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CHAPTER 9. PROTEIN TYROSINE PHOSPHORYLATION IN FBR AND 208F 
CELLS: IDENTIFICATION OF A POTENTIAL REGULATOR OF MAP KINASE 
SIGNALLING
9.1. Tyrosine phosphorylation controls activation of the ras pathway
Protein tyrosine kinases play a major role in the transmission of extracellular signals to the 
cytoplasm and to the nucleus (Schlessinger and Bar-Sagi, 1994). Two types of protein kinases 
are involved in this process namely the receptor (RTK) and non-receptor protein tyrosine 
kinases (PTK). In the case of the RTK’s, polypeptide growth factors such as EGF bind to the 
extracellular domain (Pawson, 1995) and activate the intrinsic tyrosine kinase activity of the 
receptor leading to receptor autophosphorylation (Schlessinger, 1988) and the generation of 
binding sites for other signaling proteins (Anderson et al., 1990b; Matsuda et al., 1990). Non­
receptor tyrosine kinases, such as v-src (Collett et al., 1980; Hunter and Sefton; 1980; 
Levinson et al., 1980), v-fps (Pawson et al., 1980 Neil et al., 1981), and v-fes (Barbacid et 
al., 1980; Beemon, 1981) have been identified as retroviral oncogenes suggesting an important 
role of Protein Tyrosine Kinase in transformation and cell proliferation (Jove and Hanafusa,
1987). The protooncogene ras and the MAP Kinase pathway are also involved in several such 
protein tyrosine kinase systems. Both v-src and the activated EGFR stimulate guanine 
nucleotide exchange on ras (Satoh et al., 1990a; 1990b).
Many proteins that participate in mitogenic signalling are substrates for protein tyrosine 
kinases (Ellis et al., 1990), they are regulated by protein tyrosine phosphorylation (Nishibe et 
al., 1990; Meisenhelder et al., 1990; Margolis et al., 1990) or serve a binding proteins at 
specific phosphotyrosine-docking sites of protein tyrosine kinases (McGlade et al., 1992; 
Rozakis-Adcock et al., 1992). Several of these proteins such as rasGAP, she and GRB2 are 
involved the regulation of MAP Kinase signalling.
Because changes in tyrosine phosphorylation are associated with the mitogenic 
response and transformation, differences in protein tyrosine phosphorylation in FBR and 208F 
cells were investigated which might ultimately regulate downstream mitogenic pathways such as
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MAPK pathway. An antibody which recognises tyrosine phosphorylated proteins was used 
together with western immunoblotting and immunoprecipitation to determine whether difference 
exist between FBR and 208F cells.
9.2. Identifcation of Focal Adhesion Kinase as a potential regulator of MAPK signalling in FBR 
and 208F
Phorbol ester TPA, a tumour promoter, induces a variety of cellular responses such as protein 
tyrosine phosphorylation (Gilmore and Martin, 1983; Cooper et al., 1984; Ferrel and Martin, 
1990), MAP Kinase activation (Hoshi etal., 1988) and also cytoskeletal reorganisation (Lewis et 
al., 1996). To identify if TPA has the ability to stimulate protein tyrosine phosphorylation in FBR 
and 208F cells, cell lysates were prepared from each cell type and analysed for the tyrosine 
phosphorylated- protein content using western immunoblotting.
Serum deprived FBR and 208F cells were incubated with 20 ng/ml TPA for 10 minutes 
and the dishes were washed twice with ice cold PBS and lysates were prepared by lysis with the 
standard Triton X-100 containing buffer. The lysates were clarified by centrifugation and the 200 
fxg of total cell lysate proteins were separated in 7.5% SDS-PAGE gels and transferred to PVDF 
membranes. A monoclonal antibody against phosphotyrosine (anti-ptyr, PY20) was used to 
identify tyrosine phosphorylated proteins between 60 and 220-250 kilodaltons.
At quiescence FBR and 208F cells share some similarities in tyrosine phosphorylation of 
proteins (Figure 9.1). Phospho-proteins of approximately 50-55 kD were detected. A protein at 
120kD becomes heavily phosphorylated after induction with TPA in 208F but not in FBR cells. 
Another single band of approximately 150 kD appears to be heavily phosphorylated in response 
to TPA in 208F cells but not in FBR’s.
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Figure 9.1. TPA-induced protein tyrosine phosphorylation in FBR and 208F 
cells.
Cells were grown in DMEM supplemented with 10% FCS and when 
subconfluent, serum-deprived for 48 hours (0.1% FCS). Stimulation was for 10 
minutes with 20 ng/ml TPA.
Cell lysates were prepared and proteins were separated by 7.5% SDS-PAGE, 
transferred to PVDF membranes and probed with an antibody specific for 
phosphotyrosine (PY-20, Transduction labs, KY, USA).
To confirm equal loading the membranes were stripped, and probed with an 
antibody specific for Sos-1 (Transduction Labs, KY, USA).
Two independent experiments are shown.
Another mitogen, EGF was used to compare the induction of protein tyrosine 
phosphorylation in FBR and 208F cells. Cell lysates from EGF-treated FBR and 208F cells for 
10 minutes were prepared, and examined for phosphotyrosine content using the same 
conditions as in the previous experiment. When quiescent 208F cells were treated with EGF a 
dramatic increase in tyrosine phosphorylation of proteins around 60-70 kD, and also as in the 
TPA-treated 208F in 120 and 150 kD (Figure 9.2). Three major tyrosine phosphorylated proteins 
were identified in EGF-treated 208F cells of the following molecular masses: 60-70kD, 120- 
150kD and 160-180kD. A protein of approximately 160-180 kD is heavily tyrosine 
phosphorylated in 208F cells in response to EGF (Figure 9.2). In contrast to what was found in 
208F samples, no increase in the content of tyrosine phosphorylated proteins in FBR cells 
treated with EGF was found. One only protein of approximately 180 kD displayed an increased 
phosphotyrosine content in FBR cells and its was unresponsive to extracellular stimulation. This 
was also seen in TPA-treated FBR cells (Figure 9.1 lane 1 and 2, Experiment 1 and Experiment 
2). It should be noted that the variation observed between the experiment 1 and 2 in the Figure
9.2. is due to the fact that different amounts of lysate were loaded in these gels. In the 
experiment 1 50 ng were used and in the experiment 2, 100 jxg of total cell lysate. In both cases 
the membranes were incubated with identical dilution of the primary anti-phosphotyrosine 
antibody PY-20.
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Experiment 1 Experiment 2
Figure 9.2. EGF-induced Protein tyrosine phosphorylation in FBR and 208F cells.
Cells were grown in DMEM supplemented with 10% FCS and when subconfluent, 
serum-deprived for 48 hours (0.1% FCS). Stimulation was for 10 minutes with 50 
ng/ml EGF.
Cell lysates were prepared and proteins were separated by 7.5% SDS-PAGE, 
transferred to PVDF membrane and probed with a specific antibody for 
phosphotyrosine (PY-20, Transduction labs, KY, USA).
Two independent experiments are shown
Schlaepfer et al (1998) have identified a variety of different tyrosine phosphorylated 
proteins in lysates prepared from NIH 3T3 fibroblasts replated on fibronectin. These 
investigators have shown that FAK and p130CAS proteins are associated with a 120-140 kD 
protein complex, heavily tyrosine-phosphorylated upon adhesion.
Focal Adhesion Kinase is a protein tyrosine kinase localised to the focal adhesions and 
regulates biological functions of these cell structures. Focal adhesions serve as areas of cell 
attachment to the substratum and consist of many proteins that are tyrosine phosphorylated and 
which play a role in cell attachment and migration. It has been suggested that Focal Adhesion 
Kinase is tyrosine phosphorylated by src kinase and this phosphorylation event serves as a 
docking site for the binding of the GRB2 adaptor protein (Schlaepfer et al., 1994; Schlaepfer 
and Hunter, 1996; Schlaepfer et al., 1997; Schlaepfer et al., 1998) providing a link to ras and 
MAP Kinase pathway (Pawson, 1992 ; Rozakis-Adcock eta!., 1993).
Since FBR cells are poorly adherent to the plastic substratum but 208F cells attach even 
in the absence of serum, it was hypothesized that FAK could be tyrosine phosphorylated in 208F 
cells and not in FBR cells. Thus the nature of the 120 kD protein found to be tyrosine 
phosphorylated in 208F cells was further investigated.
Immunoprecipitation experiments using a monoclonal antibody specific for FAK was 
performed using lysates from quiescent, EGF and TPA stimulated FBR and 208F cells to 
investigate the tyrosine phosphorylation state of FAK. Cells were stimulated with 25 ng/ml EGF, 
20 ng/ml TPA or left untreated and lysates were prepared using the standard Triton X-100 
containing buffer. The lysates were clarified by centrifugation and the supernatant was 
normalised for protein content and 1000 |Lig of lysate was used to immunoprecipitate FAK and its 
associated proteins with a monoclonal antibody against FAK. After overnight incubation of the 
antibody, the immunoprecipitates were washed with lysis buffer, boiled in a small volume of 2X 
SDS sample buffer and the complexes were separated by 7.5% SDS-PAGE gels, transferred to 
PVDF membranes and blotted with the monoclonal antibody against phosphotyrosine.
As shown in Figure 9.3 FAK is tyrosine phosphorylated in quiescent and stimulated 
208F cells but not in the FBR treated or control samples. This correlates with the data presented 
in Figures 9.1 and 9.2 and with published studies of Hunter and co-workers where FAK tyrosine 
phosphorylation was detected in response to adhesion and attachment in rodent fibroblasts. We
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were unable to identify tyrosine phosphorylation of FAK in immunoprecipitates from quiescent or 
stimulated FBR cells. Even after prolonged exposure, no tyrosine phosphorylation of Fak could 
be detected in quiescent or stimulated FBR lysates. To confirm that FAK was 
immunoprecipitated from all the cell lysates used, the same membrane was stripped and probed 
with the FAK-specific monoclonal antibody in all samples. This is shown clearly in Figure 9.3 c, 
where equal amount of FAK are present in each lane (Figure 9.3c).
It is well established that FAK plays a significant role in MAP Kinase signalling in 
fibroblasts. Oncogenic transformation associated with non-receptor tyrosine kinases such as v- 
src v-fps and v-abl or Receptor Tyrosine Kinases such as the EGFR, results in tyrosine 
phosphorylation of FAK and activation of MAP Kinase signalling. In FBR cells the absence of 
strong tyrosine phosphorylation signals derived from activated or overexpressed tyrosine 
kinases upstream of fos, together with the results presented which indicate that FAK activation 
might be important in the regulation of MAP Kinase signalling pathway. FAK, a membrane- 
associated tyrosine kinase , which is phosphorylated in FBR cells suggesting a role for FAK in 
the down-regulation of MAP Kinase signalling pathway
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Figure 9.3. EGF and TPA-induced tyrosine phosphorylation of FAK in FBR and 208F 
cells.
Cells were grown in DMEM supplemented with 10% FCS to subconfluence and 
serum-deprived for 48 hours (0.1% FCS). Stimulation was for 10 minutes with 20 
ng/ml EGF, 20ng/ml TPA or the cells remain untreated.
Cell lysates were prepared and 1000 pg of total cell lysate was immunoprecipitated 
with a FAK-specific antibody (Transduction Labs, KY, USA). Immunoprecipitates were 
incubated overnight rotating at 4°C, washed with lysis buffer, separated by 7.5% 
SDS-PAGE, transferred to PVDF membrane and probed with A) and B) specific 
antibody for phosphotyrosine (PY-20, Transduction labs, KY, USA).
C) To verify equal loading the membrane was striped, washed, blocked and probed 
with the FAK-specific antibody.
Two different exposures are shown to identify tyrosine phosphorylation of FAK in 
208F cells.
9.3. Conclusion
Phosphorylation of FAK by tyrosine kinases occurs in response to adhesion to extracellular 
matrix components and this function is implicated in the association of FAK with signalling 
proteins such as GRB2, PLC-y and NCK and also in the activation of MAP Kinases. FAK also is 
activated in response to stimulation with extracellular signals such as phorbol esters (Woods 
and Couchman, 1993 Vuori and Ruoslahti, 1993 ; Lewis et al., 1996), LPA (Takeda et al., 
1998) growth factors (Chen e ta l, 1998; Casamassima and Rozengurt, 1998) and ultimately in 
the activation of MAP Kinases. These events make FAK an important mediator of extracellular 
signals in the activation of the MAP Kinase pathway. Recently it was also shown that serum or 
growth factor-dependent activation of MAP Kinases is strongly dependent on cell adhesion to 
the extracellular matrix (Renshaw et al., 1997). These data suggest that adhesion to ECM 
components activates or enhances positive MAP Kinase through a mechanism that involves 
activation of a FAK-dependent ras-sensitive pathway.
Here the tyrosine phosphorylation state of FAK is reduced both in resting and agonist 
stimulated FBR cells, whereas it is tyrosine phosphorylated in 208F cells. Lack of FAK activity 
could significantly contribute to the loss of adhesion properties associated with FBR cells.
A differential hybridisation approach used in this lab has shown that the mRNA of a 
membrane-associated Protein Tyrosine Phosphatase is overexpressed in FBR compared to 
208F cells (H.J. Spence, I. Johnston and B.W. Ozanne, unpublished observations). One could 
speculate that this phosphatase could contribute to the loss of phosphotyrosine containing 
proteins in FBR cells, resulting in FAK de-phosphorylation and ultimately leading to a diminished 
response to different signals leading to the activation of MAP Kinases.
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CHAPTER 10. DISCUSSION
ISOLATION OF FBR REVERTANT CELL LINES HELPS TO UNDERSTAND 
THE REQUIREMENT OF MAP KINASE PATHWAY DURING ONCOGENIC 
TRANSFORMATION
10.1. Properties of flat revertants derived from oncogenicaiiy transformed cells 
In cancer biology the term reversion describes the conversion from the transformed, malignant 
state to a non-transformed one, as it appears in established cell lines (Noda, 1993). A number 
of flat revertant cell lines derived from transformed cells by RNA-containing sarcoma viruses 
have been isolated and characterised previously (Ozanne and Vogel, 1974; Deng et al., 1974; 
Deng eta!., 1977; Noda e ta i, 1983).
Kuzumaki et al. (1989) have classified the revertant cell lines into three different 
classes. The first consists of those which either retain an inactive oncogene or have lost the 
relevant viral oncogene (MacPherson, 1965). The second category contains revertants that bear 
mutations in cellular genes which interfere with morphological transformation (Zarbl e ta i, 1987). 
The third class includes cells derived by activation of somatic transformation suppressor genes 
(Nodae ta i, 1983, 1989 ; Kitayamae ta i, 1989).
To generate revertant cell lines from oncogenicaiiy transformed cells, different methods 
have been used, for example treatment with mutagens (Kuzumaki et a i, 1989), or the 
application of tissue culture methods such as selective adhesion of sub-colonies of non­
transformed cells from transformed cells and enrichment under low serum conditions (Noda et 
ai, 1989; Wisdom and Verma, 1990). Usually these stringent procedures have the 
disadvantage of generating cell lines with variations due to chromosomal aberrations or 
unidentified mutations that might lead to non-reproducible results.
Previously Wisdom and Verma (1990) and Joliqoeur and co-workers (Zarbl e ta i, 1987) 
have isolated FBR and FBJ revertant cell lines respectively and have shown that these are 
resistant to transformation by other oncogenes.
To generate revertant cells lines of the FBR v-fos transformed cell line a transfection 
approach was used. Dominant negative mutants of the c-jun protooncogene, and of the MEK-1 
and Raf-1 protein kinases which are upstream of AP-1 were used. The cell lines isolated after
222
these transfection experiments exhibit the properties of a revertant. The growth properties of 
these cell lines demonstrate the requirement of one at least of the three well established the ras 
pathways, during the induction of cellular transformation by the FBR-MuSV. The ras proto­
oncogene is known that can activate except the MAP Kinase pathway the PI3K-PDK- PKB and 
the Ral-GDS pathway.
These cell lines appear also to be useful to study genes that are involved in 
morphological transformation by fos and ras oncogenes.
10.1.1. Isolation of FBR revertants following transfection of TAM-67
In order to demonstrate the requirement of Fos and Jun proteins in cellular transformation 
Muller and co-workers have made use of mutant Fos proteins that bear alterations in functional 
domains such as the NT-A, the C-terminal transactivation domain and the Basic-Leucine Zipper 
region (Neuberg etai., 1991; Wick et al., 1992) These studies showed that multiple regions in 
the Fos protein are important for the induction of transformation, and that the leucine zipper was 
necessary for these biological responses. Fos proteins have impaired transforming potential 
when the leucine repeat is substituted with the Jun leucine repeat (Neuberg et al., 1989b). 
These chimeric Fos proteins, termed W-Fos, are able to form dimers composed only of W-Fos 
proteins. These dimers capable of binding DNA but do not exhibit any transforming potential, 
suggesting that dimerization with Jun family members is required for transformation (Neuberg et 
al., 1991). In transfection assays the induction of transformation was maximal when Fos and 
Jun were combined in the assays, compared with Fos transfected alone (Neuberg et al., 1991). 
These studies together with the observation that ES cells lacking c-jun are non-tumourigenic 
(Hilberg and Wagner, 1992), suggest that the c-jun protooncogene is an critical factor in AP-1- 
mediated transformation activity in vitro and in vivo.
Previously Iba, Curran and co-workers have used point mutants and N-terminally 
truncated c-jun genes to investigate AP-1-mediated cellular transformation (Okuno et al., 1991; 
Suzuki et al., 1994). These studies showed that AP-1 is a downstream component of signal 
transduction pathways, and that the mutant Jun proteins can efficiently inhibit oncogenic 
transformation by diverse oncogenes such as v-src, v-fps, c-Ha-ras and raf (Suzuki etai., 1994).
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A transfection assay with the truncated c-jun protooncogene deletion mutant TAM-67 
was used to investigate AP-1-induced transformation by v-fos in vitro and to inhibit its 
transforming potential. Dominant negative c-jun TAM-67 has been developed by Birrer, Karin 
and co-workers (Alani etai., 1991; Brown et ai., 1993, 1994) down-regulates AP-1 activity in 
transfection experiments, inhibits transformation by ras, myc and SV40 and counteracts TPA- 
induced focus formation. More importantly it has been shown to suppress malignant conversion 
of epithelial cells to squamous cell carcinomas in mouse models (Domann e ta i,  1994). These 
findings make it an attractive suppressor of transformation in tissue culture and animal models, 
although care should be taken when interpreting these data since the squamous cell 
expressing-TAM-67 cells can still induce tumours with a longer latency in this particular mouse 
model (Domann etai., 1994).
Recently it was shown that TAM-67 when expressed in A431 epidermoid carcinoma 
cells inhibits motility, invasion and actin reorganisation by EGF, suggesting that AP-1 activity is 
downstream of the EGFR and that negative modulation of signalling by TAM-67 affects these 
biological processes (Malliri etai., 1998).
TAM-67 was transfected into FBR cells and after selection with G418, FBR TAM-67 
stable cell lines were isolated. In these cells TAM-67 functions in a dominant negative fashion, 
causing reversion of fos-induced morphological transformation and inhibiting cell proliferation. In 
this study it a reduction of the proliferative potential of the 208F TAM-67 and FBR TAM-67 
expressing cell lines compared to their controls was found (not shown). This is in contrast to 
other studies with TAM-67 in epithelial cells (Domann etai., 1994; Malliri etai., 1998).
In an analogy with the dominant effects of TAM-67 previously Muller and co-workers 
have also shown that there is not any significant alteration in the proliferative potential of 
fibroblasts after transfection with dominant negative mutants Fos proteins. These mutants also 
reversed ras transformation but did not interfere with the rate of proliferation of these cells (Wick 
etai., 1992).
These observations make it difficult to understand the role of TAM-67 in the inhibition of 
208F and FBR cell proliferation and how it could be related to cellular transformation. This could 
distinguish the fibroblast model of transformation from that of cells of epithelial origin such as 
A431 cells. One could speculate that the role of TAM-67 in fibroblastic cells is associated with 
inhibition of proliferation by sequestering complexes involving AP-1 components, such as c-fos
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or FBR v-fos. Previous studies with c-fos antisense vectors (Holt et al., 1986; Nishikura and 
Murray, 1987) and microinjection experiments with /bs-specific antibodies (Riabowol et al.,
1988) suggested that c-fos could possibly function as a positive modulator of fibroblastic cell 
growth.
However studies with fos -/- fibroblasts have shown that fos is not required for cell 
proliferation (Brusselbach et al., 1995). Again it is difficult to compare the proliferative potential 
of knockout cells to that of TAM-67 transfected cell lines. Recent work from Greenberg and co­
workers suggests that fos plays a role in cell cycle progression through the regulation of cyclin 
D1 expression levels and that its expression positively regulates cell proliferation (Brown et al., 
1998).
TAM-67 inhibits also anchorage independent growth of the FBR TAM-67 cells, reducing 
colony number and size when compared to FBR cells. Therefore TAM-67 inhibits colony 
formation of FBR cells but not to a 100%. This could be due to the fact that in all FBR TAM-67 
revertant cell lines the p75 v Fos oncoprotein is expressed at levels similar to the parental FBR 
cells. Therefore several of the transforming and immortalising properties that p75v Fos initiates 
are not fully suppressed. Dong et al. (1994) also reported that some epithelial cell lines when 
grown in the presence of phorbol ester or EGF are resistant to complete suppression of 
anchorage independence by TAM-67. These results show that some transformation-sensitive 
cell lines maintain a potential for anchorage independent growth after transfection with TAM-67.
TAM-67 also has the ability to inhibit EGF-induced morphological transformation of 
208F cells. EGF-induced morphological transformation is associated with anchorage- 
independent growth (de Larco and Todaro, 1978) and stress fibre disorganisation (Ozanne et 
al., 1980). This biological function of EGF occurs via the EGFR signalling pathway through the 
GRB2 adaptor (Matuoka etai., 1993) and the ras-GTPase Activating Protein, rasGAP (McGlade 
et al., 1993). In 208F TAM-67 transfectants, TAM-67 inhibits the disorganisation of actin stress 
fibres upon EGF treatment for 24 hours. This phenotypic effect of TAM-67 is associated with its 
ability to inhibit the transforming potential of growth factors coincident with its ability to prevent 
oncogene-induced transformation (Brown et al., 1993; Dong etai., 1994; Lamb etai., 1997).
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10.2. Growth Factors and Transformation
The proliferation and survival of cells in culture is dependent on the presence of peptide 
mitogens known as growth factors (Holley, 1975). Cells transformed by RNA- or DNA-tumour 
viruses and some human tumour cell lines can proliferate in the absence of added growth 
factors in the medium (Kaplan, 1983). The v-Ki-ras oncogene has been reported to transform 
cells independent of the presence of growth factors (de Larco and Todaro, 1978; Ozanne etai., 
1980) and to induce growth under anchorage-independent conditions (Kaplan and Ozanne, 
1983). These findings led Todaro to propose that autocrine mechanisms could be relevant to 
the growth of cancer cells in vitro as well as in vivo (Sporn and Todaro, 1980).
Some primary evidence suggest that v-fos exerts a different function in terms of the 
growth factor requirement in vitro compared to other oncogenes. Zhan and Goldfarb (1986) 
have found that cytoplasmic oncogenes e.g. v-mos, v-s/s, v-src and v-ras can release the 
growth factor dependency of NIH and BALB/c 3T3 cell lines, while FBJ v-fos does not support 
such a function. In addition Vennstrom and Bravo (1987) reported that the FBR-MuSV and FBJ- 
MuSV do not support the growth of BALB/c 3T3 cells in semi-solid medium, in the absence of 
competence type growth factors such as Platelet Poor Plasma (PPP) or PDGF (Pledger et al., 
1977), however they are able to do so when co-infected with the MMCV retroviruses carrying the 
v-myc oncogene of the avian retrovirus OK10 (Vennstrom etai., 1984).
A previous study in this laboratory has shown that incubation of FBR v-fos transformed 
fibroblasts in serum-free medium led to a marked decrease in DNA synthesis, suggesting that 
there was no autocrine growth factor activity from this transformed cell line which could induce 
DNA synthesis and proliferation (Hawker etai., 1993; Hennigan etai., 1994). Thus the FBR and 
FBJ v-fos transformed fibroblasts are serum-dependent for DNA synthesis and cell proliferation 
(Hennigan, 1993).
These observations lead to this investigation of growth factor-dependent signals of the 
MAP Kinase pathway in the context of cellular transformation by FBR v-fos oncogene.
To address this, the first question concerned whether conditioned medium collected 
from serum-deprived FBR could induce MAP Kinase activation. Results indicated that FBR- 
derived conditioned medium did not induce any activation of MAP Kinase neither FBR nor in 
208F cells. Thus the activation of the MAP Kinase pathway in FBR cells is serum-dependent. 
The growth factor dependence of FBR cells shows that DNA synthesis and mitogenic signals
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that emerge from the activation of the MAP Kinase pathway could be -required for cell 
proliferation. DNA synthesis and ultimately proliferation are also required for transformation 
(McCormick, 1994 , 1995). This lead us to speculate that the growth factor dependency of 
MAPK signals in FBR might be also be relevant and important for morphological transformation.
10.2.1. Is MAP Kinase signalling important for cellular transformation ?
Previously other groups have reported that oncogenic transformation results in defects in 
activation of MAP Kinases (Kizaka-Kondoh and Okayama, 1993; Greulich et al., 1996; Stofega 
et al., 1997). In these experiments different fibroblastic cell lines have been used for 
experiments that demonstrate the down regulation of MAP Kinase signalling by oncogenes 
including NRK, NIH 3T3 and chicken embryo fibroblasts. These studies indicate that different 
oncogenes such as v-src (Stofega et al., 1997), v-raf-1 (Kizaka-Kondoh and Okayama, 1993), v- 
crk (Greulich et a i, 1996) are involved in the downregulation of MAP Kinase signalling in 
different cell settings in vitro.
In human tumour cells, recent data suggest that MAP Kinase signalling might be related 
to tumorigenesis. ERK1 and ERK2 are over-expressed in human breast tumours compared to 
normal control tissue. In addition the tyrosine phosphorylation of MAP Kinases ERK1 and ERK2 
is higher in tumours compared to normal controls as detected by immunoprecipitation and 
western immunoblotting. Unfortunately these studies do not provide any mechanistic 
explanation for these over-expression patterns. Two other reports also suggest a connection 
between MAPK activity in hepatocellular carcinomas and tumour progression of this type of 
cancer (Schmidt et al., 1997; Ito e ta i, 1998).
A rather intriguing report deals with the role of an activated Estrogen-dependent mutant 
of Raf-1 kinase : DRaf-1:ER in cell cycle entry of human lung cancer cells (Ravi et al., 1997). 
DRaf-1:ER transfected into human lung cancer cells negatively regulates their growth by 
induction of the cyclin-dependent kinase inhibitor p27k,p.
Two possible reasons may account for these differences. Firstly the studies with breast 
tumours use material derived from tissues and not cultured cell lines that may have undergone 
additional alterations. Secondly, cell type specificity also contributes to observed differences in 
the experimental systems mentioned.
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These examples show that there could be a variation in the nature of activation of MAP 
Kinase signalling both within naturally occurring tumours and when established cell lines are 
compared to oncogenicaiiy transformed cells (Gupta et al., 1992; Gallego et al., 1992; Greulich 
etai., 1996; Greulich and Erikson, 1998).
It is possible that MAP Kinase activation could result in the up-regulation of mechanisms 
controlling cell proliferation and DNA synthesis. From experiments with fibroblasts there is 
evidence that a dominant negative MAP Kinase mutant can have negative effects on cell cycle 
entry, DNA synthesis and AP-1-dependent transcriptional activity (Pages et al., 1993). Also 
transfection of fibroblasts with plamsids encoding antisense ERK2 and inactive ERK2 kinase 
resulted in impaired colony formation in a dose-dependent manner (Pages etai., 1993).
In these studies stimulation of FBR and 208F cells with various stimuli resulted in 
differential activation of MAP Kinase signalling, with the magnitude of serum-induced activation 
of ERK1 and ERK2 decreased in FBR compared to the parental 208F cells. When growth 
factors and activators of lipid signal transduction pathways e.g. LPA, the response was similar to 
that found with serum: decreased levels of phosphorylated MAP Kinases in FBR cells compared 
to 208F controls. These observations suggest an apparent paradox: why is MAP Kinase 
signalling important and relevant to cell transformation, but maintained at such low levels ?
A similar paradigm is addressed by Cambell, Der and co-workers in the context of ras 
transformation, as seen in the case of various ras mutants which are able to induce cellular 
transformation without activating fully the Raf/MEK/MAPK pathway. It is interesting that the 
blockage of these pre-existing, low levels of MAPK activity resulted in the inhibition of ras 
transformation The answer to this question is that there is a series of events that follows 
tumourigenic transformation by ras, and that suppression of one pathway involved could 
significantly reverse the transformed phenotype (Cambell etai., 1998).
By analogy to ras-induced transformation, blocking of the MAP Kinase pathway could 
yield insights into the regulation of morphological transformation by FBR w-fos. To address this 
question dominant negative mutants of the ras effectors Raf-1 and MEK-1 were transfected into 
FBR cells and analysis of isolated drug-resistant clones, showed that this pathway was required 
for fos-induced transformation. The FBR cell lines transfected with dominant negative MEK-1 
and Raf-1 had the properties of revertant cells suggesting a putative role of the MAP Kinase 
pathway in /bs-transformation. These results are discussed in more detail below.
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10.2.2. Isolation of FBR revertants after transfection of of MEK-1A221
MEK-1 is a MAP Kinase Kinase, with dual specificity kinase activity towards Threonine and 
Tyrosine residues (Alessandrini et al., 1992; Rossomando et a l, 1992; Asworth et al., 1992; 
Nakielny et al., 1992; Seger et al., 1992). MEK-1 phosphorylates the ERK family of MAP 
Kinases ERK1 and ERK2 (Extracellular signal Regulated Kinase) (Boulton et al., 1991) on 
Threonine and Tyrosine residues in vitro and in vivo. MEK-1 is activated by phosphorylation of 
two serine residues Serine 217 and Serine 221 by the product of the protooncogene Raf-1, a 
Serine/Threonine protein kinase. This phosphorylation is required for activation of MEK-1 by 
Raf-1 in vitro and in vivo (Alessi etal., 1994).
Experiments with mutant MEK-1 showed that substitution of either Serine 217 or Serine 
221 with Alanine residues is sufficient to impair the catalytic properties of the enzyme (Alessi et 
al., 1994). When a mutant MEK-1 bearing such mutations is microinjected into v-ras or v-src 
transformed NIH 3T3 fibroblasts, DNA synthesis is inhibited up to 50% (Cowley et al., 1994). 
This result suggests that MEK-1 is downstream of the v-ras and v-src oncogenes and it can 
block signal transduction mechanisms downstream of Receptor Tyrosine Kinases and 
oncogenic ras. When the Serines 217 and 221 residues of MEK-1 are replaced with Glutamate 
or Aspartate the resulting enzyme is constitutively active with activity independent of growth 
factor stimulation. This gain of function mutant of MEK-1 can promote serum-independent 
growth of NIH 3T3 transfected cells (Alessandrini etal., 1996; Greulich and Erikson, 1998) and 
promote serum and growth factor-independent growth in tissue culture (Cowley et al., 1994). 
Additionally it induces tumours when injected into nude mice (Cowley etal., 1994).
This evidence highlight a role for MEK-1 in cellular transformation (Cowley et al., 1994) 
and cell cycle progression by the ras oncogene (Greulich and Erikson, 1998). Since the ras 
oncogene is upstream of fos oncogenes the role of the dominant negative MEK-1 in cellular 
transformation by the FBR fos was examined. Introduction of dominant negative MEK-1 with the 
Alanine 221 substitution into FBR cells inhibited anchorage-independent growth in serum- 
containing semi-solid medium.
MAP Kinase activation also seems to be related to AP-1 activation in tissue culture 
cells. Microinjection experiments with ERK-specific substrate peptides inhibits AP-1 activation by 
serum and phorbol esters (Frost et al., 1994) and over-expression of ERK1 and ERK2 kinase-
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inactive mutants blocks activation of AP-1 reporters by ras, serum and phorbol esters (Frost et 
al., 1994).
All these data argue for an important role of MAP Kinases in signal transduction and 
activation of AP-1. Here the role of MEK-1, one of the constituents of the ras pathway in AP- 
1/fos-induced transformation was investigated.
Marshall and co-workers who pioneered these studies have examined the DNA 
synthesis patterns of ras and src-transformed fibroblasts microinjected with MEK-1 A217 and 
MEK-1 A221 mutants. These experiments resulted in a significant reduction of the ability of ras 
and src oncogenes to induce DNA synthesis after microinjection of the MEK-1 interfering 
mutants. Microinjected ras-transformed cells with MEK-1 A221 or MEK-1 A217 vectors resulted 
in are morphological reversion with concomitant restoration of the actin stress fibres. In contrast, 
the activated mutant of MEK-1 E217/E221 induces morphological transformation and promotes 
serum-free growth of NIH 3T3 cells (Cowley et al., 1994). This indicates that MEK-1-dependent 
transformation of NIH 3T3 cells is related to transformation by oncogenic ras, and that MEK-1 is 
necessary for abnormal growth control and morphological transformation. In FBR A221 
revertant cells lines similar effects were observed: restoration of the actin cytoskeleton and the 
stress fibres present in contrast to FBR where the cytoskeleton is dissolved with very few actin 
stress fibres present. FBR A221 revertant cells share another property with the parental 208F 
cells in that the adhesion components, possibly focal adhesions, are restored.
It is known that serum-, EGF- or TPA-induced MAP Kinase activation can be inhibited 
by the introduction of MEK-1 A221 and MEK-1 A217 mutants (Cowley etal., 1994; Seger etal., 
1994). This can be measured by several ways such as the activation of MAP Kinases using an 
in vitro kinase assay or by supershifts of ERK1 and ERK2 in SDS-polyacrylamide 
electrophoresis. Quiescent FBR A221 revertant cell lines when stimulated with serum have 
decreased phosphorylation of ERK1 and ERK2, as shown by western immunoblotting with 
phosphospecfic antibodies. Orthovanadate, a broad inhibitor of protein-tyrosine phosphatases 
was also tested in the activation of ERK1 and ERK2 in FBR and FBR A221 revertant cells. 
There response to activation of ERK1 and ERK2 by orthovanadate in the FBR A221 cells was 
similar to the effects of serum: there was not any significant elevation of ERK phosphorylation 
compared to 208F cells were stimulation with orthovanadate induces ERK activation.
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When these cells were tested for a high concentration of EGF, there was no inhibition 
but there was a potent response to this mutant, suggesting that the dominant negative MEK-1 
A221 could be activated under these conditions as previously shown by others (Cowley et al., 
1994; Seger et al., 1994). It should be noted that since there is no evidence for the expression 
of this mutant in FBR A221, it is not known if the observed differences are due to the presence 
of the transfected gene or are a result of transfection selection.
10.2.3. Isolation of FBR revertants after transfection ofNARaf-1
The role of Raf-1 kinase in cellular transformation has been established since the identification 
of the y-raf oncogene as the component of the transforming retrovirus 3611 (Rapp et al., 1983). 
Like most retroviral oncogenes y-raf-1 has the ability to transform established cells lines and to 
induce them to grow under anchorage independent conditions.
Raf-1 also can transform cells in co-operation with ras oncogenes in cell culture 
experiments. A truncated c-Raf-1, BXB Raf-1 kinase transforms NIH 3T3 cells in a co-operative 
fashion with ras (Kolch et al., 1991) and also in co-operation with ERK1 and ERK-2 MAP 
Kinases (Troppmair et al., 1994). A chimeric protein consisting of the Raf-1 kinase domain 
fused to the ligand binding domain of the Estrogen Receptor (ER) can transform established cell 
lines in vitro and induce them to grow under anchorage-independent conditions (Samuels et al.,
1993). This transformation function of y-raf is not independent of functional ras as shown by 
microinjection of neutralising ras antibodies (Smith et al., 1986) and by expression of the 
dominant negative allele N17ras (Feig and Cooper, 1988). Conversely ras-induced 
transformation can be suppressed by the expression of a kinase-inactive Raf-1 mutant (Kolch et 
al., 1991).
ras also plays an important role in the activation of Raf-1 by extracellular signals. The 
dominant negative allele N17ras (Feig and Cooper, 1988) is required for ligand-induced 
phosphorylation and activation of Raf-1 in PC12 and NIH 3T3 cells (Wood et al., 1992 ; 
Troppmair et al., 1992). Expression of oncogenic ras in fibroblasts results in Raf-1 
phosphorylation (Morrison etal., 1988; Wood etal., 1992). Activation of downstream effectors of 
ras signalling such as the MAP Kinases is independent of ras in y-raf transformed Swiss 3T3
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cells (Howe et al., 1992). These studies reveal a potentially important role of Raf-1 in signalling 
mechanisms induced by growth factors and intracellular transformation by ras oncogenes.
In most cases nuclear oncogenes do not enhance activation of the ras pathway and 
ultimately MAP Kinase phosphorylation and activity. Cuadrado et al. (1994) have shown that 
FBR fos does not induce hyper-phosphorylation of Raf-1 kinase nor activate MAP Kinases and 
also y-myc behaves similarly (Howe et al., 1992). These data suggest that activation of MAP 
Kinase signalling in transformed cell lines is not a consequence of transformation by nuclear 
oncogenes. Activation of this pathway depends on cytoplasmic oncogenes such as v-ras and v- 
src (Howe et al., 1992). Although this appears to be true in the case of this study, it does not 
necessarily preclude the lack of importance of this pathway in morphological transformation by 
fos.
As shown in the case of MEK-1, a dominant negative MEK-1 A221 could reverse the 
fos-induced transformed phenotype in transfection studies. Since the activator of MEK-1 is Raf- 
1 in many cell types a similar approach was taken to study the role of the dominant negative 
Raf-1 by expressing NARaf-1 in the FBR background. This truncated mutant has an intact N- 
terminus regulatory domain containing a cysteine-rich domain that is the putative binding site for 
a modulator of Raf-1 activity (Bruder et al., 1992). Also certain amino acids in this domain serve 
as interaction sites with p21ras (Vojtek et al., 1993) suggesting that when over-expressed in 
tissue culture cells, this regulatory domain will interfere with early activation events of the MAP 
Kinase pathway since Raf-1 acts as a MAP Kinase Kinase Kinase.
Transfection of NARaf-1 into COS cells inhibits MAP Kinase activation by EGF, TPA 
and LPA (Schaap et al., 1993; Howe and Marshall, 1993). Recently these results have been 
confirmed by an analysis of this inhibitory function of NARaf-1 on the MAP Kinase pathway also 
in Rat-1 cells (van Dijk et al., 1997). These studies have shown that Raf-1 is central to the 
activation of the MAPK pathway by diverse mehanisms such as growth factors and activators of 
lipid pathways, as the Phosphatidyl Choline-specific phospholipase C (PC-PLC) and atypical 
protein kinase C-t, (PKC-£). Taken together these data support the role of Raf-1 as a mediator 
of ras and growth factor-induced activation of MAP Kinases.
The biological effect of transfected NARaf-1 was tested in the context of /bs-induced 
transformation. FBR cells were transfected with NARaf-1 and G418-resistant stable cell lines
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were isolated . The stable cell lines designated FBR NARaf-1 expressed sufficient levels of the 
mutant as shown by western immunoblotting. NARaf-1 reversed /bs-induced transformation and 
the all the FBR NARaf-1 expressing cells displayed a flat phenotype. NARaf-1 also reduced the 
ability of FBR to grow in semi-solid medium, that is in anchorage-independent conditions. These 
data show that NARaf-1 reverses transformation and that the FBR NARaf-1 expressing cells 
have properties of revertant cells.
Serum-induced activation of MAP Kinases ERK1 and ERK2 in FBR NARaf-1 expressing 
cells was examined by western immnuoblotting with phospho-specific antibodies. When serum- 
starved FBR NA Raf-1 revertants are stimulated with serum there is a 2-fold reduction in ERK 
activation compared to FBR cells suggesting that dominant negative NARaf-1 has a functional 
role and blocks serum-induced MAP Kinase phosphorylation. Apart from growth factors and 
phorbol esters (Schaap et al., 1993; van Dijk et al., 1997) other activators of MAP Kinases are 
sensitive to inhibition by NARaf-1. Howe and Marshall (1993) showed a 60-80% inhibition of 
MAP Kinase activity in response to LPA stimulation of COS cells transfected with NARaf-1. 
Therefore NA Raf-1 is an effective inhibitor of MAP Kinase induction by multiple stimuli as 
measured by different assays in Rat-1 and COS cells. Although these data are consistent others 
(van Dijk et al., 1997), other reports have provided contrasting evidence regarding the role of 
dominant negative Raf-1 mutants (Chao et al., 1994). In this latter report the Raf-1 mutant 301, 
was employed to investigate the requirement of Raf-1 in the activation of MAP Kinases by EGF, 
IGF-I, calcium and phorbol ester. This particular mutant of Raf-1, has a Lysine to Tryptophan 
substitution in the kinase domain which renders it inactive (Kolch et al., 1991). In these 
experiments a stable transfected Balb/c3T3 cell line with Raf-1 301 was tested for MAP Kinase 
activation using in-gel kinase assays. Stimulation with IGF-I and Thapsigargin, a calcium 
mobilising agent, found to be sensitive to this mutant, whereas Raf-301 did not block activation 
of MAP Kinases by EGF and phorbol ester in these cells (Chao etal., 1994).
There is the possibility that cell type specificity determines some parameters of signal 
transduction mechanisms of Raf-1 activation and the suppression of MAPK pathway by 
dominant acting forms of the Raf-1 kinase. Most groups have similar data obtained from 
transient transfection assays, and this suggests that dominant negative Raf-1 kinase mutants 
are able to inhibit growth factor activation of MAP Kinases as measured by various methods.
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It seems that in most cases activation of the MAPK pathway is associated with Raf-1 
kinase activation by mitogenic signals. In experiments where DNA synthesis is induced by 
activators of other pathways, such as cAMP activation of PKA, a dissociation between MAPK 
activation and DNA synthesis is observed (Withers etal., 1995).
FBR cells are spindle shaped, retractile and exhibit a loss of actin stress fibres when 
plated onto plastic in the repsence of serum (Hennigan, 1993 ; Lamb etal., 1997). FBR NARaf-1 
revertants are flat and have an increased number of stress fibres as shown by staining with 
Rhodamine-labelled Phalloidin. This is an interesting correlation between suppression of 
anchorage independence by NARaf-1 in FBR cells and morphological reversion (Weber et al., 
1974). FBR cells also have increased membrane ruffling activity in the area of the pseudopods. 
Despite the morphological reversion in FBR NARaf-1 revertants, no decrease in ruffling activity 
was observed but instead this remained persistent in cells actively growing in 10% FCS. This 
suggests that the introduction of NARaf-1 into FBR cells, unlike FBR MEK-1 A221 revertants, 
did not interfere with membrane ruffling but only with the formation of microfilaments. Therefore 
in the case of FBR NARaf-1 revertants the re-formation of the microfilament network might lead 
to anchorage-dependence, although the membrane ruffling activity remains unchanged. 
Previous microinjection studies with the activated mutants of Ras and Raf suggested that Raf-1 
is not sufficient to induce potent membrane ruffling activity in fibroblasts. Microinjection of an 
activated form of ras, V12 Ras to Swiss 3T3 and REF-52 fibroblasts resulted in the induction of 
membrane ruffling (Ridely et al., 1992; Joneson etal., 1996). Conversely, microinjection of REF- 
52 fibroblasts with an activated, membrane-localised RAF-CAAX is not sufficient to induce 
membrane ruffling. The Ras mutant Ras(V12C40) efficiently transforms NIH3T3 cells and also 
co-operates with Raf in fibroblast transformation but itself does not induce loss of actin stress 
fibre formation, suggesting a Rho-depedent transforming function of this mutant. This is in 
contrast to other studies where the introduction of a constitutively active V12 GTPase cdc42 into 
NIH 3T3 fibroblasts resulted in tumourigenicity, increased membrane ruffling but not full 
morphological transformation (Qiu et al., 1997). It seems that the signals elicited during FBR 
transformation are different when compared to the signals after introduction of the V12 mutant 
of Rac-1 and RhoA activated GTPases. The mechanisms of transformation in a Raf- 
independent manner are believed to be dependent on Rho-like GTPases such as Rac1, Rho
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and cdc42. The reversion mode that exists in the FBR NARaf-1 revertants is likely to be 
associated with the function of Raf-1 in the context of FBR transformation, leaving a window for 
other mechanisms to occur as those mentioned above.
The Raf-1 kinase inhibitor L-779 450 was also tested in its response to serum-induced 
MAPK phosphorylation in FBR, 208F and v-Ki-ras transformed 208F cells. These experiments 
also confirmed previous results. A dramatic decrease in the response to serum-induced MAP 
Kinase activity was observed in the FBR cells compared to 208F cells. The serum-induced 
phosphorylation of MAP Kinases in FBR cells was inhibited approximately 1.5-fold by L-779 450. 
This result suggests that the function of L-779 450 is similar to that by the dominant negative 
mutant of Raf-1 kinase, NARaf-1. In 208F cells, L-779 450 exerted a more potent inhibitory 
function since it inhibited MAPK phosphorylation approximately 7-fold but it did not significantly 
reduce the levels of activated MEK-1 suggesting the existence of different MEK-1 activators 
alternative to Raf-1. Serum-starved v-Ki-ras transformed cells displayed low levels of 
phosphorylated MAP Kinases. Similarly also to what others had observed this activity was not 
induced upon serum stimulation (Olson et al., 1998). In v-Ki-ras cells L-779 450 inhibited the 
activity of MAP kinases by 1.5-fold and reduced the levels of phosphorylated MEK-1, suggesting 
that the v-Ki-ras oncogene is the major activator of Raf-1 kinase in these cells.
The distribution and organisation of actin in FBR and v-Ki-ras transformed cells was 
also examined, to determine if L-779 450 could reverse fos-induced transformation of FBR cells, 
as in the case of the the MEK-1-specific inhibitor PD98059 where reversion appeared to 
correlate in a time- and concentration-dependent manner. Treatment of FBR with L-779 450 
resulted in partial morphological reversion of /bs-transformation. In the case of v-Ki-ras cells the 
reversion was evident but different from the mode of reversion after treatment with PD98059: 
the cells lost the membrane ruffling activity and became flat but reversion was not accompanied 
with the reformation of stress fibres.
Considering the biochemical and the biological data from the three different cell types 
examined, it is obvious that Raf-1 activity leading to MAP Kinase stimulation is reduced in FBR 
cells and sensitive to inhibition by L-779 450, and in general its levels are low in this cell type. 
Despite the fact that the Raf-1 activity is possibly low in FBR cells its inhibition could possibly still 
be sufficient for the reversion of morphological transformation as shown by transfection
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experiments with the NARaf-1. In this case it is not clear why pharmacological inhibition with L- 
779 450 did not result in the reversion of /bs-induced transformation.
In terms of Raf-1 kinase activation, evidence is limited since various technical obstacles 
were encountered in kinase assays with bacterially produced substrates of GST-MEK-1 and 
GST-ERK2. The lack of evidence does not allow us to determine the activity of did not allow 
determination of Raf-1 kinase activity from lysates of stimulated FBR cells compared to 
stimulated 208F cells. This could have been potentially interesting since it has been proposed 
that alternative activators of MEK-1 exist (Zheng et al., 1994). Previously Raf-1 activation as 
shown by Roberts and co-workers by the relatively straightforward method of measuring 
activation in lysates of tissue culture cells. These investigators have shown by western 
immmunoblotting, in vitro auto-kinase assays and in vivo [^P] labelling that Raf-1 could become 
autophosphorylated and activated (Morrison etal., 1988; Williams etal., 1992 ; 1993). This was 
shown by the mobility shift of the protein to a slower migrating electrophoretic species by 
western immunoblotting. The electrophoretic mobility of Raf-1 is similar between FBR and 208F 
cells and in case of the FBR samples there is a multiple pattern of Raf-1 specific- 
immunoreactivity which resembles the situation seen in v-Ki-ras transformed cells were Raf-1 is 
dramatically activated (see Figure 7.7). Raf-1 activation however does not correlate with MEK-1 
activation in FBR cells following mitogenic stimulation, suggesting that this way of measuring 
Raf-1 activation is perhaps not a reliable assay to determine the activity of Raf-1. Previously a 
similar mechanism that involves the activation of Raf-1 phosphorylation by MAPK has been 
suggested (Ueki et al., 1994). Lowy and co-workers have found that this type of activation of the 
Raf-1 C-terminus is due to the modification of a Serine residue by a MAPK-dependent 
mechanism, since activated MEK-1 induces this shift in vivo (Ferrier et al., 1997). In our case, 
the multiple immunoreactive Raf-1 bands in serum-induced lysates from FBR cells are not 
explained by down-modulation of the MAPK pathway in these cells. It is therefore possible that 
this mode of Raf-1 activation in FBR cells results from another, as yet unidentified mechanism, 
most probably dissociated from the MAP Kinase signals that are relatively low in FBR. The 
existence of other activators of MEK-1 apart from Raf-1 suggests that there could be alternative 
ways to activate MAP Kinases (Okazaki and Sagata, 1995 ; Withers et al., 1995 ; Seufferlein et 
al., 1996). There is some evidence that MEK-1 could be phosphorylated by another activator in
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PC12 (Pang et al., 1995) and Swiss 3T3 cells (Zheng et al., 1994) not yet molecularly cloned. 
One possibility to be excluded however is the activation of MEK-1 by B-Raf (Papin etal., 1995). 
In Rat-1 cells B-Raf levels are not detectable by western immunoblotting (Erhardt et al., 1995) 
and this makes the possibility of activation of Raf-1 in 208F and FBR cells very small, unless a 
genetic event has occurred that might lead to selection, and over-expression of B-Raf mRNA 
and protein in FBR cells. A lack of appropriate reagents has prevented further investigation of 
this possibility.
10.3. Identification of high molecular weight tyrosine phosphorylated proteins in FBR and 2 0 8 F : 
A putative relationship to MAP Kinase pathway down-regulation
Ligand activation of growth factor Receptor Tyrosine Kinases (RTK’s) results in their 
autophosphorylation, dimerisation (Schlessinger, 1988; Schlessinger and Bar-Sagi, 1994), and 
phosphorylation of downstream target proteins involved in signal transduction (Kazlauskas and 
Cooper, 1989). These targets serve as components of mitogenic pathways and include proteins 
of high molecular weight such as Phospholipase Cy-1 (Meisenhelder etal., 1990; Nishibe et al.,
1990), Phosphoinositide 3-Kinase (Valius and Kazlauskas, 1993), rasGTPase activating Protein 
(Gibbs et al., 1990; Molloy etal., 1989), the tyrosine phosphatase SHP-2 (Feng etal., 1993), the 
family of the IRS proteins (Lavan et al., 1992), and Focal Adhesion Kinase (FAK) (Chen et al., 
1998). Proteins of small molecular weight such as the She proteins are also regulated by 
tyrosine phosphorylation (Pronk et al., 1993). These signal transducing proteins regulate and 
are required for downstream signal transduction to MAP Kinase activation (Margolis etal., 1990; 
Medema et al., 1991; Medema et al., 1992; Lowenstein et al., 1992; Stephens et al., 1994; 
Roche et al., 1996).
These mitogenic components are subject to regulation by retroviral oncogenes which 
contain a tyrosine kinase activity associated with their catalytic domain (Ellis et al., 1990). Such 
oncogenes as v-src, v-abl, v-fps, v-yes, v-fes are members of the non-receptor Protein Tyrosine 
Kinases (PTK’s) as are their cellular homologues. This family of oncogenes is relatively large 
suggesting that they might exert an important role in cell proliferation and oncogenic 
transformation of different vertebrate species. Most studies in this field rely on the over­
expression of oncogene products such as v-src and v-abl or the over-expression of growth
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factor Receptor Tyrosine Kinases (Di Fiore et al., 1987) in order to facilitate biological 
responses, to potentiate substrate recognition and to understand phosphorylation mechanisms. 
However in some cases this appears naturally, as in the case of EGFR over-expression in the 
A431 carcinoma cell line (Ullrich etal., 1984).
From these studies it is apparent that the components of tyrosine phosphorylation- 
related signal transduction are modulators of early mitogenic signals occurring in the plasma 
membrane resulting in activation of pleiotropic cellular responses and gene expression.
The patterns of tyrosine phosphorylation in the cell lines used throughout this thesis 
were examined in an attempt to identify any differences that could account for the down- 
regulation of MAP Kinase pathway. The 208F cell line, a derivative of Rat-1 cells has been used 
to generate FBR transformants. The 208F cells are attached well to the substratum and one 
would expect that mitogenic activation would involve some adhesion components. In contrast 
FBR cells are retractile, rounded and poorly adherent, features common in many oncogenically 
transformed cell lines. To investigate this, western immunoblotting with anti-Phosphotyrosine 
antibodies seemed to be a relatively straightforward approach to such a complicated issue.
This approach suggested that a reproducible differential pattern of tyrosine 
phosphorylation existed between FBR and 208F under relatively low concentrations of 
extracellular stimuli used. This event could be relevant to transformation since a subtractive 
hybridisation approach yielded a variety of gene expression alterations, a phenomenon that was 
expected since FBR v-fos is a trans-regulator of gene expression (Johnston et al., submitted). 
Some of the transactivated genes identified are possibly involved in the regulation of mitogenic 
signalling including a Protein Tyrosine Phosphatase and a Raf-1 kinase-binding protein.
During these experiments the 120 kDa Focal Adhesion Kinase was identified as a 
possible modulator of MAP Kinase pathway in 208F but not FBR cells. Increased tyrosine 
phosphorylation of FAK content was detected in 208F but not in FBR cells. Previous reports are 
consistent with a role for FAK in potentiation and regulation of MAP Kinase signalling. It was first 
identified by replating NIH 3T3 cells on ECM proteins (Schlaepfer etal., 1994). FAK was shown 
to be activated and linked to the ras pathway through GRB2 binding and Sos-1 association with 
the plasma membrane and also by induction of its tyrosine phosphorylation status by 
extracellular ligands or activation of PKC. The finding that FBR cells contain less tyrosine
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phosphorylated FAK compared to 208F could shed some light on the mechanisms of MAP 
Kinase activation in this cell type.
The reduced tyrosine phosphoprotein content in FBR cells is somewhat surprising 
considering the high mitogenic rate of these cells (Hennigan, 1993 ; Hawker et al., 1994). If 
tyrosine phosphorylation is involved in the generation of positive mitogenic signals across the 
membrane, then possibly another factor could contribute to the effects seen in FBR cells. A 180- 
190 kDa protein that is tyrosine phosphorylated in FBR cells to a greater extent was also 
identified, which is independent of ligand stimulation. Whether or not this could account for the 
observed differences in the mitogenic potential of FBR cells is not known. It would be interesting 
in the future to identify the nature of this putative signalling molecule and determine its role in 
the activation of trans-membrane signals in FBR cells.
10.4. Multiple effectors determine activation of the MAP Kinase pathway 
MAP Kinases are stimulated by various agonists and serve as transducers of multiple 
intracellular signals (Ray and Sturgill, 1987, 1988). MAP Kinases have cytosolic and nuclear 
substrates with multiple functions. In the cytosol and the plasma membrane MAP Kinases 
phosphorylate enzymes such as the EGFR (Alvarez et al., 1991) and phospholipase A2 (Lin et 
al., 1993). As a result of mitogenic stimulation a fraction of MAP Kinases translocates to the 
nucleus and regulates gene transcription by phosphorylating transcriptional activators (Chen et 
al., 1992, 1993), such as Elk-1 (Gille etal., 1992; 1995; Marais et al., 1993; Janknecht et al.,
1993).
MAP Kinases are stimulated by growth factors, such as NGF and EGF (Boulton et al.,
1991) and lipids, such as LPA (Cook et al., 1993; Howe and Marshall, 1993; Hordijk et al.,
1994). The main elements that compose the MAP Kinase pathway are the small GTP-binding 
protein p21ras and its target the Raf-1 kinase (Howe et al., 1992) which phosphorylates and
activates the major MAP Kinase activator, MEK-1 (Gomez and Cohen, 1991; Ahn et al., 1992;
Seger et al., 1992;).
Fibroblasts, such as Rat-1 cells stimulated by multiple agonists show an increase in the 
phosphorylation and activation of MAP Kinases ERK1 and ERK2 (Boulton et al., 1991; Ahn et 
al., 1990; Ahn and Krebs, 1990; Haystead et al., 1990). This action is a sequential event that 
requires growth factor Receptor Tyrosine Kinase stimulation of guanine nucleotide exchange on
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p21 ras et ai ' 1990a, 1990b) and Raf-1 kinase activation (Troppmair etal., 1992; Wood et
al., 1992; Howe etal., 1992). Activation of the MAP Kinases is regulated also by dual specificity 
protein Tyrosine/Threonine phosphatases products of immediate early genes that reduce MAP 
Kinase activity (Keyse and Emslie , 1992; Alessi etal., 1993).
Cytoplasmic oncogenes are also known to activate the MAP Kinase pathway. 
Membrane-associated oncogenes such as v-src and gip2/Gi2 activate MAP Kinases in a 
constitutive manner (Gupta et al., 1992; Gallego et al., 1992) and also cytoplasmic oncogenes 
associated with protein kinase activity such as y-raf, v-abl and v-mos (Howe etal., 1992; Dent et 
al., 1992; Troppmair et al., 1994; Okazaki and Sagata, 1995).
The specificity of the interaction of MEK-1 with Raf-1 and p21ras is high and it seems 
likely that p21ras is one of the major upstream activators of this signalling complexe. However 
recent evidence suggests also that the MAP Kinase pathway can be more complex than 
previously thought and not linear (Meier and Evan, 1998; Sternberg and Alberola-lla, 1998). The 
regulation of early events leading to the activation of a MAP Kinase Kinase Kinase such as Raf- 
1 is dependent on p21ras activity and also a Tyrosine Kinase signal is necessary (Morrison etal., 
1993; Fabian et al., 1993; Dent et al., 1995; Marais et al., 1995). However recently the 
identification of new proteins that participate in ras signalling in Drosophila and C. Elegans show 
that this activation could be the result of the participation of a protein network leading to the 
activation of Raf-1 (Sternberg and Alberola-lla, 1998). The KSR protein: Kinase Suppressor of 
Ras identified in drosophila is a putative alternative regulator of Raf-1 kinase that is activated by 
other mechanisms (Therrien et al., 1996). Other mechanisms reported to result in a MEK-1- 
dependent Raf-1-independent mechanisms of MAP Kinase pathway is the recent demonstration 
of the role of Protein Kinase C (PKC) atypical isoforms (Schonwasser et al., 1998).
There is also evidence that oncogenic transformation is not necessarily associated with 
the MAP Kinase activation. Stimulation of quiescent FBR cells with serum or growth factors 
does not result in dramatic activation of MAP Kinase phosphorylation, as in the case of 208F 
cells. This novel finding might be associated with the up-regulation of a regulatory molecule 
which affects the intensity of MAP Kinase signals. For example a Protein Tyrosine Phosphatase 
(PTP) that will reduce the intensity of extracellular stimuli could be a possible candidate in FBR 
cells. Such an enzyme could interfere with the de-phosphorylation of Protein Tyrosine Kinases
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such as Focal Adhesion Kinase (FAK). A schematic representation of such alterations is 
depicted in Figure 10.1.
The MAP Kinase pathway has been shown to be activated by adhesion to Integrins and 
this event can be augmented by growth factors such as EGF (Miyamoto etal., 1996). Recently it 
was shown that the Protein Tyrosine Phosphatase PTEN, down-regulates the MAP Kinase 
pathway by dephosphrylation of the adaptor protein She, without interfering with activation and 
tyrosine phosphorylation of the EGFR (Gu et al., 1998). Over-expression of such an enzyme 
could potently reduce the signals downstream of RTK’s and also from FAK and other integrin- 
mediated pathways (Danen etal., 1998; Gu etal., 1998) making the hypothesis of the presence 
of a putative Protein Tyrosine Phosphatase in FBR more realistic (Figure 10.1). A transient 
transfection approach can be employed in order to identify if this phosphatase could 
dephosphorylate proteins in FBR cells that are not tyrosine phosphorylated to the same extent 
into FBR cells compared to 208F cells.
In Figure 10.1 a schematical representation of multiple activators of MAP Kinase 
pathway is shown.Raf-1 kinase can be activated by a mechanism that involves p21ras and a 
protein kinase such as the recently identified Pak3 (King et al., 1998) and v-src (Marais et al.,
1995). The existence of other activators of MEK-1 is also presented. It has been reported that 
NEK-1 might have alternative activators except the Raf-1 kinase (Zheng et al., 1994; Pang et 
al., 1995). A candidate approach to identify a different activator of MEK-1 except Raf-1, in FBR 
cells is to use a bacterially expressed recombinant activated form of MEK-1 immobilised in a 
column and pass through the column FBR cytoplasmic lysates to identify any proteins that might 
associate with MEK-1. These proteins could be subsequently identified by sequence 
determination and molecular cloning.
Finally in the Figure 10.1a a possible biological role for the different dominant negative 
mutants in the FBR v-/bs transformation system is presented, derived mainly from the 
experimental results presented in this thesis. The function of NA Raf-1 is to suppress anchorage 
independence although its role in MAP Kinase phosphorylation is less apparent (see Figures 7.4 
and 7.5). MEK-1 A221 has a significant effect in cell morphology and also suppresses serum- 
induced MAP Kinase phosphorylation (see Figures 6.3 and 6.8). The dominant negative 
deletion mutant of c-Jun TAM-67 can effectively inhibit FBR v-fos transformation (see also 
Figure 4.4 for anchorage independent growth of FBR TAM-67 revertants).
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Figure 10.1. Activation of MAP Kinase Pathway in FBR cells by extracellular signals.
MAP kinase activation can be elicited by extracellular signals. These include soluble growth 
factors, such as EGF and PDGF that act through Receptor Tyrosine Kinases (RTK’s). 
Signals through the Extracellular Matrix (ECM) which is composed from insoluble ligands 
such as Fibronectin act by binding to Integrins which in turn activate the Focal Adhesion 
Kinase (FAK). Both signalling pathways activate ras signalling and MAP Kinase pathway 
through the formation of complexes containing the adaptor protein GRB2 that links ras to the 
exchange factor Sos-1 and the GTPase activating protein rasGAP. This process can be 
attenuated in FBR cells by the over-expression of putative Protein Tyrosine Phosphatase 
(PTP) that might dephosphorylate FAK or components of Receptor signalling pathways. 
Downstream of RTK’s Raf-1 kinase can be activated by ras and by another signals emerging 
from a Serine Kinase such as Pak3 or by Tyrosine Kinases such as v-src. The MAP Kinase 
activator MEK-1 can be also activated by other mechanisms except Raf-1. For example 
MEK-1 can be inhibited by the mammalian version of the Kinase Suppressor of Ras (KSR) a 
protein recently identified in Drosophila. Alternative activators of MEK-1 have been reported 
in mammalian cells although their identity is not fully established. A candidate for such a 
function is the atypical Protein Kinase C £.
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Figure 10.1a. Putative biological function of dominant negative mutants in fos-induced 
transformation.
MAP kinase activation can be elicited by extracellular signals. These include soluble growth 
factors, such as EGF and PDGF that act through Receptor Tyrosine Kinases (RTK’s). 
Signals through the Extracellular Matrix (ECM) which is composed from insoluble ligands 
such as Fibronectin act by binding to Integrins which in turn activate the Focal Adhesion 
Kinase (FAK). Both signalling pathways activate ras signalling and MAP Kinase pathway 
through the formation of complexes containing the adaptor protein GRB2 that links ras to the 
exchange factor Sos-1 and the GTPase activating protein rasGAP.
The dominant negative mutants of Raf-1 ND Raf-1, MEK-1 A221 and c-Jun TAM-67 could 
have multiple roles in regulating MAP Kinase signalling, morphology and transformation. For 
example the truncated dominant negative mutant of Raf-1. ND Raf-1 prevents growth under 
anchorage independent conditions. The mutant MEK-1 A221 inhibits serum-induced MAP 
Kinase phosphorylaytion and reverses morphological changes in FBR cells. Finally TAM-67 
is an inhibitor of oncogenic transformation, proliferation and induces effectively reversion of 
the transformed phenotype..
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